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CHAPTER 1: INTRODUCTION
One of the life-threatening diseases that require intense care is chronic kidney disease
(CKD) and it is associated with morbidity and mortality. CKD is defined as losing kidney
function over time measured by a decline in glomerular filtration rate (GFR) which is
irreversible. CKD is asymptomatic in the early stages; however, in the late stages, the
symptoms are related to its complications. Kidney failure (KF) is the final stage resulting
in end-stage kidney disease (ESKD), treated with a kidney transplant or dialysis (peritoneal
dialysis (PD) or hemodialysis (HD)) [1]. According to a report from Saudi Center for Organ
Transplantation (SCOT) in 2017, there were 19,659 dialysis cases, and 93% of them
underwent HD and the mortality among KF was 9% [2]. While diabetes (DM) and
hypertension (HTN) are the leading causes of CKD in Saudi Arabia (SA); both along with
obesity and heart disease are risk factors of KF[3]. Although HD is considered a lifesustaining therapy, it is associated with higher mortality due to a higher risk for
cardiovascular disease (CVD) or infectious disease [4]. Also, CKD and KF patients are at
a higher risk for poor nutritional status, inflammation and dyslipidemia [5-8].
Moreover, protein-energy wasting (PEW) is a form of malnutrition and is common among
CKD undergoing HD [9]. In SA, there are a few studies done on PEW in HD patients[10].
A decline in energy and protein consumption (because of insufficient intake of food or poor
absorption of nutrients), sedentariness, hormonal disorders, hypermetabolism, decreased
anabolism, metabolic acidosis, dialysis procedure, and inflammation may cause it [11].
PEW could increase the risk of poor quality of life, morbidity and mortality among these
patients [11, 12]. It is therefore essential for most HD patients to follow their prescribed
diet to reduce risks and medical complications [13, 14].
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Every year, during Ramadan (R) month, Muslims change their eating pattern. R is
an Islamic holy month during which Muslims abstain from eating and drinking each day
from dawn to sunset and eating only within a short overnight period [15, 16]. Therefore, as
the lifestyle is affected, this results in changes in sleeping, eating, and physical activity
levels. These changes can affect health and nutritional status of healthy subjects [17-28].
Dietary intake during Ramadan is different from other months and between countries and
cultures, so effects on health may also differ. Various studies have found no adverse effects
of the dietary changes and fasting during R in healthy individuals. Although sick people are
exempted from fasting during R; some of these patients (pts) who suffer from mild or
moderate medical conditions or are on HD do want to fast. While some studies have found
R–associated changes in HD patients on serum phosphorus and potassium, few studies are
looking at the effect of R on nutrient intake, lipid and lipoproteins among them, especially
in SA [29-33].
Chronic Kidney Disease
CKD is a health problem worldwide and as CKD the disease progresses, the
structure and function of the kidneys are altered gradually and irreversibly and this leads
to a decrease in glomerular filtration rate (GFR), retention of waste products and water in
the blood and changes in the demand and utilization of various nutrients [34]. CKD is
defined as a presence of kidney damage or glomerular filtration rate (GFR) less than 60
ml/min/1.73m2 for three consecutive months or more [35]. CKD is classified based on the
GFR and albuminuria category according to Kidney Disease: Improving Global Outcomes
(KDIGO) (Table 1-1) [35-40]. The GFR category (G1 – G5) based on estimated GFR start
from ≥90 ml/min/1.73m2 (Kidney damage but with normal function) to <15 ml/min/1.73m2
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(kidneys have lost almost all ability to function effectively), while the albuminurea
category (A1-A3) is based on albuminurea level start with <30 mg/g (normal to mild
increase) to >300mg/g (severely increase).
CKD is estimated to affect between 11% to 13% of the global population [41] and
was the eleventh leading cause of death worldwide (in 2018) [42]. In Saudi Arabia, the
CKD status has increased over the last three decades attributed to a rapid change in
lifestyle, population development, life expectancy, and urbanization [43]. The proportion
of total mortality attributed to kidney disease in SA is currently 1.5 to 2% [1]. Only a few
research have been conducted to determine the prevalence of CKD in different regions of
SA. In a multi-center cross-sectional study in the Hail region, of the 946 patients, whose
estimated GFR was available, CKD was identified in 278 patients (9.4%) and was more
common among males [44]. Similarly, in a pilot community-based screening study for
CKD in 491 subjects from Riyadh, CKD was estimated to be 5.7% and was more common
among males [45]. Another population screening study done in Hail in 299 subjects,
reported an overall prevalence of 24% of which 61.4% were females [46]. Moreover, a
cross-sectional community-based study from Arar city that including 276 participants 60
years and older, 52% females, to investigate the prevalence of CKD, observed that 1.4%
had chronic kidney failure [47]. Based on the above knowledge that the prevalence was
dependent on the population chosen, with a limitation of being single centered and
therefore cannot be applied to population at large.
Among the various causes of CKD, DM and HTN are considered as the leading
contributors. Also, obstructions to the kidneys, tumors, repeated urinary infections, and
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drugs may contribute to CKD [1, 48]. Regardless of the causes, CKD is associated with
increased morbidity and mortality [49].
Kidney failure (KF) and maintenance hemodialysis (HD)
KF is considered life-threatening since it is the last stage where the kidney’s
function is reduced to 10 to 15% of its normal capacity. At this stage, renal replacement
therapy (RRT) is lifesaving and is warranted through either HD, peritoneal dialysis (PD) or
kidney transplant [50]. Hemodialysis is the most prevalent RRT worldwide followed by PD
and kidney transplants.
The prevalence of KF is rising; in 2004 it ranged from 70 to 2045 per million
population (PMP) in different countries and in 2013 it increased to ~ 100 to 3170 PMP [51,
52].
In SA, the number of KF patients who are treated with dialysis is increasing
annually by 7.8% [53]. According to SCOT, in 2015, the estimated prevalence of KF
patients undergoing dialysis was 513 case/PMP, mortality was 1,655 (10.5%), and the
estimated treated KF incidence was 136 cases/PMP. In 2017, the estimated prevalence of
KF undergoing dialysis was 604 case/PMP, mortality 1,726 (9%) and the estimated treated
KF incidence was 163 case/PMP. Furthermore, out of 18,270 KF patients undergoing HD,
4,820 were new HD patients, 56% were male, 84% were native Saudi. The majority of the
HD patients were between 26-65 years old (69%), and about 9% were older than 75 years,
and 1% are under 15) [2, 53, 54].
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Etiology of Chronic Kidney disease (CKD):
While the major causes of CKD and KF are HTN and DM worldwide, but
glomerulonephritis is one of the leading causes in developing countries, [55], Lupus,
obstruction, congenital malformation, vasculitis, rare genetic conditions (such as Alport
syndrome) and inherited diseases (for example polycystic kidney disease) are other causes
of CKD [56, 57].
Diabetes Mellitus (DM):
DM is a leading cause of CKD and KF worldwide [58] and can initiate kidney
damage. 40% of the diabetic patients develop diabetic kidney disease (DKD). Also, the
presence of microalbuminuria (now referred to albuminuria) leads to the development of
DKD and risk of cardiovascular disease (CVD) [59-61]. It is not clear whether CKD and
KF vary in prevalence between the two forms of DM. However, there are a few studies that
distinguish between the two types of diabetes and are related to CKD in SA.
SA is one of the top 5 leading countries in the middle east in term of diabetes
prevalence (18.3%), and its incidence is 1 in 8 adults [62]. According to the Saudi Health
Interview Survey, (data were collected from all the 13 regions in SA) the prevalence of
DM is higher (50.4%) in older people (more than 65y/o); and is higher in females than
males (17% vs 15.5%). Moreover, among the patients who were treated for DM (22.9%
males and 23.4% females), their blood glucose levels were uncontrolled [63].
Uncontrolled blood glucose levels are prevalent among patients who have DM type
2 [64-68]. Longstanding of inadequate control of blood glucose can progress to DKD,
causing an increase in morbidity and mortality [69, 70]. In a study done in SA, reported
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that DKD was the second prevalent complication (32.1%) among 1952 type 2 DM patients;
out of which, 15.2% developed KF, and 12.6% were on dialysis [71]. Moreover, the Saudi
diabetic kidney disease (SAUDI-DKD) study reported, among 714 Saudi with type 2 DM,
DKD was prevalent among 427 subjects. Furthermore, the prevalence is higher among
older subjects > 45 years old (94.85%) and in females (51.76%), and 37% had KF [72].
Another cross-sectional study of 54,670 T2DM patients were selected from the Saudi
National Diabetes Registry (SNDR) found that the prevalence of DM at 10.8% and 1.5%
had KF. The factors that are associated with the prevalence of DKD were age and duration
of having DM (patients 65 years or older and the duration of diabetes 15 years or more)
[73]. In another study among 276 SA participants, whose age was 60 years or more, found
5.8% had diabetic kidney disease [47]. Additionally, another SA study performed on 200
CKD subjects found 69% of the subjects had DM; which is the highest rate compared to
previous studies carried done in SA; and 87.7% had HTN. The study also concluded that
females were at a higher risk for CKD and its progression to KF [74]. In another study of
299 subjects, 24% were identified with CKD and 70% out of them were cases of DM [46].
Hypertension (HTN):
Hypertension is a leading cause of CKD and KF and is highly prevalent in these
patients [75]. Also, 80 to 85% of CKD patients have hypertension [76]. Meta-analysis
studies showed that systolic blood pressure (SBP) was associated with CKD and mortality,
its prevalence lower in females and higher in middle-income countries [77, 78].
However, in SA, the definition of HTN among the studies is varied; therefore, the
prevalence is variable. Interestingly, from the Saudi Health Information Survey (SHIS) of
10,735 Saudis, which included blood pressure measures, there were 15.2% HTN
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diagnosed, and 40.6% were borderline HTN. 57.8% were undiagnosed and 55% were
uncontrolled HTN. The risk of HTN was higher among male patients, older, having DM,
obesity and /or hypercholesterolemia [79]. Various studies done in SA have shown a
prevalence from 5 – 28% [45, 80, 81].
A study in Hail region, SA, screened 299 individuals for CKD and identified 70
CKD patients, of which 64% of the patients were hypertensive [46]. Another study with 50
patients was conducted to assess the relationship of risk factors to Chronic Kidney Failure
(CRF), where 90% of CRF patients had HTN as a risk factor. [82]. Hypertension is
considered either a primary or a secondary cause of CKD; also, a complication of it [83].
In a multi-center prospective cross-sectional survey among 712 HTN patients, showed the
prevalence rate of 46.9% for CKD at various stages (1-5) concluding the need for screening
programs to identify CKD at earlier stages. [84].
Glomerulonephritis
Glomerulonephritis (GN) is a group of disorders that cause renal inflammation and
can complicate to kidney failure. Systemic lupus erythematosus (SLE), lupus nephritis
(LN)), Alport Syndrome and focal segmental glomerulosclerosis (FSGS) are GN examples.
Studies suggest that FSGS is generally the primary and Lupus is secondary GN [85-88].
The prevalence of GN globally is different [89].
From different regions of SA, a study with 1294 participants, found 77.2% had a
form of glomerulonephritis (GN) out of which 21.3% was FSGS [87]. Another study on
100 who underwent native kidney biopsy in SA, found 35% FSGS, 36% LN [90]. A study
from Riyadh in Saudi Arabia from 348 patients reported, 27.6% FSGS and 37.9% were LN
[91]. A recent multicenter study in SA showed from 405 cases, 24.1% had FSGS, and 66%

8
LN [92]. Moreover, among 296 adult selected cases of primary GN, Alport syndrome was
0.7% [93]. Furthermore, a study showed from 296 selected cases of primary GN, 25.7%
were membranous GN (MGN) and 25.7% were FSGS [93]. In another recent study, among
112 SLE patients, 2.7% developed kidney failure and went through dialysis [94].
Etiology of KF:
Diabetes and or hypertension are considered as 80% of the cause of KF worldwide
[95]. In SA (2017), the first two causes of kidney failure among ESKD undergoing HD
were diabetic nephropathy (DN) and hypertensive nephropathy (HN) with a prevalence of
39% and 36.5% respectively. Other causes of kidney failure among HD patients were
unknown causes, primary glomerular disease, obstructive uropathy, hereditary kidney
disease, congenital malformation, vasculitis, primary tubule-interstitial disease,
pregnancy-related and others. The trend of the major causes of kidney failure (DN, HN,
and unknown causes) from 2010 to 2017 has been rising, for example, DN in 2010 was
3941 cases and in 2017 was 7130 cases; HTN in 2010 was 3805 cases and in 2017 was
6685 cases. However, the unknown causes were stable from 2010 (1272 cases) to 2016
(1100) but in 2017 increased to 1829 cases [2, 53].
Risk factors of CKD:
CKD risk factors are associated with increased risk of CKD progression. The most
common risk factors for CKD are DM, HTN, obesity, genetic along with CVD,
dyslipidemia, smoking, and older age. [1, 49, 96-98].
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Obesity
Obesity is a modifiable risk factor that is associated with increase in blood pressure
which inturn can increase the risk for CVD and CKD [99]. Also, within CKD, obesity is
associated with an increased risk for CVD and mortality [100]. The prevalence of obesity
is increasing, especially in SA. A study aimed to predict obesity among Saudis estimated
an increase in obesity in females more than male ( 21% in 1992 to 78% by 2022 in females
and from 12% in 1992 to 41% by 2022 in males) [101]. Furthermore, obesity prevalence
in 2016 was higher in SA 35.4% than its neighboring countries like the United Arab
Emirates (31.7%) and Oman (27%), according to World Health Organization (WHO) data
[102]. The SA national survey showed among 10,735 participants that there were 28.7%
obese with body mass index (BMI) greater than or equal to 30 kg/m2 on average in females
more than in males (33.5% vs 24.1%) [103]. Another study among 411 healthy SA showed
a high prevalence of obesity especially among female (high in body fat and poor fitness)
[104]. Another study showed that among the older population in SA (60y or more), obesity
was prevalent and it was 45.7% obese based on their BMI and among them, 3.2% had
chronic kidney failure and 6.3% had diabetic nephropathy [47]. Different studies report
that obesity is associated with CKD [99, 105]. Consistent with that, a study performed
among 28 CKD Saudis reported that CKD was associated with obesity (by measuring waist
circumference and waist to hip ratio) and the prevalence was 60.7% [45]. Another study
included 5025 Saudi participants, 5.1% were CKD and their BMI was 29.9±5.2 [106].
Genetic
Genetics are a risk factor for CKD such as polycystic kidney disease (PKD) which
is inherited disease resulting from a single gene defect [107, 108]. Patients who have PKD
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can develop KF faster [56]. There is no data available on the prevalence of PKD
worldwide, however, in countries like United Kingdom (UK), Norway, and United States
(USA), the prevalence is 6%, 11%, and 2.2% respectively [108]. Also, in SA, studies
reported that Saudi children compared to other children in other parts of the world have a
high incidence of PKD [107, 109-111]. A study that investigated the risk factors of chronic
kidney failure (CRF) have done among 50 adults with CRF found 20% of the subjects had
PKD [82].
Furthermore, Alport’s syndrome is another inherited disease that can result in CKD.
A study done among primary glomerular diseases patients, who are under 18y in SA,
showed that Alport’s syndrome was 2.4% [108]. Another study, among 1000 CKD patients
found 1.2% had Alport’s syndrome [112].
Moreover, most of the kidney disease cases in childhood found to be congenital
with a likely genetic basis [113]. In SA, 56% of the marriage is consanguinity marriage
and between these marriages, the marriage between cousins is common [114]; therefore,
the Saudi population has close homology and this could lead to increase CKD prevalence
because of consanguineous marriage. [115].
Smoking
The CKD risks can increase by cigarette smoking; not only that but also, the risk
of CVD morbidity and mortality can increase with cigarette smoking in patients with CKD
and KF [116-118].
In Saudi Arabia, different studies indicated that the prevalence of smoking among
female is lower than male. According to the SA national survey, a higher prevalence of
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smoking is among male with 62.2% while female 1.5% [119]. A screening study for CKD
risk factors conducted among 5000 Saudi found 1213 subjects smoke and all of them just
males [120].
A study done among 28 Saudi’s CKD patients, investigating CKD’s risk factors,
found 28.6% were smoking [45], also, in another study among 310 CKD patients
undergoing HD, 20.4% were cigarette smokers [121]. A study found, among 54670, type
2 diabetic patients, that smoking was prevalent among 10.9% of diabetic kidney disease
and 13.9% of KF [73].
Inflammation:
Inflammation is a risk factor of CKD and KF; also, HD patients have a great risk
for inflammation from dialysis and dialysis risk factors. Also, inflammation increases the
risk of mortality due to cardiovascular disease (CVD) and protein-energy wasting (PEW).
It damages the organs and blood vessels and is characterized by the production of
proinflammatory cytokines like interleukins which lead to production of C - reactive
protein (CRP). [122-125].
A study done among 120 Saudi HD patients reported that inflammation was the
cause of chronic kidney failure with a prevalence of 16% [126].
Cardiovascular disease (CVD):
Many studies showed a tight association between CKD and CVD; also, CKD is an
independent risk factor for developing CVD morbidity and mortality. The mortality due to
CVD among CKD is much higher than the risk of requiring RRT [117, 127-129]. On the
other hand, CVD is the leading cause of mortality among HD patients. CVD risk factors
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can be divided into traditional and non-traditional risk factors. Among CKD, traditional risk
factors include age, diabetes mellitus (DM), hypertension (HTN), dyslipidemia, and low
high-density lipoprotein cholesterol (HDL-C). Non-traditional risk factors include
malnutrition, oxidative stress and inflammation [127, 130-133]. CVD events and mortality
include left-ventricular hypertrophy, coronary heart disease, fatal cardiovascular disease,
non-fatal myocardial infarction, stroke, and heart failure.
CVD is associated with malnutrition, oxidative stress and inflammation among HD
patients [134, 135]. Moreover, adequate nutrition and healthy food intake (especially
carbohydrate and fat) could reduce the CVD risk factors by impacting the clinical outcomes,
mortality rate, and hospitalization rate [133, 136-139].
In SA, a community-based survey examined the prevalence of CVD among CKD
patients. Showed among 2700 patients, 27% had congestive heart failure (CHF), 52% had
a heart attack, 41% had a stroke and 58% identified with peripheral vascular disease (PVD)
[140]. Another study investigated CKD risk factors, found among 5000 Saudi, 64 cases
identified with stroke, 98 cases of heart attack, and 37 cases with chronic heart failure
[120].
Dyslipidemia:
Dyslipidemia could be a consequence of CKD and a factor of its progression, also,
is a major cause of CVD and can increase the risk of CVD mortality [141-143]. It is defined
as an impairment in the regulation of lipids and lipoproteins and its pattern is different
between all CKD stages [144]. CKD patients have a high level of triglyceride (TG), TC,
ILDL-C, low-density lipoprotein (LDL-C), Apo C and VLDL-C, and low level of HDL-C
and Apo A1 [145]. Among KF undergoing HD, dyslipidemia is characterized by a decrease
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in HDL-C and an increase in TG with normal and/or low LDL-C and TC [142]. Although
numerous studies have shown that serum LDL-C and HDL-C affect dyslipidemia, recent
studies are focusing on their subfractions because they have a different effect on health. A
study done on both healthy and KF populations found that small HDL subfraction is more
predominant in healthy population while large HDL in KF group and they suggested that
this shift among KF could increase CVD risk [146]. Focusing on the type of food intake
could explain some changes in lipid and lipoprotein subfractions too. Various studies
suggest that food intake such as fat and carbohydrate could impact circulating blood lipid
level and lipoprotein subfractions and the risks of CVD and mortality [133, 139, 147, 148].
In a study, adjusted for the adult misreporting energy intake, they assessed the relationship
between the intake of low nutritive value foods (foods high in fat, saturated, trans, sodium,
sugar, and sugar beverages) and cardiometabolic risks factors like lipid profile. They found
that the consumption of these type of food increases the serum level of TC, non-HDL-C,
TG and TC/HDL-C ratio [149]. Among the Saudi population where the prevalence of
dyslipidemia is high, a study found that their pattern of food intake was characterized by
high fat intake, sugar and sweeteners [150, 151]. Another Saudi study looked at the pattern
of food intake during R using a questionnaire and found high consumption of fat and
carbohydrates [152].
Among Saudi KF undergoing HD and PD, a study investigated the change in lipid
profile among 174 male and 206 female and among the two types of dialysis (338 HD and
42 CAPD) found the female has higher levels of TC, TG, HDL-C, LDL-C and PD had
worse levels of TC and LDL-C compared to HD. Also, when they evaluated the change in
lipid profile between the first five years of RRT and after the five years in both group
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together found no change in TC, TG, HDL-C, LDL-C [153]. In another study, 21 HD
patients, there were significant low levels in TC and LDL-C at 6,9,12 months when
compared to baseline [154].
HD – related health problems:
Early mortality:
Although HD is life-sustaining therapy, the mortality rate is high and nine times
higher than individuals in the general population [4]. This could be a result of an increase
in dialysis vintage which can increase mortality risk to 6%, hyperkalemia, CVD which is
responsible for 50% of death, and infection[155] [156-158].
Moreover, the first year of initiation of dialysis is considered a critical period; the
mortality rate among HD patients is higher in the first few months of initiation dialysis from
8% to 16% [4, 159-162]. The leading cause of mortality is CVD with a prevalence of 46%
in the first 6 months. Also, it could be due to infection 18%, malignancy 7%, dialysis
withdrawal 4%, and other reasons 25% [162]. In China as an example, a study investigated
the incidence of early mortality, found the mortality rate is higher in the first sixty days of
initiation of HD with a rate of 42% especially in old, female, diabetic and hypertensive HD
patients [163]. On the other hand, no report exists about early mortality in SA.
Malnutrition before initiation of dialysis is a factor that can increase the risks of
mortality after dialysis initiation [164].
Malnutrition:
Although HD is considered a life-sustaining therapy, dietary management by
limiting certain nutrients such as potassium, sodium and phosphorus is essential to slow
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disease progression and to reduce the accumulation of metabolic waste products in the
blood and risks of comorbidities (such as proteinuria and hypertension) and mortality [14,
165, 166]. Moreover, ensuring the adequacy of protein (1.2g/kg/day) and energy intake (3035kcal/kg/day) is necessary for HD patients to achieve neutral nitrogen balance [167, 168]
and to maintain protein lost in the dialysate during dialysis and/ or in catabolic processes
[169, 170]. Therefore, following healthy dietary patterns is correlated with a lower risk of
CKD and all-cause death among CKD subjects [171].
In addition to HD nutrition, poor nutritional status is prevalent among HD patients
and many factors play a role such as inadequate food intake, impaired ability to prepare or
to digest food, and dislike for the prescribed diet. While malnutrition is related to increased
risk of morbidity, mortality and poor quality of life [172, 173]; treating poor nutritional
status can improve HD health status and reduce morbidity [174].
Moreover, one of the adverse outcome of KF and HD associate with morbidity and
mortality is protein-energy wasting (PEW) syndrome [175, 176] and it is also a form of
malnutrition. PEW prevalence is varied from 28 to 52% among HD patients [177]. It results
from the breakdown of muscle protein, reduced food intake, nutrients loss during dialysis
and inflammation [11]. Criteria used to define PEW were not consistent among studies. One
of them as an example, diagnose PEW by coordinate the use of the International Society of
Renal Nutrition and Metabolism (ISRNM) panel (body mass, muscle mass, biochemical
markers, and dietary intake) [178]. Others like subjective global assessment (SGA), serum
albumin or BMI levels.
To the best of our knowledge, in Saudi Arabia, no study assessed the food intake
for chronic kidney disease; however, there are a few studies conducted among the HD
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population. A study aimed to assess the nutritional status of 40 HD patients, found the
intake is less than the recommendation from the calories and protein. 32.5% of the patients
had a mid-arm muscle circumference (MAMC), less than the 5th percentile, respectively.
Biochemical assessment among the studied patients shows that 20.0% had protein <64 g/L,
and 72.5% with albumin <40 g/L, which they indicate for PEW [179]. A cross-sectional
study recruited 269 HD, of whom 146 identified as moderately to severely malnourished
depending on albumin, BMI, and MAMC [5]. Another cross-sectional study of 120 KF
patients undergoing HD showed 6.7% had moderate malnutrition with 17.19±1.80 BMI,
136.75±2.61 TC and 35.07±4.06 albumin while 14.1% had mild malnutrition with 19.59
± 1.44 BMI, 136 ± 3.60 TC and 35 ± 3.20 albumin [126]. Also, a cross-sectional study for
200 HD patients used SGA to identify PEW, classified HD patients into 68% normal, 24%,
mild to moderately malnourished and 8% severely malnutrition. Moreover, 4% of the
patients were found to be underweight, 27.5% were overweight, followed by obese and
morbid obesity 14% and 5.5% respectively [10].
Additionally, CKD and KF patients are presented with comorbidities like diabetes,
hypertension, cardiovascular disease risk, therefore, routinely assessing the nutritional
status is mandatory to diagnose and treat these patients [180]. In fact, the clinical symptoms
are hard to detect in the early stage of malnutrition [181, 182]. Therefore, various methods
to determine malnutrition can be used such as assessing their body weight, body mass index
(BMI), skinfold thickness, muscle arm circumference, serum albumin, lipid profile, and
malnutrition inflammation score (MIS) [7, 183-185]. Also, assessing dietary intake is
essential to determine nutritional status and to improve nutritional interventions and health.
Therefore, it is essential to identify under- and over-reporting (misreporting) energy intake
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to avoid bias and misleading interpretation of nutritional risk and diet- health associations
[186, 187].
Fluid and electrolyte disturbances
Hyperkalemia is when kidneys no longer can remove excess potassium in the blood
and results in potassium retention. It is common among KF patients and is life-threatening.
Also, hyperkalemia can cause serious cardiac consequences. Hemodialysis helps to remove
potassium from the body; however, between dialysis sessions potassium, accumulate in the
body and hyperkalemia could occur, in this case, it is recommended to restrict the intake
of potassium to reduce the risk of mortality [188-190].
Another risk of mortality among HD is fluid overload or hypervolemia, and it is
when the body builds up extra fluid, especially between dialysis sessions. It can raise blood
pressure, swelling, shortness of breath or heart problems. Therefore, it is essential to
manage the amount of fluid intake [191-195].
In SA, a study investigated the cause of morbidity and mortality among 110 dialysis
patients found 3.7% hospitalized due to fluid and electrolyte disturbances [196]. Another
study done among 32 HD during Ramadan month, found hyperkalemia developed in 25%
of the patients and 37% developed hypervolemia [197].
Ramadan month:
Ramadan (R) is the ninth month in the lunar calendar. During this month Muslims
abstain from food, fluid, tobacco, medication, and sexual activities during the daylight from
dawn to sunset throughout 29 or 30 consecutive days. The duration of Ramadan fasting
varies from 10 to 18 hours or more according to the year's season and geographic location.
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R every year moves 11 days back which means R can occur in any season; so, the fasting
duration is longer in summer than in winter, particularly for Muslims who are far from the
tropics and equator. [16, 198]. During R, there is a restriction in eating time but not in type
and amount of food. Eating in a short span, during the night, could affect the pattern of
sleeping and eating [199, 200]. It can results in a delay in bedtime due to the increase of
the body temperature after eating [201] and less meal frequent [202]. Also, the other
significant change during R is a delay in the wake-up time especially in some countries
like SA due to the delay in starting school and work, having a large meal just before sunset,
and change in physical activity level during the day and night. Those changes could also
affect non-fasting groups who live in the same Islamic country. [17, 27, 203-206].
Lifestyle in Ramadan month:
The lifestyle in this month in some countries like SA is disturbed. Not only delay
in bedtime occur but also the duration of night sleeping because it is delegated to eat food
in the late night before start fasting again [201, 207]. Moreover, the activity of malls
increased until late at night and families gathering until late at night; and both of them can
cause a delay in circadian rhythms [22, 23].
In some Islamic countries during Ramadan not allowed to eat, drink or smoke in
the street, also, the restaurants are open during the day and night in which the rest of the
year the restaurant do not open all night.
Moreover, the physical activity level is different between male and female during
Ramadan. Male more likely to sleep more during the daylight than the female who assessed
in food preparation and other household work [200]. Also, it differs between the day and

19
night because people perforce more praying (Traweeh) during the night. Moreover, some
studies found a reduction in activity level during Ramadan. While others reported no
change in activity when compared between R and other time points [208, 209].
Furthermore, a study found no change in resting metabolic rate (RMR) and total energy
expenditure (TEE), but there was a reduction in activity [210].
Food habit in Ramadan month:
In this most special occasion of the year, the type and amount of food intake during
the nights of Ramadan in some culture different from the rest of the year. Some cultures
like to consume in festival season food that rich in fat and protein or fat and carbohydrate
or high in sugar [152, 198, 211-214]. While in other countries, reduction in intake and
calories can occur [202, 215, 216] and in other no change at all [214, 217].
After Sunset, Muslims break their fasting with breakfast (called Iftar) starting with
dates and water or any drink like sugary drinks, coffee, milk, or yogurt drink, then it is
common to eat one snack followed with dinner (called Sohor) before dawn [20]. Also,
cultures are different in the preference intake quantity. In some cultures, Muslims like to
consume heavy Iftar and light Sohor [212, 218-220]. Interestingly, In SA, Sohor was the
heaviest and they consume five meals. Also, they like to break their fasting with dates
followed by soup and samosa (filled with cheese or meat), and they like to eat Sohor cooked
vegetables, salad and rice with any type of meat. Also, they like to eat sweet and drink
coffee in snack time [152]. While in Egypt, they break their fasting with dates, green salad,
samosa (filled with cheese or meat), stuffed vegetables, kabab, and rice and in Sohor, they
like to eat beans (ful medammes), eggs, cheese, and bread. Also, they like to drink milk in
snack time. On the other hand, in Bangladesh, people like to break their fasting with
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seasonal fruits (like mango, guava and jackfruit), rice, meat or fish, lentils and potato cakes
and they like to eat in Sohor chapatti and lentil soup. Also, they like to drink lassi in snack
time [221]. Furthermore, in some countries like the United Arab Emirates during Ramadan,
the intake of fresh vegetables is less than the other season and less than the
recommendation; on the thither hand, the cooked vegetables is higher. Moreover, the intake
of fruit is less and comes from dates and juice. Milk and milk products also are less during
R [214].
There is, however, only one study that examines dietary pattern during Ramadan in
Iran, they found four patterns high cholesterol and sweet junk food pattern, western-like
pattern, and Mediterranean –like pattern; and the fourth unique pattern was Ramadan- style
pattern [28].
Regards the intake of energy and macronutrients, many studies evaluated the effect
of R on energy and macronutrients. Studies from Tunisia [211, 222] and Singapore [217]
found an increase in fat intake. Another study from United Arab Emirates [214], found a
decrease in protein and an increase in fat. In addition, a study from SA found an increase
in protein, carbohydrate and fat [204]. While studies from Malaysia found no change in
protein and decrease in carbohydrate and fat [223, 224].
On the other hand, studies showed during R the intake of water is less than their
need and this could affect the kidney function badly [225, 226]. Therefore, during the nonfasting time, it is essential to be aware of the hydration levels, especially for CKD patients.
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Ramadan and health:
During Ramadan, several physiological changes occur supported by several review
studies on healthy people which showed Ramadan has positive and negative effects. A
systematic review and meta-analysis studies showed in people there was a reduction in
body weight and fat, LDL-C, TC, and TG and improvement in HDL-C levels, during R
[208, 227, 228]. Moreover, the inflammatory markers levels (for example, C- reactive
protein, interleukin-6 and homocysteine) could decrease [229].

However, headaches,

heartburn, constipation, dehydration, and decreased sleep quality are considered as adverse
effect of R [230]. [231] Also During Ramadan fasting, serum levels of metabolites
including uric acid, urea, and creatinine have been showed to be regular or slightly
elevated. [232].
Sick people and Ramadan:
Children, pregnant, lactating, sick people are exempted from fasting, but many sick
people do still choose to observe the fast. Studies found that transplant kidney patients with
normal function can fast safely during Ramadan [233, 234].
Many CKD and KF Muslims are keen to fast during Ramadan. The alteration in
lifestyle, food intake (for example, frequency, mealtime, and type of food) and sleeping
pattern during Ramadan could impact the nutrition and health status like body homeostasis
and metabolism, especially for CKD and KF.
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The hypothesis and rationale for the study
As Ramadan is associated with changes in temporary dietary habits, the central
hypothesis was that these changes would not produce adverse health outcomes in HD
patients.
The objective of this PhD proposal was to document nutritional changes before,
during and after Ramadan on biochemical and health parameters in HD patients.
The rationale for this research is ultimately to provide HD patients with a user-friendly
nutrition resource to allow them to choose more effectively during the Ramadan festival.
Hence, the following specific aims were pursued:
Specific Aims
Specific aim 1a: To determine the impact of Ramadan month on CKD and HD
patients. This was evaluated by:
1) Reviewing the studies regarding the impact of Ramadan month on CKD and
hemodialysis patients.
2) Evaluating the impact on anthropometric, renal and biochemical profiles among
hemodialysis patients.
Specific aim 2: To evaluate the food intake and to identify Acceptable-Reporters (AR).
Also, to document the changes in renal, lipid and anthropometric profile for these AR. This
was be evaluated by:
1) Identifying the AR of energy intake during study period especially during Ramadan
and describing the changes in the intake in AR.
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2) Describing the changes of anthropometric and biochemical profiles in the
acceptable- reporters and implausible reporters during the study period.
Specific aim 3: To assess the prevalence of protein-energy wasting among HD patients
and document the changes in the food intake during the study period.
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Tables and Figures
Table 1-1 Classification of Chronic Kidney Disease based on GFR and albuminuria
categories according to KDIGO (Kidney International Organization, 2013) [40]:
Persistent albuminuria categories
Description and range

GFR categories
(ml/min/ 1.73 m2)
Description and range

G1
G2

G3a

G3b

A1

A2

A3

Normal to
mildly
increased

Moderately
increased

Severely
increased

< 30 mg/g
< 3 mg/mmol

30-300 mg/g
3-30 mg/mmol

> 300 mg/g
> 30 mg/mmol

moderately
increased risk
moderately
increased risk

Normal or high

≥ 90

Low risk

Mildly decreased

60–89

Low risk

45–59

moderately
increased risk

high risk

very high risk

30–44

high risk

very high risk

very high risk

Mildly to moderately
decreased
Moderately to severely
decreased

high risk
high risk

G4

Severely decreased

15–29

very high risk

very high risk

very high risk

G5

Kidney failure

<15

very high risk

very high risk

very high risk
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CHAPTER 2: REVIEW OF LITERATURE
CKD and HD during Ramadan:
Many CKD and KF Muslims are keen to fast during Ramadan. Some of HD patients
practice fasting on only non-dialysis day because they consider the IV fluid intake during
the dialysis break the fast since they are contrary to fasting. In contrast, others consider
dialysis is deemed permissible.
The alteration in lifestyle, food intake (for example, frequency, mealtime, and type
of food) and sleeping pattern during R could impact the nutrition and health status,
especially for CKD and KF.
Different studies found a correlation between food intake and CVD [133, 235, 236].
A study among CKD were followed for major adverse cardiovascular events (MACE)
reported that the risk of MACE is higher during Ramadan with pre-existing cardiovascular
disease especially among the fasting group [237]. Moreover, feeling thirsty during the day
in Ramadan has to be ignored; however, hydration is considered as a major problem for
HD. Also, a study done on HD patients to investigate the impact of R on mortality found a
higher mortality rate than other months during the year [238].
Studies on the effect of R on patients with CKD or HD health were summarized in
(Table 2-1 and Table 2-2). In general, different results were observed: some found no
changes, others did find changes but no adverse effect, and while others found adverse
effects happened. However, there is insufficient evidence on the change in kidney function
and to conclude that R has an adverse effect on CKD patients. In fact, these studies are
mixed, controversial, and not comprehensive. The variance in the results is probably
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attributed to several confounding variables that can lead to variability in results and may
not reflect the actual effects like ethnicity and cultural factors (like food practices), CKD
stages, age of the participants, the weather during R (cold or hot), and physical activity.
Moreover, there are differences between studies length and fasting duration that investigate
the effect of R on HD patients. Some included subjects who fasted the full month, some
any number of fasting days, and others who fasted 80%–100%. It is difficult to determine
obtaining an exact measure on the latter since it is a subject that is culturally sensitive.
Individuals who do not participate either in part or for the full month in the practice of the
fasting may be reluctant to reveal this information. There are some inconsistencies about
the methods used to get blood samples throughout the studies of the patient. To study the
effect of fasting, the blood sample has to be taken in the evening before breaking fasting.
There are differences exist between countries and cultures in food intake (quantity and
quality) during this month. Therefore, studying the food intake and pattern of food intake
help to understand some of the changes in the health and nutritional status among those
patients who have to be aware of their intake. However, the studies in these areas are few
and not enough to conclude and most of them do not have a control group.
Until we have a study that considers these factors, CKD and HD patients who opt
to fast have to be advised before R start about diet and medication plan; also, during and
after R should be followed up, checked and assessed of their body weight, blood pressure,
food intake, biochemical parameters especially fluid and electrolytes during R. Also, CKD
has to be aware of dehydration and worsening of renal function while HD patients have to
be aware of fluid overload hyperphosphatemia and hyperkalemia. Moreover, limit the
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intake of sodium, potassium, and phosphorus (such as dates, apricots, fried foods, nuts,
cheese, and, tea, and coffee)[239].
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Tables and Figures

El-Wakil, et al., 2007, Egypt
[241]

Bernieh, et al. 2010, UAE [240]

Reference

Table 2-1 CKD and fasting Ramadan:

Subjects

31 CKD (54 ± 14 y)
Out of them:
• CKD stages:
o III: 14
o IV: 12
o V: 5
• Gender:
o Male: 19
o Female: 12
• Cause of CKD:
o DM: 61%
• HTN: 71%
• hyperlipidemia:
26%

Sampling time

1 month pre-R,
last week in R
and 1-month
post-R
12h fasting

6 healthy subjects (48
± 3 y)
15 CKD pts (53 ± 16 y)
• Cause of CKD
Pre- and during
o DM: 21.4%
R.
o HTN:
21.4%

Materials

Wt, systolic and
diastolic BP,
renal and lipid
profile, BG,
HbA1C,
hemoglobin,
protein, and
osmolality.

BUN, serum
creatinine,
electrolytes,
albumin, and BG.
lipid profile. 24 h
urine protein
excretion, and Nacetyl-Dglucosaminidase
(NAG). GFR

Main finding

No adverse complication during
fasting.
Statistically, changes but not
clinically significant was
observed.
• Statistically increase in
o eGFR
o HDL-C
• Statistically significant
reduction in
o HbA1C
o LDL-C

Between the 2 groups: no
differences in the change of
GFR but in CKD group found a
significant increase in the
percentage change of urinary
NAG (tubular cell injury
biomarker).

Al Muhanna. 1998, Saudi
Arabia [243]

Mbarki, et al., 2015, Morocco [242]
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60 CKD patients (46 ±
16 y):
• Gender:
o Female: 35
o Male:25
• Divided the
subjects depend on
o Creatinine
clearance
Group 1: >60
mL/min
(n=29)
Group 2: 30–
59 mL/ min
(n=26)
Group 3: 15–
29 mL/min
(n=5)
o Occurrence or
not of acute
renal failure
(ARF)
With ARF
Without ARF
36 CKD (39 ± 5 Y)
• Moderate to severe
CKD
• Gender
o Male: 18
o Female: 18

Arterial pressure,
Pre-R, and first daily urine
and last week of volume, wt and
R
creatinine
clearance

During R and 2
weeks after.

11.7% of the fasted during R
developed ARF
In the first week of R: 3
participants developed ARF
at the end week of R: 4
participants developed ARF

Statistically significant increase
in:
serum creatinine, BUN, CCT
Serum Creatinine, and Uric Acid during R
BUN, Uric Acid
These changes persisted to post
and Creatinine
R.
clearance (CCT)
There was the development of
fluid accumulation, lower
edema, wt gain, uncontrolled
BP.

Kara, et al. 2017,
Turkey [245]

Bakhit , et al. ,2017,
Saudi Arabia [244]

NasrAllah & Osman, 2014, Egypt [237]

30
Pre-R (within
the 5 days pre106 CKD stage 3-5
R),
(stable serum creatinine During-R (after
for 3 months before R) a week of R),
• Groups:
and
RF: 52 (58 ± 12 y)
Post-R (within 5
NRF: 54 (61 ± 15 y)
days after R)
• Cause of CKD:
But serum
o RF: 40.4%
Creatinine was
DM and
collected Pre-R
13.4% HTN
(within the 5
o NRF: 29.6%
DM and 22% days pre-R),
during-R
HTN.
(within 5 days
• Baseline eGFR:
o RF: 27.7± 13 after R), and
after (after 3
and
months of R)
o NRF:
21.5±11.8
mL/min/ 1.73 Sampling time
during R: after
m2.
2-4 h after
breakfast
65 CKD (53±15 y)
3 months pre-R,
stage ≥3.
during-R: (after
10 days), post-R
• Gender:
(3 months after
o Male: 40
R)
o Female: 25
15 h fasting/day
94 CKD (65 ± 11 y)
stage ≥3.
• Gender:
o Male: 56
o Female: 38
• Groups:
o RF: 45
o NRF: 49

1 month pre-and
post- R.
17.5 h fasting/
day

eGFR, serum
creatinine, the
occurrence of
adverse
cardiovascular
events (MACE).

Wt, SBP, BDP,
serum urea,
electrolyte,
creatinine,
glucose, HbA1C,
uric acid
hemoglobin, and
a lipid profile.
Wt, SBP, DBP,
serum,
electrolyte, urea,
uric acid,
creatinine, and
renal and lipid
profile.
eGFR.

More than half of the pts
had increased in serum
creatinine during R.
The increase in creatinine
was associated with intake
of renin-angiotensin
aldosterone system
antagonists (RAAS
blockers) and diuretics.
MACE occurred in 6 pts in
RF group (5 of the 6 had
preexisting CVD)
After 3 months the serum
creatinine did not change in
23% RF group and in 35%
NTF group

worsening of renal function
was developed in 33% of
the pts

≥ 25% Decrease in eGFR
after Ramadan in both
group (15.5% RF group and
12.2% of NRF group).
The decrease in eGFR
occurred in older and who
were using diuretics.

Chowdhury, et
al., 2019 [247]

CKD stage 3 with DM
type 2
• Group:
o RF: 68
o NRF: 71

Al Wakeel, 2014, Saudi Arabia [197]

31 CKD stage 2,3and 4
• Gender:
o Male: RF: 17
and NRF: 14
o Female: RF: 14
and NRF: 12
• Groups:
o RF:31 (63 ± 9 y)
o NRF: 26 (64 ± 8
y)

39 CKD (52 ± 18 y):
• Stages
o Stage 2: 2.6%
o Stage 3: 41%
o Stage 4: 43.6%
o Stage 5: 12.8%
• Gender:
o Male: 23.1%
o Female:76.9%
• Comorbidities:
o HTN: 94.9%
o DM:35.9%
o Dyslipidemia:
56.4%
o Ischemic heart
disease: 30.8%

Dogan, et al.,
2019, Turkey
[248]

Hassan et al., 2018, Israel
[246]

31

CKD stage 3 and 4
o 24 RF (68 ± 13
y)
o 55 NRF (69 ± 9
y)

Pre-R (before R
one week),
during-R (last
week of R), and
post-R (4 weeks
post-R)

hydration status
(using BIS),
serum urea,
creatinine, and
plasma brain
natriuretic peptide
(BNP), eGFR

eGFR did not change
significantly
Reduction significantly in
hydration status and BNP
levels at the end of R but
the values return the
baseline levels.

18h fasting/ day

BP, BMI,
glycated
hemoglobin, urea
and electrolytes,
TC, and urine
protein creatinine
ratio [PCR]),

Median days fasted was 21
(12–29 days)
No major difference
between the two groups,
and no negative effect.

Serum creatinine,
Creatinine
clearance, eGFR,
SBP, DBP,

No significant change

Pre-R (1-week
pre-R), duringR (between 7th
and 1oth day,
between day 21
and day 24) and
post-R (3 to 4
weeks post-R)
14 h fasting/
day

Pre-R, the week
immediately
following the
end of the Ra,
and 3- and 6months post R

no statistically significant
difference in both groups

Balogu, et al., 2020Turkey[249]

32
CKD stage 2 and 3
• Divided the
subjects depend
on
o 90 RF (24-30d):
(43-70y)
o 27 RF (10-23d):
(56-70 y)
• Gender:
o Female:36
o Male: 81

During R only
every 10 days
(for AKI)
17h fasting/ day
Sampling time
during R: after
≥ 10h fasting
early morning

The occurrence of
acute kidney
injury (AKI),
whole blood,
serum creatinine,
electrolyte,
hemoglobin, uric
acid and BP.

AKI was developed in
27patients
• they fasted for a few
days
• Urea levels and
frequency of HTN were
higher.

Megahed et al., 2019, Egypt [30]

Al Wakeel, 2014, Saudi
Arabia [197]

Reference

Table 2-2 HD and Ramadan:

Subjects

Sampling time

32 HD (48 ± 17 y)
• Gender:
o Male: 53.1%
o Female: 46.9%
• Comorbidities:
o HTN: 75%
o Dyslipidemia: 34.4%
o DM:40%
o Ischemic heart
disease:15.6%
2055 HD
• Gender:
o Male: 57.1%%
o Female: 42.9%
• Groups:
o Fast nearly all
Ramadan’s day
(RF): 381 pts (50
±12 y)
o Fast non-dialysis
day (17 days or
less) (PRF): 584
pts (49 ±13 y)
o Non-Fasting (NRF):
1090 pts (54 ±13 y)

Pre-R (one-week
pre-R), during-R
(between (7th and
15th day in R and
on last day of R)

Dialysis sessions
in R were set
after sunset

Pre-R (before R
month)
And After-R (at
the end or post –
R) Collected
according to
availability
16 h fasting/day

33

Materials

Main finding

Kt/V, wt, SBP,
DBP,
electrolyte,
serum
creatinine, urea,
bone profile

There were a significant increase
in erythrocyte count, serum
creatinine, blood urea, serum
phosphorus, serum albumin, and
serum uric acid levels during R.
Hyperkalemia and hyponatremia
developed during and after R.
Also, there was the development
of hypertension fluid overload.

hemoglobin
(Hb), blood
urea, urea
reduction ratio
(URR),
serum albumin,
creatinine,
calcium,
phosphorus,
potassium, and
iron.

Serum albumin and phosphorus
creatinine increased after R in all
groups.
Intradialytic hypotension and
hypoglycemia was observed
more frequently in RF.
A significant reduction in both
Systolic and diastolic BP in both
the RF and NRF.
Fasting results in suppression of
insulin release

Khazneh et al., 2019, Palestine [31]
Al-Khader et
al., 1991 [143]
Wan Md Adnan , et
al., 2011, Malaysia
[250]
Imtiaz et al., 2016,
Pakistan [32]

320 HD
• Groups:
o RF: 31 (57 ±12 y)
Gender:
Female: 10
Male: 21
DM: 38.7%
HTN: 41.9%
o PRF: 102 (55 ±14 y)
Gender:
Female: 42
Male: 60
DM: 31.6%
HTN: 38.2%
o NF: 136 (59 ±13 y)
Gender:
Female: 66
Male: 70
DM: 58.1%
HTN: 43.4%

40 HD

35 HD (54 ± 11 y)
• Gender:
o Female: 19 (54%)
o Male: 16 (46%)
• Co-morbidities:
o DM: 17 (49%)
o HTN: 31 (89%)
o IHD: 7 (20%)

282 HD
• Group:
o PRF: 34 (52 ± 15 y)
o NRF: 252 (48 ± 15 y)

Inter-dialytic
weight gain
Pre-R (one-month
(IDWG), the
pre R), during-R
serum of
(during the
potassium,
second week of
phosphorus,
R) and Post-R (2
albumin,
weeks after R)
calcium,
sodium, blood
16 h of
urea nitrogen
fasting/day
(BUN), and
creatinine.

pre- and end
Ramadan
Wt, IDWG,
SBP, DBP
Renal, bone,
and lipid profile

Any number of
fasting days
Pre-R (2 weeks
pre-R) and
during-R (last
week of
Ramadan).
fast on a nondialysis day
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RFG and RPFG had a
significant increase in
mean serum potassium as
compared to RNFG.

Not clinically change.
Statistically significant increase
in the IDWG and serum
potassium.

Fasting on nondialysis day

14 h of
fasting/day

RFG and RPFG had
higher IDWG than
RNFG.
Diabetes was
independently associated
with increased IDWG.

Wt, BP, serum
potassium,
serum albumin,
and serum
phosphorus

Significant increase albumin and
decrease in serum phosphate
especially in non-diabetes
patients.

In both group: a Statistically
significant increase in serum
albumin.
In NRF: statistically reduction in
Phosphorus and DBP.

Alshamsi et al., 2016, Saudi Arabia [29]
Adanan et al., 2019, Malaysia [33]

635 HD
• Groups:
o RF: 64.1% (53 ± 16 y)
Gender:
Male: 52%
Female: 48%
DM: 51.6%
o NRF: 35.9% (58 ± 16
Pre-R (a month
y)
pre-R), during-R
Gender:
Male: 56.4%
Female: 43.6%
DM: 59.6%

87 HD (54 ± 12 y)
• Gender:
o Male: 48 (55.2%)
o Female:
39
(44.8%)
• Groups:
o RF ≥ 20 day: 68
o RF <20 day: 19

Pre-R (2 weeks
pre-R), during-R
(fourth week of
R), and post-R (4
weeks post-R)

35

Wt, BP, serum
potassium,
phosphorus,
albumin
12-14h
fasting/day

Anthropometry,
body
composition,
BP, HGS,
albumin, renal
and lipid
profile,
inflammatory
markers, and
Food intake.

Serum phosphorus was
significantly higher in the fasting
group compared to non-fasting
In non-fasting significantly
increase serum phosphorus.

Not clinically significant
Statistically, reduction in BMI,
IDWG, waist circumference,
mid-arm circumference, fat
tissue mass, and body fat
percentage.
Also, reduction in serum
phosphorus, albumin, urea, and
creatinine.
Increase in HGS.

CHAPTER 3: METHODOLOGY
This present chapter describes the methods that were used for this study. The chapter
begins by describing the study design, subjects, the time schedule of measurements,
assessments and assays conducted, then ends with describing the methods used to analyze
each of the research aims.

Study design:
This is a prospective cohort study that was carried out among hemodialysis patients
in an out-patient hemodialysis clinic of King Abdul Aziz University Hospital in Jeddah,
Kingdom of Saudi Arabia. It was conducted in the summer of 2017 where the Ramadan
month comprised of 29 days with an average dawn-dusk time period of about 10 hrs.

Study population:
The study included all patients (n=45) from an outpatient HD clinic who were KF
undergoing hemodialysis, ≥ 18 years of age, not pregnant and who had been on dialysis
treatment for three months at least. Research approval was obtained from the Biomedical
Ethics Research Committee, King Abdulaziz University Hospital, Saudi Arabia (IRB No.
263-17). Written informed consents were collected from all part for participation in the
study.
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Time schedule of measurements:
Data was collected every four weeks, (pre-Ramadan [T-1], during Ramadan [TR],
1 month-post Ramadan [T1] and 2 months post-Ramadan [T2]) (Error! Reference source
not found.). Food intake, blood samples and anthropometric measurements for T-1 were
not collected due to IRB approval obtaining.
Sociodemographic and clinical data
Sociodemographic and clinical data was obtained from either the medical records
or by directly asking the participants which included gender, age, education, income,
marital status, nationality, employment status, smoking, comorbidities, duration and
number of hemodialysis sessions/week, and the cause of kidney disease.
Also, pre-dialysis laboratory tests included renal profile (serum albumin, creatinine,
glucose, phosphorus, potassium, sodium, and corrected calcium and pre and post dialysis
Blood Urea Nitrogen (BUN)), serum random blood Glucose, Total Iron Binding Capacity
(TIBC), ferritin, and Kt/V were collected from patient’s medical record each month.
Anthropometric assessment
From the medical records, the pre and post dialysis weight (in kg) and height (in
cm) for each patient was obtained to calculate Body Mass Index (BMI), using the
Quetelet’s Index [251].
=

ℎ ( )

ℎ (

)

(Post dialysis weight is called dry body weight which is collected after removing
excess water and wastes.)
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Mid-Arm Circumference (MAC) and Triceps Skinfold thickness (TSF) were
measured after the dialysis session, in a standing position, using a non-elastic Lufkin®
metal measuring tape (Apex Tool Group, LLC, NC, USA) with Harpenden skinfold
calliper (HSK-BI, British Indicators, West Sussex, UK). The measurements of MAC and
TSF were based on the International Society for Advancement of Kinanthropometry
protocol. Then, Mid-Arm Muscle Circumference (MAMC) and corrected Mid-arm Muscle
Area (cAMA) were calculated based on the following equations [252].
MAMC (cm) = MAC (cm) – [( x TSF (cm)]
(

cAMA=

cAMA=

(

) ! " #$% (
(!

) ! " #$% (
(!

)&'
)&'

– 10 (men)

– 6.5 (women)

Handgrip strength (HGS), to assess muscle strength, was measured post-dialysis by
taking three readings from the non-fistula hand while the subjects were sitting using a
Jamar dynamometer (BK- 7498; Fred Sammons, Inc., Burr Ridge, IL) with at least 1 min
rest between each trial using the American Society of Hand Therapists standard protocol
[253]. The highest value recorded was used for assessment.
Malnutrition-inflammation score:
Malnutrition-inflammation score (MIS) questionnaire was administered for the
subjects during TR, T1 and T2. The MIS had ten components, and each had four levels of
severity ranging from 0 (normal) to 3 (very severe) [254]. The sum of all the components
was added, which could range from 0 to 30. A higher total score indicated a more severe
degree of malnutrition and inflammation.
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Blood sampling and lipid measurements:
Non-fasting pre-dialysis blood samples (10 mL) were collected monthly into tubes
containing either Ethylenediaminetetraacetic acid (EDTA) and Lithium Heparin (LH)
[255]. Plasma samples were isolated by centrifugation at 3500 rpm for 10 minutes, and
aliquots were immediately stored at -80oC. Ten months later, they were shipped frozen to
Wayne State University for further analysis. Total Cholesterol (TC) and Triglyceride (TG)
were measured using enzymatic assays (Point Scientific Inc, Canton, MI, USA) as per
manufacturer’s protocol. The concentration of each sample was calculated using the
following formula:
mg
)*
Concentration 5 : =
dL
)+

; <; =>
; <; =>

=

<

× > => = <

=

=

<

High-Density Lipoprotein Cholesterol (HDL-C) was measured in the supernatant
fraction of the plasma and assayed using an enzymatic method (Point Scientific Inc,
Canton, MI, USA) as per manufacturer’s protocol. The following formula of the
concentration of each sample was calculated:
@A Concentration (mg/dL)
=

; <; =>
; <; =>

=

<
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=

=
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Low-Density Lipoprotein Cholesterol (LDL-C) was calculated using Friedewald
equation [256]:
LDL − C = TC − HDL − C − (
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TG
)
5

HDL and LDL Lipoprotein subfractions were analyzed in plasma with the use of
polyacrylamide gel electrophoresis technique - LipoprintTM system (Quantimetrix
Corporation, Redondo Beach, CA, USA). Briefly, 25 μL of the sample and 300 μL of HDL
loading gel or 200 μL of 300 μL of HDL loading gel were added to its (HDL or LDL) gel
tube and mixed. After photopolymerization them for 30 min, the tubes were
electrophoresed for 65 min for HDL and 50 min for LDL. After completion of
electrophoresis, the gel tubes were allowed to rest for 30 min. Following, the subfractions
were quantitated using the computerized method developed for the Quantimetrix
Lipoprint®system). The measurements provide information for all LDL and HDL
subfractions (Figure 3-2 and Figure 3-3).
Food intake assessment:
Food intake was collected using one 24-hour dietary recall on a non-dialysis day
during TR and three 24-hour dietary recalls (1 dialysis day, 1 non-dialysis day and 1
weekend day) for T1 and T2 using standard household utensils. This information of the
intake was transformed into grams and, to be analyzed using the Food Processor Software
(version 11.2.274, ESHA Research, Salem, OR) to get the nutritional information for
energy, macronutrients, potassium, and phosphorus. For mixed dishes that were not in the
Food Processor Program, we had to come up with recipe construction for each one of them.
For example, people had samosa but with different fillings and preparation—baked or
fried. We took three recipes from different sources and showed their common ingredients
to determine a recipe. Then the nutritional information, such as calories and
macronutrients, was verified by searching various food database websites and comparing
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them. The last data for each individual ingredient was entered in the recipe builder within
the Food Processor Software to get the nutritional analysis.
Total energy expenditure (TEE):
The TEE was estimated by multiplying the basal metabolic rate (BMR) by a
Physical Activity Level (PAL). First, BMR was calculated using Harris and Benedict
equation [257] which depends on body weight, height and age. For the body weight (BW),
when the standard bodyweight was between 95% and 115% we used the actual dry body
weight and when it is less than 95% or more than 115% the adjusted edema-free body
weight was used as recommended by NKF/KDOQI [258]. The equation for adjusted
edema-free body weight is:
Adjusted edema free body weight

= Actual dry BW + (Actual dry BW − Standard BW) × 25

To calculate the standard bodyweight, since we did not measure the frame size, we
assumed a medium frame area and used NutriCare application to calculate it.
We did not determine the PAL for each patient, therefore, used 1.35 which is the lowest
PAL associated with bodyweight maintenance for our calculations [259, 260].
To calculate the intake of energy, protein and phosphorus per kilogram of body
weight, we used the ideal body weight, calculated using BMI 23 (kg/m2) as an indicator
for nutritional status [259, 261].
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Acceptable and under-reporting of energy intake:
Since we did not collect information about patients physical activity level, the
implausible -reporting (IR) of energy intake (EI) was assessed using McCrory method
updated by Huang et al [262, 263] according to the following equation:
+\
±1Z@ = [

]

+ +\

)]] + ^+\

)]]

Where the coefficient of variation (CV) calculated by SD/mean, CVwEI is CV
within sample-specific in energy intake reporting over the number of reporting food intake
days (d), CVwpTEE is the CV measuring the TEE by the doubly labelled water method,
and CVpTEE is the CV of predicting the TEE. In our study, the CVwEI for R was 42%
estimated based on 1-day of the food recall, for 1- month post R was 45% estimated based
on 3-days of the food recall, and for 2- month post R was 66% estimated based on 3-days
of the food recall and CVwpTEE was 8.2% as previously reported in the literature [260,
263]. Also, CVpTEE was 18% as estimated from predicted equations of TEE which are
described above.
Misreporting was estimated based on a cutoff of ±1 SD for reported energy intake
(EI) and predicted TEE (TEE). In this present study, the ±1 SD cutoffs for the agreement
between EI and TEE was ± 0.47 in R, ±0.33 in 1- month post R, and ±0.43 in 2- month
post R. So, in each time point the participants grouped based on average of EI and TEE;
Thus, in our study, the acceptable-reporters range (%EI: TEE) was 53 – 147% in R, 67 –
133% in 1- month post R, and 57 – 143% in 2- month post-R. Furthermore, subjects with
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calculated values of the ratio EI: TEE <-1SD were classified as UR and subjects with
computed values of the ratio EI: TEE >+1SD were classified as OR.
Diagnosis of Protein- Energy Wasting (PEW):
Subjects with protein-energy wasting were identified according to the International
Society of Renal Nutrition and Metabolism (ISRNM) [178]. So, patients who meet at least
three of four different categories (and at least one criteria in each category) were identified
as PEW patients. The 4 categories that we selected consist of: (1) biochemical assessment:
serum albumin <3.8 g/dL and TC <100 mg/dL (from T2); (2) body mass: weight loss >5%
for 3 months (calculated from TR, T1 and T2) and BMI <23 kg/m2 (from T2); (3) muscle
mass: reduction >10% in MAMC in relation to 50th percentile of reference population
(from T2); and (4) dietary intake: energy intake for 2 months <25kcal/kg of body weight
and protein intake for 2 months <0.8 g/kg of body weight (calculated from T1 and T2). In
order to enhance the reliability of dietary intake, we exclude any food recall that has a ratio
of energy intake and TEE from analysis (<0.53 or > 0.147 in TR, <0.67 or > 0.133 in T1,
and < 0.57 or > 0.143 in T2) then the energy intake was averaged in each time point.
Statistical analysis:
SPSS software was used to analyze our data (Version 24, SPSS Inc, Chicago,
Illinois, USA). Means and standard deviations (SD) were calculated for continuous
variables and frequencies and percentages for categorical variables. An intention-to-treat
(ITT) protocol was used to analyze, whereby missing values were imputed as the last
known values. For our study, the generalized estimated equation procedure (GEE) was
used. GEE allows for robust standard error or sandwich estimates and is useful even if the
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correlation between the outcomes is not known. Also, to locate differences of interest
between PEW and non-PEW groups independent t-test was used in parametric data and
Mann–Whitney test was used for nonparametric variables. A p-< 0.05 is statistically
significant.
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Tables and Figures

Figure 3-1 Study Flow:
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Figure 3-2 HDL Subfractions profile [264]
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Figure 3-3 LDL subfractions profile [265]
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CHAPTER 4: RESULTS
The following chapter presents the results of this study. It is organized into three
sections: first, the demographic characteristics of the participants and changes in the
anthropometric and biochemical profiles during the study time; second, the food intake and
the effects of its interaction on the anthropometric and biochemical profile by consulting
both the acceptable- and implausible- reporters of energy; third, the prevalence of PEW
among the subjects and the changes in the food intake during the study period.
Results of Aim 1:
To evaluate the effect of Ramadan month on anthropometric and biochemical
profiles among HD patients. This part of the work has been published (Tashkandi et al.,
2019).
To analyze this aim, we first described the demographic and clinical characteristics
of the study samples followed by the changes in the anthropometric and biochemical
profiles during the study period. A Generalized Estimated Equation (GEE) was used to
assess the changes during the study times and significance at p<0.05.
The characteristics of demographics and clinical of the subjects are depicted in
(Table 4-1 and Table 4-2) Our study population consisted of 49% males and 51% females
with ages ranging from 33 to 67 years old. More than half of the subjects (60%) were
identified as non-Saudi and included nine different nationalities. Moreover, out of 45 HD
patients, 69% were married, 36% had a college education, 31% had no formal education,
80% identified themselves as not employed, 47% lived in homes with 3 – 5 individuals,
and 27% lived with more than five individuals. Almost all subjects (98%) were dialyzed
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three days/week, and the average dialysis session duration was 3.2, hours with an average
dialysis vintage of ~6.5 years. 51%, 40%, and 9% and were dialyzed with fistulas,
catheters, and grafts, respectively. The causes of kidney failure were hypertension (49%),
diabetes (27%), systemic lupus erythematosus (7%) and other causes (17%).
The changes of biochemical profiles over the study period, T-1 (pre-Ramadan), TR
(Ramadan), T1 (1-month post-Ramadan), and T2 (2-months post-Ramadan) are presented
in (Table 4-3). During the study period, Kt/V, calcium, ferritin, and phosphorus did not
show any significant differences. However, random glucose levels during T1 were
transiently increased when compared with T2 and vitamin D levels during TR compared
to T-1. In addition, variability between time points was noted in serum albumin, potassium,
TIBC, pre-BUN, post-BUN, creatinine, and sodium. However, these changes are not
clinically significant.
Plasma lipid concentrations and ratio during the study period are shown in (Table
4-4) and (Figure 4-1) (samples in T-1 were not available for analysis). During TR, we
observed significantly lower levels for TC, HDL-C, and LDL- C compared with T2, but
they were not significant for TG. However, T1 had a low TG level compared to T2.
Concurrently, the above changes between TR and T2 have been linked to significantly
lower levels in the TC / HDL-C and LDL-C / HDL-C values during R with no significant
differences in the value of TG/HDL-C.
The changes in lipoprotein particle size distribution are shown in (Table 4-5) and
(Figure 4-2). Based on the absolute values for cholesterol carried in HDL and LDL
subfractions, the HDL values were significantly higher in T2 than in TR (s-HDL 4.9±2.4
vs 4.2±2.0 mg/dL, i-HDL 21.3±6.7 vs 19.7±4.4 mg/dL and l-HDL 13.8+9.7 vs 11.2±7.1
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mg/dL). In addition, T2 values were higher than T1 (s-HDL 4.9±2.4 4.0 ± 2.2 mg/dL, iHDL 21.3±6.7 vs 16.0 ± 4.6 mg/dL, and l-HDL 13.8+9.7 vs 10.1 ± 7.0 mg/dL). The same
pattern for cholesterol was carried in LDL (s-LDL 5.3±9.0 vs 1.8±3.0 mg/dL and i-LDL
13.6±10.0 vs 89.0±8.4 mg/dL, respectively), but there was no change for l-LDL. Also,
there was no significant change between T1 and T2.
Although the changes were very small, a significant decrease in LDL particle
diameter was observed in T2 compared with TR. No significant changes were observed at
T1 compared with TR or T2, as seen in (Figure 4-2).
Changes in the anthropometric assessment including muscle mass, muscle strength,
and MIS are shown in (Table 4-6) (T-1 samples were only available for analysis for BMI).
We observed that the BMI values did not change throughout the study period. Regarding
the calculated MAMC and cAMA, there was also no difference between the time points.
On the other hand, there was a very small change in the TSF values. It was lower at TR
when compared to T2 but not when compared to T1 (21.1 ± 10.1 vs 16.1 ± 17 mm).
Moreover, there was also no difference between the HGS time points. The mean MIS total
score was significantly higher at TR when compared to T1 and T2 (11+3.4 vs 10+3.1 and
11+3.4 vs 9+3.8) respectively.
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Results of aim 2:
To evaluate the food intake and to identify AR. Also, to document the changes in
renal, lipid and anthropometric profile for these AR. This was be evaluated by the
following:
Identifying the AR of energy intake during study period especially during Ramadan and
describing the changes in the intake in AR.
The subjects who had diet recalls (we had 32, 31, and 30 subjects for TR, T1, and
T2, respectively) were divided into two groups AR and IR depending on their EI ratio
(average of each month) and TEE ( in TR, the AR: EI/TEE 0.53–1.47 and the IR: EI/TEE
< 0.53 or >1.47; in T1, the AR: EI/TEE 0.67–1.33 and the IR: EI/TEE < 0.67 or >1.33; and
in T2, the AR: EI/TEE 0.57–1.43 and the IR: EI/TEE < 0.57 or >1.43) as the previously
described in the method.
A GEE was used to assess the changes in each group within the study time points
(TR, T1, and T2) and between the two groups for each time point. A p value <0.05 was
statistically significant.
The proportion of subjects who were considered as being AR and IR during the
study time points is depicted in (Table 4-7). Since we only included diet-recall subjects for
this analysis, we excluded 13, 14, and15 subjects from TR, T1, and T2, respectively. We
noticed, first when the two groups were compared during R (TR), the number of subjects
considered to be AR is greater than the number of subjects considered to be IR. Second,
when we compared the two groups at time points (TR, T1, and T2), we noted that during
R (TR), the number of AR subjects was higher than the other months (T1 (22 vs 18) and
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T2 (22 vs 21)), whereas the number of UR subjects was lower than the T1 (10 vs 13) and
higher than the T2 (10 vs 9)). Moreover, we had OR and UR at the TR time point, but other
months had only UR.
The energy and nutrients (macro and micronutrients) intake of both groups are
reported over the study time points in (Table 4-8). We first noticed that the intake pattern
during the study time points was significantly different between the two groups (AR and
IR) only in T1 and T2 but not in TR. Next, calorie and macronutrients consumption, the
overall calorie intake during TR was significantly high for AR compared to T2. The calorie
intake increases mainly came from fat. On the other hand, there was a difference in calorie
and macronutrient consumption between the time points within the UR group. Last, in
terms of micronutrients, potassium intake was higher in TR compared to T1 and T2 in the
AR group, but significantly lower in T2 compared to T1; however, it was not significant in
TR when compared to T2 in the UR group. Intake of phosphorus in the AR group, there
was presented no significant change in AR during the three time points. However, in the
IR group, there was only a significant increase in T1 time points when compared to T2 in
the IR group. Last, we also noticed also, that the recommended caloric intake was only
achieved during the R time point but the recommendation of the phosphorus intake was
achieved at all of the study’s time points. However, the recommendation for the protein
intake was not achieved at all of the time points. Regarding the type of food consumed
during R, the consumption of fried food such as samosa (filled with meat or cheese), rice
(with meat or chicken), and bread (with beans), as high among the subjects.
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Describing the changes of biochemical profiles and anthropometric in the acceptablereporters and implausible-reporters during the study period
To analyze this aim, both the AR and IR groups were used.
A GEE was used to assess the changes and in between both groups during study time points
(TR, T1, and T2). A p value <0.05 was statistically significant.
The biochemical profiles between the AR and IR groups during the study period
(samples in T-1 were not available for analysis) are shown in (Table 4-9). During TR, we
noticed that there was no significant difference between the two groups except for albumin
(IR was higher than AR in T2) and phosphorus (IR was lower than AR in TR but lower in
T1). Moreover, regarding the AR group, albumin was significantly lower in T2 than T1,
potassium was significantly higher in T2 than TR, creatinine was lower in T2 than T1,
sodium was lower in TR than T1 and T2, and phosphorus was higher in TR than T1.
Furthermore, in the IR group, the sodium level was lower in TR than in both T1 and T2,
and phosphorus was lower in TR than in T1.
Besides that, there were no significant changes in plasma lipid profile between the
two groups during TR. Furthermore, when compared between the time points for each
group, in AR, only the HDL-C level in T2 was higher than that of both TR and T1; thus,
the TC/HDL-C, LDL-C/HDL-C, and TG/HDL-C were lower in T2 than of T1. Also, in
IR, the level of TG was lower in T2 compared to T1 (Table 4-10).
Next, cholesterol distribution in lipoprotein subfractions showed variability in both
groups over the study’s time points (Table 4-11). For the HDL subfraction, in the AR
group, in T2, the large HDL level was higher in T2 than both TR and T1; in T1, the
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intermediate HDL level was lower than in T2. However, in the IR group, in TR, the small
HDL level was lower than T2, while in the LDL subfraction, in the AR group, the large
LDL level was higher in T2 compared to T1. The intermediate LDL level was higher in
TR compared to T1 and T2, and the small LDL level was higher in T1 compared to TR and
T2. The only change in IR was in small LDL, so the T2 level was lower when compared
to TR.
Moreover, during the study period among the AR group, LDL particle diameters
changed significantly; the increase was observed throughout TR and T2 compared with
T1. However, this change was very small. On the other hand, among IR, particle diameters
changed significantly; the increase was observed throughout TR compared with T1 and
T2. Moreover, there was a difference existed between the two groups during T2; the AR
group had a higher LDL size than the IR group.
Finally, concerning anthropometric measurements, there was no significant change
or difference in both groups during each of the recorded time points. However, in terms of
muscle mass (TSF, MAMC, and cAMA), the AR measurements did not change
significantly during the study time points. However, there was a significant difference
between the two groups during TR (the IR group had lower measurements). In terms of
muscle strength, there was no significant difference between the two groups and their
different time points. In terms of MIS, the AR group had higher scores during TR than
during T1 and T2, while the IR group had lower scores during T1 than during TR and T2
(Table 4-12).

54

Results of aim 3:
To assess the prevalence of protein-energy wasting among HD patients and document the
changes in food intake during the study period. For this aim, from T2, we conducted our analysis
by using the same subjects, excluding two patients (no PEW data available for them total subjects
43). Next, we grouped the participants into two groups PEW (subjects who met at least three
criteria) and non-PEW (subjects who had missing data or did not match the criteria).
A GEE was used to assess the changes during the study times. Moreover, an independent
t-test was used to locate differences of interest between PEW and non-PEW groups, and the Mann–
Whitney test was used for nonparametric variables. A p value <0.05 was statistically significant.
In this study, the prevalence of protein-energy wasting, according to the ISRNM category, was
39% of the subjects had one category, 33% had two categories, and 23% had three or more
categories (Figure 4-3).
The distribution of malnutrition indicators according to PEW criteria among HD patients
was as follows: biochemical criteria most subjects 90% had Albumin <3.8 g/dl, but no subjects
had TC <100 mg/dL, body mass 50% had BMI <23 kg/m2 and 6% had Wt. loss >5%, muscle
mass: 33% had AMAC reduction, and dietary intake: 7% (three subjects out of 29) had EI
<25kcal/kg and 7% (3 subjects out of 29) had protein intake<0.8 g/kg of body weight (Table 413).
As seen from the number of the subjects who met the criteria we found from the
characteristics of the PEW and non-PEW subjects in the baseline regarding the PEW categories
(Table 4-14), there is no difference between both groups in serum albumin and TC. However, the
BMI values were significantly lower in the PEW group than in non-PEW group (18.82 ± 2.15 vs
55

25.2±5.9 kg/m2, respectively). Moreover, only significantly lower measurements of MAMC were
recognized in the PEW group than in the non-PEW group. Furthermore, regarding the intake, there
was only a significant difference between both groups in protein intake; thus, the non-PEW had
lower intake.
Overall, the demographic characteristics of the 10 (23%) PEW patients according to the
ISRNM panel, were 60% female; most of the subjects were Saudi 40% and Yamani 40%, and 89
± 55 months dialysis vintage. Moreover, comparing the two groups, the PEW group was
significantly younger than the non-PEW, 40 ± 15 versus 54 ± 16 years, respectively (Table 4-15).
Regarding the other characteristics in the patents with PEW and without PEW groups (Table 416), there was no significant difference in the biochemical biomarkers. Also, there was no
significant difference in the lipid profiles between the groups (Table 4-17). The same finding was
also found in cholesterol distribution in lipoprotein subfractions (Table 4-18) and in muscle
strength and MIS (Table 4-19)
The changes in the caloric and nutrient intake (macro and micronutrients) during the study
time and the differences between the two groups are presented in (Table 4-20). First, we observed
that the PEW group had a significantly high intake of both calories (during TR when compared to
T1 and T2) and potassium (during TR when compared to T1). Second, variation was noted in the
intake for the non-PEW patients during the study time points (higher intake during TR when
compared to T1 and T2). Third, the difference between the two groups at each time point was
observed only for protein/IBW in both time points T1 and T2 (PEW group had higher intake than
non-PEW) and for carbohydrate and potassium at T1 (PEW had lower intake than non-PEW).

56

Tables and Figures
Table 4-1 Demographic Characteristic

Demographic Characteristic
Age (years)
Gender
Males, %
Females, %
Nationality
Saudi, %
Yamani, %
Filipino, %
Eritrean, %
Myanmar, %
Sudanese, %
Palestinian, %
Somalian, %
Syrian, %
Chadian, %
Marital status
Single
Married
Divorced
Education
None
Elementary school
Middle school
High school
Diploma
Bachelor's degree
Master’s degree
Ph.D.
Employed
Yes
No
No. of people in home
<3
3-5
>5

50±17
22 (49%)
23 (52%)
18 (40%)
10 (22.2%)
5 (11.1%)
3 (6.7%)
2 (4.4%)
2 (4.4%)
2 (4.4%)
1 (2.2%)
1 (2.2%)
1 (2.2%)
13 (29%)
31 (69%)
1 (2%)
14 (31%)
5 (11%)
5 (11%)
5 (11%)
1 (2%)
14 (31%)
0 (0%)
1 (2%)
9 (20%)
36 (80%)
12 (27%)
21 (47%)
12 (27%)

Values are mean ± SD for n=45 or sample number and
(percentages).
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Table 4-2 Clinical Characteristic
Clinical Characteristic
Dialysis session duration (hrs)
Dialysis frequency
3 days/week
2 days/week
Dialysis Vintage (months)
Vascular Access
Catheter
Fistula
Graft
Cause
Hypertension
Diabetes Mellitus
Systemic Lupus Erythematosus
Alport Syndrome
Toxic Nephropathy
Sickle cell anemia
Gout Nephropathy
Unknown
Comorbidities
Diabetes Mellitus
Secondary hyperparathyroidism
Hepatitis C
Smokers

3.22 ± 0.12
44 (98%)
1 (2%)
78 ± 61
18 (40%)
23 (51%)
4 (9%)
22 (49%)
12 (27%)
3 (7%)
3 (7%)
2 (4%)
1 (2%)
1 (2%)
1 (2%)
16 (36%)
15 (33%)
1 (2%)
5 (11%)

Values are mean ± SD for n=45 or sample number and
(percentages).
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Table 4-3 Biochemical profiles
T-1

TR

T1

T2

Reference
Value

Albumin (g/dL)

3.0 ± 0.1 (45)ab

3.2 ± 0.0 (45)ac

3.2 ± 0.1(45)bd

3.1 ± 0.1 (43)cd

≥4.0

Potassium (mEq/L)

5.0 ± 0.1 (45)a

4.7 ± 0.1 (45)b

4.9 ± 0.1 (45)

5.0 ± 0.1 (43)ab

3.5 to 5.5

TIBC (mg/dL)

219 ± 10 (39)a

181 ± 5 (40)ab

235 ± 20 (17)

211 ± 12 (40)b

BUN Pre-D (mg/dL)

47.5 ± 2.3 (45)a

51.9 ± 2 (45)

53.7 ± 2.1 (45)a

51.3 ± 2.2 (43)

20 to 80

BUN Post-D (mg/dL)

15.4 ± 0.8 (40)abc

18.0 ± 1.0 (41)a

18.8 ± 1.1 (41)b

18.9 ± 1.6 (41)c

7 to 20

Creatinine (mg/dL)

0.92 ± 0.04 (44)abc

0.99 ± 0.04

1.05 ± 0.05

1.01 ± 0.05

F: 0.6 to 1.1;

(44)a

(44)b

(44)c

M: 0.9-1.3

134 ± 0.5 (45)ac

136 ± 0.7 (45)

137 ± 0.4 (43)bc

135 to 145

1.36 ± 0.06(30)

1.38 ± 0.05(34)

8.8 ± 0.1 (45)

8.9 ± 0.1 (45)

Time

Sodium (mEq/L)

135 ± 0.4 (45)ab

Kt/V

1.34 ± 0.05 (30)

1.34 ± 0.05
(34)

Calcium (mg/dl)

8.7 ± 0.1 (45)

8.7 ± 0.1 (45)

Ferritin (ng/mL)

1206 ± 166(39)

1222 ± 190(40)

129 ± 10 (42)

138 ± 14 (42)

Vitamin D (ng/mL)

24 ± 1 (40)a

30 ± 1.5 (41)a

Phosphorus (mg/dL)

5.5 ± 0.3 (45)

6.0 ± 0.4 (45)

Glucose
Random(mg/dL)

1101.4 ±
90(33)
155 ± 21 (41)a
No data
available
5.9 ± 0.4 (45)

1218 ± 180(40)

>1.2

8.4 to 9.5
≤500

127 ± 12 (42)a

26 ± 1.5 (41)
5.8 ± 0.3 (43)

>30

3.5 to 5.5

Data are reported as mean ± SD for the numbers in parentheses. Abbreviations: Pre-D. Wt.: predialysis weight; F: female; M: male; DM: Diabetes. A Generalized Estimated Equation was used,
and values in a given row with the same superscript letters were considered significantly
different from each other at p value<0.05.
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Table 4-4 Plasma lipid concentrations:
TR

T1

T2

Reference
Value [266]

TG (mg/dL)

143±18(35)

139±15(38)a

162±17(38)a

<150

TC (mg/dL)

169±10(35)a

173±6(38)b

184±8(38)ab

<200

HDL-C (mg/dL)

36±2(35)ab

30±2(38)ac

40±2(38)bc

>40

LDL-C (mg/dL)

104±8(35)a

115±5(38)

114±6(38)a

<100

Time

Values are mean± SEM for the numbers in parentheses. Abbreviations. TC: Total Cholesterol;
HDL-C: High-Density Lipoprotein Cholesterol; TG: Triglyceride; Calc. LDL-C: Calculated
Low-Density Lipoprotein Cholesterol. A Generalized Estimated Equation was used. Values in a
given column sharing a common superscript were considered significantly different p<0.05.
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Table 4-5 Cholesterol distribution in lipoprotein subfractions
TR

T1
a

T2
b

Large HDL (mg/dL)

11.2 ± 7.1(35)

10.1 ± 7.0(38)

13.8 ± 9.7 (38)ab

Intermediate HDL (mg/dL)

19.7 ± 4.4(35)ab

16.0 ± 4.6(38)ac

21.3 ± 6.7 (38)bc

Small HDL (mg/dL)

4.2 ± 2.0(35)a

4.0 ± 2.2(38)b

4.9 ± 2.4 (38)ab

Large LDL (mg/dL)

21.0 ± 13.3(35)

18.3 ± 8.7(38)a

23.5 ± 13.0 (37)a

Intermediate LDL (mg/dL)

9.0 ± 8.5(35)ab

12.9 ± 9.0(38)a

13.6 ± 10.0 (37)b

Small LDL (mg/dL)

1.8 ± 3.0(35)ab

6.0 ± 9.3(38)a

5.3 ± 9.0 (37)b

Data are mean± SD for the numbers in parentheses. Abbreviations: HDL: High-Density
Lipoprotein; LDL: Low-Density Lipoprotein. A Generalized Estimated Equation was used and
values in a given row with the same superscript letters were considered significantly different
from each other at p <0.05.
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Table 4-6 Anthropometric Assessment and Malnutrition-Inflammation Scores
BMI

T-1
24.0 ± 6.16(35)

TR
23.9 ± 6.42(35)

T1
23.9 ± 6.33(35)

T2
23.8 ± 6.36(35)

HGS (kg)

No data

19 ± 7.1(33)

19 ± 6.8(32)

19.0 ± 7.9(33)

TSF (mm)

No data

16.8 ± 10.8(19)ab

20.5 ± 9.9(19)a

21.1 ± 10.1(19)b

MAMC (cm)

No data

21.4 ± 5.6(19)

22 ± 5.1(19)

22.2 ± 5.2(19)

cAMA

No data

30.8 ± 22(19)

32.8 ± 22(19)

33.3 ± 22(19)

MIS total scores£

No data

11 ± 3.1(34)ab

9 ± 3.8(33)ac

10 ± 3.4(34)bc

Data are mean± SD for the number in parentheses. Abbreviations: BMI: Body mass index; PreD. Wt.: Pre-dialysis weight HGS: Hand Grip Strength; MIS: Malnutrition-Inflammation Score;
TSF: triceps skinfold; MAMC: Mid-arm muscle circumference; cAMA: corrected arm muscle
area. £ Total score= sum of 10 components (0-30). A Generalized Estimated Equation was used
and values in a given row with the same superscript letters were considered significantly
different from each other at p <0.05.
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Table 4-7 Sample distribution and characteristics:

n/total samples

Male
Female

TR

T1

T2

AR

22 (69%)

18 (58%)

21 (70%)

IR

10 (31%)

13 (42%)

9 (30%)

UR

5 (50%)

13 (100%)

9 (100%)

OR

5 (50%)

0

0

AR

7 (54%)

7 (58%)

8 (67%)

IR

6 (46%)

5 (42%)

4 (33%)

AR

15 (79%)

11 (58%)

13 (72%)

IR
4 (21%)
8 (42%)
5 (28%)
Values are sample number and (percentages). Abbreviations: AR: acceptable reporters; IR:
implausible reporters; UR: under-reporters; OR: over-reporters.
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Table 4-8 Energy and macronutrient intake according to energy reporting status during
the study
TR

T1

T2

Reference
values[258]

All
1.01 ± 0.43
0.70 ± 0.17
0.70 ± 0.22
ab
a$
AR
EI/TEE
0.98 ± 0.23
0.82 ± 0.11
0.82 ± 0.16b*
IR
1.08 ± 0.71de
0.53 ± 0.08df$
0.44 ± 0.08ef*
All
1843 ± 782
1280 ± 295
1294 ± 423
Calorie (kcal)
AR
1793 ± 405ab
1456 ± 234a$
1482 ± 355 b*
IR
1956 ± 1306de
1036 ± 170df$
856 ± 149ef*
All
33 ± 14
23 ± 6
24 ± 10
30–35 kcal/kg
ab
a$
AR
Calorie/IBW
32 ± 8
27 ± 5
26 ± 6b*
IBW
IR
34 ± 22de
17 ± 3df$
15 ± 4ef*
All
60±24
42±10
45±16
a
a$
Protein (g)
AR
60 ± 19
46 ± 9
51 ± 15*
IR
60 ± 35de
35 ± 9 d$
31 ± 7e*
All
1.05 ± 0.42
0.74 ± 0.19
0.79 ± 0.27
a
a$
1.2 g /kg IBW
AR
Protein/IBW
0.85 ± 0.15
0.90 ± 0.24*
1.06 ± 0.36
de
d$
e*
IR
1.03 ± 0.55
0.58 ± 0.12
0.52 ± 0.10
All
217±94
170±45
165 ±53
$
Carbohydrate (g)
AR
214 ±62
190 ± 44
189 ± 45*
IR
225 ± 147d
142 ± 28e$
110 ± 22de*
All
82 ± 42
51 ± 15
53 ± 20
ab
a$
Fat (g)
AR
59 ± 13
61 ± 19b*
78 ± 20
IR
92 ± 71de
40 ± 9df$
34 ± 5ef*
All
1381 ± 753
1169 ± 597
922 ± 341
Based on Serum
ab
a
Potassium (mg)
AR
1136 ± 412
1007 ± 343b*
1490 ± 780
Levels
IR
724 ± 252d*
1142 ± 665
1215 ± 804d
All
10 ± 5
8±2
9±4
$
AR
10-17mg/kg
Phosphorus/IBW
11 ± 5
10 ± 2
10 ± 4*
d$
d*
IR
9±6
7±2
6±2
Data are reported as mean ± SD for the numbers in parentheses. Abbreviations: AR: acceptable
reporters; IR: implausible reporters; IBW: ideal body weight. A Generalized Estimated Equation
was used to assess changes during the study times and between the AR and IR groups at each
time point and between the same groups at different time point. Values in a given row with the
same superscript letters were significantly different between time points at P<0.05 and values in
a given row with the same superscript signs were considered significantly different between the
two groups at p <0.05.
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Table 4-9 The change in the biochemical profile during the study period:

Albumin (g/dl)
Potassium (mEq/L)
Creatinine (mg/dl)
Sodium (mEq/L)
Glucose - Random (mg/dl)
Phosphorus (mg/dl)

TR

T1

T2

AR

3.3 ± 0.3(22)

3.3 ± 0.4(18)a

3.1 ± 0.4(21)a*

IR

3.3 ± 0.3(10)

3.4 ± 0.3(13)

3.4 ±0.2(9)*

AR

4.6 ± 0.8(22)a

4.9 ± 1.0(18)

5.2 ± 0.8(21)a

IR

4.61 ± 0.8(10)

5.0 ± 1.1(13)

5.2 ± 0.8(9)

AR

10.7 ± 3.0(22)

11.6 ± 3.7(18)a

10.5 ± 3.5(21)a

IR
AR

11.2 ± 2.5(10)
134 ± 2.7(22)ab

11.9 ± 1.9(13)
136 ± 4.3(18)a

11.9 ± 3.5(8)
137 ± 3.2(21)b

IR

134 ± 1.8(10)de

138 ± 3.2(13)d

138 ± 2.7(9)e

AR

137 ± 100(22)

158 ± 187(18)

115 ± 84(21)

IR

140 ± 88(10)

135 ± 83(13)

129 ± 81(9)

AR

6.5 ± 2.5(22)a&

5.6 ± 2.3(18)a$

6.1 ± 2.1(21)

IR
5.2 ± 1.1(10)d&
7 ± 1.9(13)d$
6.3 ± 1.5(9)
Data are reported as mean ± SD for the numbers in parentheses. A Generalized Estimated
Equation was used between the AR and IR groups in TR and between each group in different
time point. Values in a given row with same superscript letters were considered significantly
different between time points at p <0.05 and values in a given row with same superscript signs
were considered significantly different between the groups at p <0.05.
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Table 4-10 The change in the plasma lipid concentration during the study period:
TR

T1

T2

AR

150 ± 121(21)

155 ± 95(18)

136 ± 101(19)

IR

147 ± 99(8)

131 ± 91(13)d

197 ± 102(9)d

AR

179 ± 65(21)

178 ± 44(18)

186 ± 61(19)

IR

170 ± 39(8)

168 ± 29(13)

185 ± 37(9)

AR

36 ± 11(21)a

31 ± 14(18)b

43 ± 16(19)ab*

IR

33 ± 8(8)

31 ± 10(13)

32 ± 10(9)*

AR

114 ± 48(21)

116 ± 35(18)

118 ± 43(19)

IR

106 ± 33(8)

110 ± 26(13)

114 ±32(9)

AR

5.59±3.02(21)

6.57±2.76(18)a

4.98±2.29(19)a

IR

5.64±2.36(8)

5.94±2.52(13)

6.66±3.25(9)

AR

3.57±2.13(21)

4.38±2.14(18)a

3.21±1.61(19)a

IR

3.46±1.57(8)

3.88±1.8(13)

4.09±2.18(9)

AR

5.1±4.97(21)

5.96±4.57(18)a

4.09±4.21(19)a

IR

5.59±5.74(8)

5.14±5.24(13)

7.83±6.33(9)

TG (mg/dL)

TC (mg/dL)

HDL-C (mg/dL)

LDL-C (mg/dL)

TC/HDL-C

LDL-C/HDL-C

TG/HDL-C

Data are reported as mean ± SD for the numbers in parentheses. A Generalized Estimated Equation
was used between the AR and IR groups in TR and between each group at different time point.
Values in a given row with the same superscript letters were considered significantly different
between time points at p <0.05 and values in a given row with the same superscript signs were
significantly different between the two groups at p <0.05.
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Table 4-11 Cholesterol distribution in lipoprotein subfractions during the study period

Large HDL (mg/dL)
Intermediate HDL
(mg/dL)
Small HDL (mg/dL)

Large LDL (mg/dL)

Intermediate LDL (mg/dL)

Small LDL (mg/dL)

Mean LDL size (Å)

TR

T1

T2

AR

10.5 ± 7.3(21)a

9.9 ± 9.6(18)b

16 ± 11(19)ab*

IR

7.9 ± 3.8(8)

9.2 ± 4.5(13)

6.7 ± 5.0(9)*

AR

19.5 ± 4.71(21)a

16.6 ± 5.7(18)ab

22.2 ± 6.8(19)b

IR

20.8 ± 5.7(8)

17.9 ± 4.9(13)

19.6 ± 6.8(9)

AR

4.8 ± 2.0(21)

4.6 ± 1.9(18)

4.6 ± 2.4(19)

IR

4.1 ± 1.5(8)d

4.4 ± 2.1(13)

5.4 ± 1.9(9)d

AR

21.3 ± 17.2(21)

20.4 ± 10.7(18)a

25.6 ± 14.1(19)a

IR

25.1 ± 12.3(8)

18.1 ± 9.2(13)

24.2 ± 13.6(9)

AR

6.7 ± 9.0(21)ab

14.3 ±7.6(18)a

13.3 ± 10.7(19)b

IR

12 ± 6.8(8)

13.4 ± 10.5(13)

12.4 ± 7.8(9)

AR

0.6 ± 1.3(21)a

7.4 ± 11.4(18)ab

2 ± 4.3(19)b

IR

2.3 ± 3.6(8)d

3.9 ± 5.1(13)

8.7 ± 10.8(9)d

AR

274 ± 3(21)ab%

267 ± 7.0(18)ac

271 ± 3.9(19)bc

IR

271 ± 4.1(8)d%

269 ±5.6(13)

265 ± 10.9(9)d

Data are reported as mean ± SD for the numbers in parentheses. A Generalized Estimated Equation
was used between the AR and IR groups in TR and between each group in different time point.
Values in a given row with the same superscript letters were considered significantly different
between time points at p <0.05 and values in a given row with the same superscript signs were
considered significantly different between the two groups at p <0.05.

67

Table 4-12 Change in the anthropometric measurements and malnutrition inflammation
scores during the study period

BMI (kg/m2)

HGS (kg)

TSF (mm)

MAMC (cm)

cAMA

MIS total

scores£

TR

T1

T2

AR

23.7 ± 6.96(22)

22.5 ± 6.48(18)

23.1 ± 6.55(20)

IR

22.5 ± 3.77(10)

24.5 ± 6.02(13)

24.3 ± 6.25(9)

AR

19 ± 6.8(21)

19 ± 9.1(17)

19 ± 8.4(17)

IR

19 ± 7.9(10)

20 ± 6.8(13)

17 ± 7.8(9)

AR

19.6 ± 9.2(18)%

17.3 ± 9.6(13)

18 ± 11.2(11)

IR

12.5 ± 6.3(5)de%

22.5 ± 7.3(9)d

18.1 ± 7.0(7)e

AR

21.9 ± 5.4(18)

20.8 ± 4.8(13)

20.3 ± 4.4(11)

IR

18.8 ± 3.2(5)

22.0 ± 5.7(9)

21.6 ± 7.3(7)

AR

32.9 ± 21.7(18)%

28.3 ± 17(13)

26.8 ± 16.1(11)

IR

20.9 ± 8.1(5)%

33.6 ± 24.7(9)

33.3 ± 30.1(7)

AR

11 ± 3(22)ab

9 ± 4(18)a

10 ± 3(20)b

IR

10 ± 4(10)d

7 ± 3(13)de

10 ± 4(9)e

Data are reported as mean ± SD for the numbers in parentheses. A Generalized Estimated Equation
was used between the AR and IR groups in TR and between each group in different time point.
Values in a given row with the same superscript letters were considered significantly different
between time points at p <0.05 and values in a given row with the same superscript signs were
considered significantly different between the two groups at p <0.05.
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Table 4-13 Distribution of malnutrition indicators according to PEW criteria among HD
patients
PEW
Category
Albumin (n=43)
Biochemical

the criteria
<3.8 g/dL

(37) 90%

<100 mg/dL

0%

<23 kg/m2

(18) 50%

>5%

(2) 6%

>10% in relation to 50th percentile of
reference population

(14) 33%

TC (n=40)
BMI (n=36)

Body mass

patients who met

PEW Criteria

Wt. loss (n=36)

Muscle mass

MAMC reduction (n=20)

Dietary
intake

Energy intake (n=29)

<25kcal/kg

(3) 7%

Protein intake (n=29)

<0.8g/kg

(3) 7%

Values are sample number and (percentages) for n=43
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Table 4-14 Characteristics of the PEW and non-PEW subjects in the baseline depend on
PEW classification criteria
Category

All

PEW

Non-PEW

n=10 (23%)

n=33 (77%)

P value

Albumin (g/dL)

3.07 ± 0.49

3.13 ± 0.24 (10)

3.05 ± 0.54 (33)

0.766

TC (mg/dL)

181 ± 48

167 ± 34 (9)

185 ± 52 (31)

0.262

BMI

23.4 ± 5.8

18.8 ± 2.2 (10)

25.2 ± 5.8 (26)

0.041

Body weight

59.6 ± 17.3

44.5 ± 12.8 (10)

65.2 ±15.5 (27)

0.329

Muscle mass

MAMC (cm)

20.8 ± 5.4

18.1 ± 2.5 (10)

23.9 ± 6.1 (9)

0.035

Dietary
intake

Energy intake/ABW

31.0 ± 11.9

40.2 ± 7 (8)

26.1 ± 11 (15)

0.319

Protein intake/ABW

1.03 ± 0.43

1.31 ± 0.21 (8)

0.89 ± 0.45 (15)

0.073

Biochemical

Body mass

PEW subjects who met at least three criteria and non-PEW subjects who have missing data or not
match the criteria. Values are mean ± SD for the numbers in parentheses. The cut off point for
albumin is <3.8g/dL; TC is <100mg/dL; BMI is <23kg/m2; energy intake is <25kcal/kg and protein
intake is <0.8g/kg. To compare between PEW and non- PEW groups, independent t-test was used
in parametric data; Mann-Whitney U test was used in non-parametric data.
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Table 4-15 Demographic characteristics of the PEW and non-PEW subjects in the baseline
PEW

Non-PEW

n=10 (23%)

n=33 (77%)

40 ± 15

54 ± 16

Male

4 (40%)

17 (52%)

Female

6 (60%)

16 (48%)

Saudi, %

4 (40%)

15 (45%)

Yamani, %

4 (40%)

6 (18%)

Filipino, %

0

3 (9%)

Eritrean, %

0

3 (9%)

Myanmar, %

1 (10%)

1 (3%)

Sudanese, %

0

1 (3%)

Palestinian, %

0

2 (6%)

Somalian, %

0

1 (3%)

Syrian, %

1 (10%)

0

Chadian, %

0

1 (3%)

89 ± 55

78 ± 63

Time
Age (years)
Gender

Nationality

Months with dialysis

P value
0.020

0.619

PEW subjects who met at least three criteria and non-PEW subjects who have missing data or not
match the criteria. Values are sample number and (percentages) or mean ± SD for the numbers in
parentheses. To compare between PEW and non- PEW groups, independent t-test was used in
parametric data; Mann-Whitney U test was used in non-parametric data.
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Table 4-16 Biochemical characteristics of the PEW and non-PEW subjects in the baseline

Potassium (mEq/L)

5.05 ± 0.91

PEW
n=10 (23%)
4.9 ± 0.70(10)

TIBC (mg/dL)

208 ± 73.5

196 ± 26.7(10)

212 ± 84.0(31)

0.673

BUN Pre-D (mg/dL)

51.61 ± 14.52

55.34 ± 13.43(10)

50.48 ± 14.85(33)

0.226

BUN Post-D (mg/dL)

18.88 ± 9.68

14.98 ± 5.45(10)

20.10±10.43(32)

0.182

Creatinine (mg/dL)

1.01 ± 0.34

1.09 ± 0.31(10)

0.99 ± 0.35(32)

0.410

Sodium (mEq/L)

137 ± 2.82

138 ± 2.75(10)

136 ± 2.77(33)

0.134

All

Non-PEW
n=33 (77%)
5.1 ± 0.97(33)

P value
0.445

PEW subjects who met at least three criteria and non-PEW subjects who have missing data or not
match the criteria. Values are mean ± SD for the numbers in parentheses. To compare between
PEW and non- PEW groups, independent t-test was used in parametric data; Mann-Whitney U test
was used in non-parametric data.
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Table 4-17 Lipid profile characteristics of PEW and non-PEW subjects in the baseline

160 ± 104

PEW
n=10 (23%)
109 ± 28(9)

Non-PEW
n=33 (77%)
176 ± 115(28)

HDL-C (mg/dL)

40 ± 49

43 ± 19(9)

39 ± 13(29)

0.973

LDL-C (mg/dL)

114 ± 39

105 ± 27(9)

116 ± 42(28)

0.367

All
TG (mg/dL)

P value
0.154

PEW subjects who met at least three criteria and non-PEW subjects who have missing data or not
match the criteria. Values are mean ± SD for the numbers in parentheses. To compare between
PEW and non- PEW groups, independent t-test was used in parametric data; Mann-Whitney U test
was used in non-parametric data.
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Table 4-18 Cholesterol distribution in lipoprotein subfractions characteristics of the PEW
and non-PEW subjects in the baseline

Large HDL (mg/dL)

13.95 ±9.66

PEW
n=10 (23%)
16.0 ± 11.94 (10)

Intermediate HDL (mg/dL)

21.34 ± 6.87

23.78 ± 7.92 (9)

20.59 ± 6.47 (29)

0.294

Small HDL (mg/dL)

4.84 ± 2.43

4.78 ± 1.39 (9)

4.86 ± 2.70 (29)

0.903

Large LDL (mg/dL)

23.05 ± 13.49

24.67 ± 11.39 (9)

22.55 ± 14.22 (29)

0.653

Intermediate LDL (mg/dL)

13.08 ± 9.90

10.89 ± 7.77 (9)

13.76 ± 10.50 (29)

0.388

Small LDL (mg/dL)

5.11 ± 8.83

1.89 ± 3.69 (9)

6.10 ± 9.74 (29)

0.325

Mean LDL size (Å)

269 ± 7.30

272 ± 4.30 (9)

268 ± 7.92 (28)

0.213

All

Non-PEW
n=33 (77%)
13.27 ± 8.91 (30)

P value
0.794

PEW subjects who met at least 3 criteria and non-PEW subjects who have missing data or not
match the criteria. Values are mean ± SD for the numbers in parentheses. To compare between
PEW and non- PEW groups, independent t-test was used in parametric data; Mann-Whitney U test
was used in non-parametric data.
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Table 4-19 Muscle strength and MIS characteristics of the PEW and non-PEW subjects in
the baseline
All
HGS (kg)

17.7 ± 7.98

PEW
n=10 (23%)
15.37 ± 8.15(10)

MIS total scores£

9.7 ± 3.47

9.9 ± 2.64(10)

Non-PEW
n=33 (77%)
18.69 ± 7.88(25)
9.67 ± 3.77(27)

P-value
0.289
0.835

PEW subjects who met at least three criteria and non-PEW subjects who have missing data or not
match the criteria. Values are mean ± SD for the numbers in parentheses. To compare between
PEW and non- PEW groups, independent t-test was used in parametric data; Mann-Whitney U test
was used in non-parametric data.
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Table 4-20 Energy and macronutrients intake according to PEW status during the study
time points

EI/TEE

Calorie (kcal)

Calorie/IBW

Protein (g)

Protein/IBW

Carbohydrate (g)

Fat (g)

Potassium (mg)

Phosphorus/IBW

PEW

TR
1.17 ± 0.34(7)

T1
0.98 ± 0.11(8)

T2
0.98 ± 0.11(8)

Non-PEW

1.2 ± 0.31(14)de

0.94 ± 0.14(12)d

0.85 ± 0.28(15)e

PEW

1989 ± 437(7)ab

1639 ± 213(8)a

1631 ± 314(8)b

Non-PEW 2234± 707(14)de

1794 ± 354(12)d

1641 ± 558(15)e

PEW

37 ± 12(7)

32 ± 5(8)

32 ± 5(8)

Non-PEW

38 ± 10(14)de

31 ± 7(12)d

28 ± 9(15)e

PEW

63 ± 13(7)

53 ± 13(8)

55 ± 17(8)

Non-PEW

73 ± 24(14)de

58 ± 18(12)d

56 ± 23(15)e

PEW

1.2 ± 0.31(7)

1.3 ± 0.28(8)*

1.3 ± 0.21(8)$

Non-PEW

1.3 ± 0.38(14)de

0.9 ± 0.36(12)d*

0.9 ± 0.45(15)e$

PEW

216 ± 56(7)

207 ± 35(8)*

207 ± 20(8)

Non-PEW

249 ± 95(14)

254 ± 71(12)d*

212 ± 71(15)d

PEW

91 ± 36(7)

68 ± 13(8)

68 ± 15(8)

Non-PEW

97 ± 40(14)de

66 ± 20(12)e

66 ± 31(15)d

PEW

1993 ± 952(7)a

1083 ±308(8)a*

1274 ± 493(8)

Non-PEW

1356 ± 564(14)d

1577 ±723(12)e*

1002 ± 326(15)de

PEW

11 ± 2.2(7)

11 ± 3.3(8)

12 ± 4.4(8)

Non-PEW

13 ± 5.5(14)de

10 ± 2(12)d

10 ± 4.5(15)e

Data are reported as mean ± SD for the numbers in parentheses. Abbreviations: PEW subjects
who met at least three criteria and non-PEW subjects who have missing data or not match the
criteria; UR: under-reporters; IBW: ideal body weight. A Generalized Estimated Equation was
used to assess changes during the study times and between the PEW and non-PEW groups at
each time point and between the same groups at different time point. Values in a given row with
the same superscript letters were considered significantly different between time points at p
<0.05 and values in a given row with the same superscript signs were considered significantly
different between the two groups at p <0.05.
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TC/HDL-C

LDL-C/HDL-C
TR T1 T2

TAG/HDL-C

Figure 4-1 Ratio of plasma lipid concentrations
Abbreviations: TC: Total Cholesterol; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C:
Calculated Low-Density Lipoprotein Cholesterol; TG: Triglyceride. The same superscript letters
were considered significantly different from each other at p <0.05.
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a

n=35
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Mean LDL size
TR

T1
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Figure 4-2 Mean LDL size (Å)
The same superscript letter were considered significantly different from each other at p <0.05.
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Pts with no category

Pts with 1 category

Pts with 2 categories

Pts with 3 or more categories
Pts with no
category
5%

Pts with 3 or more
categories
23%
Pts with 1 category
39%
Pts with 2
categories
33%

Figure 4-3 Prevalence of protein-energy wasting according to ISRNM criteria:
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CHAPTER 5: DISCUSSION
There are a few but inconclusive studies that have been carried out in Saudi Arabia on the
nutritional status of HD patients, particularly during Ramadan. This study focused on nutritional
changes before, during and after Ramadan on biochemical and health parameters in HD patients,
by first determining the impact of Ramadan month on CKD and HD patients. Moreover, we
evaluated the food intake and to identify AR. Also, we documented the changes in renal, lipid and
anthropometric profile for these AR. Finally, we assessed the prevalence of protein-energy wasting
among HD patients and documented the changes in the food intake during the study period.
Determining the impact of Ramadan month on HD patients:
Our findings showed that there were no clinical changes in the biochemical markers,
constant body weight and muscle strength during R. We also found a high MIS, low HDL-C, and
low levels of large HDL, as well as intermediate and small LDL. Most of these changes were
consistent with other studies [33].
Current study found that statistically speaking, the value for serum albumin was lower
before and 2 months after the R period compared to R and 1-month post-R but was consistently
lower than the reference level which did not change. [29, 31]. In comparison, certain research did
find significant improvement [30, 32, 33]. The age of the individuals, the extent of kidney
impairment, study design, sampling time, and food habits in the country or the culture, are factors
that are responsible for the differences of albumin between studies. On the other hand, there is a
significant decrease in serum K during Ramadan compared to pre-R and 2 months post-R. This
change is within acceptable ranges consistent with a (Khazneh et al, 2019) study [31], while no
changes were reported in other studies [29, 33]. For serum sodium, statistically, it seems to be
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different but is still within the limit. While most studies reported changes in biochemical markers
during R, they did not compare with reference values.
With respect to anthropometric evaluation, the present study found no change in body
weight in the time points of the study, and while the same results were found in some studies [29,
30, 32, 197], other studies recorded a decrease [33, 250]. The differences in the findings may be
explained by the differences in culture, food habits, and physical activity levels that are affected
by the weather. The temporal shifts in energy intake do not reflect bodyweight all the time. The
MIS was higher compared to TR with T2 but the change is relatively the same. This small change
could be the result of changing lifestyle, routine, and quality of life. During R, a study of two
groups of fasting and non-fasting subjects showed a change in lifestyle in both groups during the
month [22]. Also, another study found MIS correlated with quality of life [267]. No significant
change in muscle strength during R compared with T2, and similar results found in a study done
on healthy subjects [18]; but another study done on HD patients found improvement in HGS [33].
However, there were no reference values available for muscle strength of HD patients [268], and
one month may not be enough to affect muscle strength. In addition, we can see that no differences
were noted in MAMC and cAMA over the study period. However, the lower values of TSF during
R as compared to 2 months post-R could be underestimated. The difference in sample numbers in
muscle mass and fat mass measurement was because patients refused to take the measurements.
As we know HGS is a device that just needs to be held and pressed while in TSF; however, to do
it correctly, subjects need to remove their long or tight sleeve, so it is Cultural prospective. In the
future, we need male and female practitioner and privet area to take the measurements.
For lipid profile, because no samples were available for analyses for pre-R, we considered
2 months post-R as the baseline. Our assumption is lipid profiles levels would resume back in T2.
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during the time points of analysis, we found there is a significant difference between 1-month postR and 2- month post R but no significant difference in TG when compared R with 2 months postR. But in the case of TC, HDL-C, and calc. LDL, there were significant decreases when we
compare R and 2-month post-R. However, these decreases for TC and HDL are still within the
reference values, and calc LDL is still above the reference level. the changes are transient and
normal, and they are not dyslipdemic. A previous study reported a significant reduction in HDLC, but only in diabetic patients undergoing HD treatment and who were fasting during R [250].
Also, a study done on HD patients to investigate the intake pattern and its effect, found that a group
with a high intake of calories and carbohydrates had a low level of HDL-C and large HDL
subfraction [269]. In our study, we found significant shifts in particle distribution over the course
of the study period. a significant decrease in large, intermediate, and small HDL during R when
compared to T2. However, we do not have a reference value for them & there is conflicting data
whether large or small HDL in HD pts increases mortality. While the findings for LDL subfraction
were, we found that the intermediate and small LDL were less during R than 2 months post-R.
And we do not have a reference value for them and Further studies examining the role of
dietary intake with lipoprotein subfraction is needed. Also, our study did find that LDL particle
diameters changed over the study period. It was significantly higher when Ramadan time point
was compared with T2. However, more studies investigate the role of dietary intake with LDL size
among HD pts is needed. In comparison, research among obese individuals on intermittent fasting,
which is an intermittent restriction of energy, noted increases in LDL particle sizes but
continuously without improvement in LDL-C [270-274]. As far as we are aware, no comparison
investigations have been conducted among HD patients that have evaluated the impact of R and
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the intake during this month on lipid subfractions, and there were no reference values available for
us to compare.
Evaluating the food intake and identifying Acceptable-Reporters (AR). Also, documenting the changes
in renal, lipid, and anthropometric profile for these AR:
The main finding drawn from the present study was that regardless of the dietary intake
collected only once during R, the calorie intake during the month was higher than at other time
points, and this is consistent with studies in healthy subjects from Saudi Arabia and other countries
[152, 213, 275]. In comparison, some of the previous studies reported a decline in food
consumption by the healthy population during R [219, 222], while a study in Malaysia among HD
subjects, found no change in the calorie intake [33]. In our study, the increase in the calorie intake
in our subjects mainly came from fat. In agreement with our finding, studies done in different
countries also found the increase was mainly due to fat intake [217, 222]. While research done
among the healthy Saudi population found an increase in carbohydrates, protein, and fat during R
[204], another study reported the increase was in protein and fat only [211]. In fact, these studies
differed in the method of assessing consumption and the number of days for collecting food intake;
the amount and types of food intake of the culture and country were also not the same, and these
factors may have affected the results. The change in calories and nutrients intake during R was
attributed to the food and drink intake. We, therefore, found the types of food that were consumed
the most among the subjects during R, were fried foods like samosas (filled with meat or cheese),
rice (cooked with meat or chicken), bread (with beans), dates, sweetened beverages or juice, and
coffee. In agreement with this, a study done on the healthy population in SA found the same type
of food intake [152]; similar to another study done in Iran [28]. It is hard to study the pattern of
the intake due to the differences in the socioeconomic backgrounds in our small sample size.
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However, to our knowledge, there was only one study that evaluated the intake during R among
HD subjects [33]. Furthermore, this was the first study done among HD patients, documenting
their intake during R in SA. Regarding micronutrients, we found that there is higher potassium
intake during R compared to 2 months post-R. However, there is no acceptable intake level because
it is dependent on serum level. As I mentioned before, there are differences between cultures in
food practices and intake which could lead to nutrient changes that are unique to different cultures.
Our sample study did not allow for any confidence in measuring sodium intake because most of
the patients do not cook for themselves, so, they do not know the amount of sodium which was
used.
Nevertheless, our work did not associate the stability of body weight with high caloric
intake during R, and this may be because we only used one 24-hour diet recall during the month.
The protocols used and the times between the samplings may also have caused differences between
the studies. For example, the evaluation time for one study was one week prior to R, then between
7–15 days during the month and at the end of R [197]. Another study was evaluated two weeks
pre-Ramadan and during the last week [32]. It is difficult to evaluate the degree of improvement.
Our study evaluated the changes every four weeks (Figure 3-1); capturing data one- and twomonths post-R. In agreement with our finding, a study assessed two weeks before R, at the end of
the month and one-month post-R and the time post-R was equal to the period of R with no change
in the intake [33]. However, even though we obtained data every four weeks, the dietary data was
collected in the second week of R and the second week of T1 and T2.
In addition to the increase in the caloric intake, we noted less prevalence of energy intake
under-reporters during R compared to other time points. Also, the over- reporters were only
observed during R compared to other time points. This finding could be attributed to seasonal
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variations in both the quality and quantity of the food eaten, so that they could consume more food
to avoid or reduce hunger. Another reason could be that the intake took place during the night, so
it could have reduced the recall issues (a systemic error that affects the absolute amount of food
and nutrient intake). Thus, we calculated the cut off for misreporting to identify acceptable
reporters and implausible reporters for each time point separately. In fact, it is essential to look at
implausible reporters and AR, to help make an accurate decision about food adequacy and to avoid
a misleading correlation between diet and disease. Over-reporting may be caused by over-reporting
of food consumed, or sometimes of good food consumed. In contrast, under-reporting may be
caused by under-eating, if respondents eat less than they need and if respondents do not record all
foods that they consume or underestimate the amounts that they consume. Interestingly, studies
among HD patients showed a high extent of UR of energy intake [276-278] and this is agreed with
our finding of the prevalence of UR in our study. However, to the best of our knowledge no
research explores the prevalence of under-reporters and over-reporters during this month.
In addition, we need to understand the nature and reasons behind the low number of UR
during this month and the lesser prevalence of OR among them. In general, misreporting energy
intake also increases the chance of misreporting the macro- and micronutrients intake and that is
what we noticed (significant high energy, macro and micronutrients intake in IR), which was this
is consistent with a study that was done on normal subjects [279-283].
Regarding biochemical markers, when we compared R with 2 months post-R, we found
that only serum potassium and sodium were lower during R. However, the levels of these
biochemical markers were within the recommended ranges, so they are not clinically significant.
In this study’s small sample size study, we also noted that among the AR group, the BMI and
muscle mass were the same as IR, while studies found UR had a significantly higher BMI in the
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normal population and HD subjects [277, 279]. The finding of BMI and muscle mass among misreporters could be explained by the fact that the effect is difficult to present in a short time. This
could also be the reason there is no difference between the IR and AR in anthropometric, muscle
strength, and biochemical markers.
After excluding misreports during R, we found significantly lower levels of HDL-C,
higher levels of LDL particle size and MIS than during other time points and these differences
could be explained by the change of energy intake. Many studies found a correlation between the
type of food intake and HDL-C and LDL particle size [269, 284-288]. In this study, we did not
analyze the pattern of food intake; we only looked at the macronutrients in general, without
studying their effects. The increase in MIS could be due to the increase of physical activity
during TR. However, it is challenging to assign health effects to a single component of the diet
[289] and difficult to analyze the dietary pattern, that is associated with a disease, when the
sample size is small. With regards to muscle mass, studies found that a relationship exists
between muscle mass and energy intake (positive correlation) [290, 291]. Besides this finding, a
study among HD patients found that protein intake affects muscle mass, and this correlation has
a favorable advantage for their health and survival in these patients [292]. In another study
among HD patients, undernutrition of energy intake was stated was stated to be the main cause
of abnormality in muscle wasting rather than protein undernutrition [293]. However, there is no
reference value for MAMC for HD subjects available to compare. In fact, it is hard to have a
significant shift in muscle mass and to determine the cause and effects during as a result of only
one month. Therefore, the change in the muscle mass in our study could be random errors (which
reduced the accuracy of the measurements), as it was the first time point to measure it.
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Assessing the prevalence of protein-energy wasting among HD patients and describe the changes in
the food intake during the study period among PEW subjects:
PEW comprised a number of nutritional and metabolic changes and was validated to
predict mortality in several CKD subjects [294]. However, the criteria used to define PEW were
not consistent among the studies, and this is the first research conducted in Saudi Arabia to identify
PEW among HD patients using ISRNM criteria as far as we are aware. First, we found that 90%
of the subjects had serum albumin lower than the reference value, 50% had BMI lower than 23,
33% met MAMC reduction, and 7% had for 2 months calories <25kcal/kg of body weight. So, the
prevalence of PEW in our samples was 23%. In SA, one study with an incidence of 32%, defined
PEW according to SGA[10]. Moreover, Moreover, research in the Arabian Gulf area that included
SA, reported PEW prevalence of 20–40%[9].
Regardless of the small sample size and missing data in this study, the subjects were young,
and this finding was consistent with some studies [295], and contrasted with others [296-298].
Subjects with PEW compared to non-PEW, had lower muscle mass and BMI, which was consistent
with [299, 300]. In fact, several studies found lower muscle mass and BMI associated with
mortality in general [301-306] and HD subjects [307-309]. However, there is no difference
between the groups in other PEW classification criteria, because, for example, most of the subjects
met the criteria (e.g., serum albumin level), or a small number of subjects met the criteria (e.g.,
protein intake) (7%) in addition to we only included AR
Identification of PEW subjects was challenging when assessing dietary intake, because of
UR of energy (under-nutrition (malnutrition) or under-intake), and as previously shown IR is
prevalent among HD patients. Therefore, we excluded them when we assessed dietary intake.
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Interestingly, we found that a small number of subjects (3 out of 29) met the dietary intake
criteria (energy intake <25 kcal/kg and protein intake <0.8 g/kg for two months). This could be
interpreted as the reason for there being no difference in the intake between the PEW and nonPEW groups, although there was still insufficient evidence to withdraw IR from the assessment.
In addition, as we reported that most of the subjects had a high intake of calorie (did not meet the
energy intake criteria < 25 kcal/kg), the culture intake could have played a role. For example, when
comparing the intake between two different cultures, our subjects and a study from Malaysia, our
subjects had a higher average intake of calories and almost the same protein intake (30 vs 23
kcal/kg) (0.95 vs 0.94g/kg) respectively [310]. The same low intake was among PEW subjects
who were undergoing HD from Morocco (23kcla/kg for calories and 0.80 g/kg for protein) [295].
As far as we are aware, no research has explored the change of nutrient intake during a particular
time among PEW subjects undergoing HD. Regardless of the study’s small sample size, the PEW,
especially during R, consumed more calories than other months, and this high intake did not reflect
their habitual eating. Therefore, it was crucial when we wanted to assess the intake, nutritional and
health status, and biochemical markers, to identify PEW, to be aware of the time of data collection
(seasonal effects). Furthermore, we collected the dietary intake during R only once (the other
months three times) thus, it could not be representative for the entire month, which could explain
that there was no change in the biochemical, anthropometric, and clinical assessments.
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Limitations of the study
First, even though we collected data every four weeks, we were unable to collect complete
data for T-1 (e.g., lipid, lipoprotein and food intake). We used the T2 values as a guide for lipid,
which may reflect T-1. We did the same for lipoprotein, which normally stabilizes within three to
four weeks. On the other hand, food intake at the beginning, middle, and the end of Ramadan could
be different.
The studies also involved R, and there are differences in the length and frequency of the
daily fast; some subjects may have fasted the entire month (29 or 30 days), while others may have
fasted only on certain days. It was difficult to obtain information of the exact days of fasting
because it is a culturally sensitive topic. So, individuals who did not fast for the entire month or
for some days of the month, may have been hesitant to share this information.
Throughout the studies, there were also differences among dialysis patients in the
techniques used to collect blood samples. It was best for blood to be drawn in the evening to get a
true, fasting sample. In one study, blood samples were consistently taken at night, with a nightly
dialysis schedule throughout R [197, 259]. Although we had not specifically requested, fasting
blood samples from our test subjects, we do not think this affected our findings. Collectively,
42.6% of all the measured TG values in our samples were < 100 mg/dL and 77.8% were < 150
mg/dL. These numbers suggested that TG values were not necessarily post-eating, and most
probably reflected values likely to be found during a fasting period. However, measures of apoB48 would be required to determine whether the individuals were fasting or not. In a recent study
[33], participants were self-reporting the number of days they fasted during R. Based on that,
participants were grouped into fasted more than 20 days during R and those that fasted less than
20 days (number of not fasting days varied between 4 and 19 days). Despite that no values for TG
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were reported, LDL and HDL values were consistent with our observation and did not clinically
change over the study period. It is worth nothing that among HD patients, the fact that subjects
undergo blood exchange during the dialysis is considered by some religious scholars a breaking
of the fast. Moreover, the recent guidelines from various agencies suggest that non-fasting lipids
are certainly reliable marker predictors of CVD risk. In this regard, three large cohort studies, using
data from a national dialysis provider, were able to link lipid values (indefinite fasting) with
mortality rates [259, 311-313].
Regarding nutritional assessment during R, subjects who were potentially over-reporting
can be difficult to distinguish from those who genuinely eat excess nutrients during the festival,
although this is impossible for dialysis patients who are usually on a restricted diet. Because of
small sample size of our study, we were unable to be confidence in assessing over-reporters.
Therefore, to reduce the errors that could have come from high intake during R and lower in other
months, we calculated the EI/TEE cutoff point for each time points. We found that some of our
samples identified with AR (58-70% during the study time points), while another study’s
corresponding figure in the sample was 25 % (the cutoff calculated once) [33].
Finally, there are differences between the cultures in food practices and intake that could
lead to nutrient changes that are unique to different cultures. Our study reported an increase in fat
intake, which may have reflected that we had many nationalities among our subjects, who likely
had different food habits. This was in contrast to recent research that reported no change in the
intake over the course of the study [33].
On the other hand, a strength of this study was first collected data after R for two
consecutive months. Further, to our knowledge, this is one of the first studies to collect
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biochemical, anthropometric, plasma lipoprotein, different lipoprotein subfractions and particle
sizes, and diet intake data in HD patients.
The data indicate that in addition to lipoproteins, kidney-specific parameters were still largely
stable as regards the overall health effects on HD patients during the study period.
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CHAPTER 6: CONCLUSION
Conclusion
In the first aim, we evaluated the effect of Ramadan month on anthropometric and
biochemical profile among hemodialysis patients. So, in our small sample of HD patients, there
were small and transient changes in renal profile, particularly for albumin and potassium levels
and in lipid and lipoprotein subfraction (they were within the reference levels). These changes are
not clinically significant, and none of the changes had sequences. These temporary changes could
be because there were people who could not complete fasting days. Also, after R some of them
accommodated fasting for the 29 days that they could not fast. After R, there is fasting, so the
intake still is not the same as in normal days. Last, there was no change in anthropometric
measurement.
The second aim was an attempt to evaluate the food intake and to identify AR. Also, to
document the changes in renal, lipid and anthropometric profile for these AR. The analyses of the
study found a high intake of energy and fat suggest eating pattern differs during R. It is essential
to determine whether similar patterns will be found among other ethnic/cultural groups. Moreover,
despite changes in nutrient intake in AR group, the change were not clinically significant changes
on nutritional health status in serum potassium and sodium, HDL-C, and MIS. Last, the diet intake
during R did not affect health status. This could be because the changes in diet could have
happened just for a few days only during R; therefore, for future study we need to collect diet
intake for many days in the first, mid and last weeks of R and consider differences between
cultures. Last, more research is also needed to examine the characteristics of under- and overreporters during R and other months.
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In the final aim, to assess the prevalence of protein-energy wasting among HD patients and
document the changes in the food intake during the study period. The analysis of the study shows
PEW was prevalent in our small samples size and no significant change in food intake during the
study period between both groups. We need further studies with big sample size to investigate the
changes in the food intake during R and the rest of the year among PEW subjects.
To sum up, there is transient change and most of them are not clinically significant.
Ramadan does not have impact on health and nutritional status.
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Future directions
Regarding Ramadan effects: an additional study with a larger sample and afternoon
sampling is needed to confirm the effect of fasting. Also, studying the changes in health and
nutritional parameters in the first, middle and at the end of R month.
Regarding the food intake during R, it would be interesting to explore the dietary pattern
during this month with using normalized protein catabolism rate (nPCR). Moreover, it is helpful
to estimate the intake of fluids among these patients.
Regarding the PEW syndrome and its effect: a larger sample size with collecting data multiple
time points could be helpful to understand the factors that affect PEW syndrome.
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APPENDIX A

CASE REPORT FORMS (CRF)
(CRF)
The effect of cyclic fasting on parameters of protein-energy wasting (PEW) in hemodialysis
patients in Saudi Arabia

File No.:

Subject Number:

Initials:

(First Two Letter of Last/First Names)

First date collection:

1

7

1

7

1

7

Second date collection:

Third date collection:
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PERSONAL DETAILS

•

Dialysis Shift: �� Sun/Tues / Thurs

•

Time of Dialysis Shift:

•

Duration of dialysis session: __________________

•

Age:

•

Date of Birth (dd/mm/yy):

•

Nationality:

•

Marital status: a Single

•

Is your residence: aOwned

•

What is the highest level of education you have completed?
aNone

�� Sat/Mon /Wed

am/pm

years old

⃝Saudi

aNon-Saudi (Specify): _________________________

aMarried

a Divorced

a Rented

a Elementary School

a Diploma a Bachelor’s Degree
a Post-Doctoral
•

Are you employed?

a Widowed

aOther (Specify): _________

a Middle School

a High School

a Master’s Degree

aDoctoral Degree

a Other (Specify) _____________
aYes

aNo

o If YES; in which employment sector do you work? a Public a Private aSelf
o If NO; are you? a Student
•

•

a Retired

aHousewife a Unemployed

What is your house income monthly?
a Less than 3000 Riyals

a3000 but less than 6000 Riyals

a 6000-10000 Riyals

a More than 10000 Riyals

How many people live in your household including yourself?
a Less than 3 people

a 3-5 people a more than 5 people
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MEDICAL HISTORY
What is the cause of kidney failure?
�Unknown

��Nephronophthisis

�Diabetes Mellitus

��APKD (Adult Polycystic Kidney Disease)

�Hypertension

��Gout Nephropathy

�HIV-Nephropathy

��Toxic Nephropathy

�Kidney Stone

��SLE (Systemic Lupus Erythematosus)

�Glomerulonephritis

��Others:

Years with hemodialysis: _______________________

Kidney Transplantation?

��Yes

��No

��Yes

��No

Diabetes?

��Yes

��No

Tobacco Use?

��Yes

��No

Secondary HPTH?

��Yes

��No

Hepatitis C?

��Yes

��No

Parathyroid Gland Removed?

Current Diagnoses:
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MEDICATION PROFILE
Prescribed Medications: Herbs or traditional medicine, Renal vitamin/ supplement, Iron, Ferric
citrate, Folic Acid, Folic Acid, Vitamin D, Insulin, Statin, Antihypertensive, ACE
inhibitor/ARB, Alpha/beta blocker, Calcium (carbonate/acetate), Calcimimetic, Ca channel
blocke, Sevelamer, Lanthanum, and other (please specify)
Prescribed
Medications

Name

Date:

Date:

Date:

Dosage/Frequency Dosage/Frequency Dosage/Frequency
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HEMODIALYSIS PRESCRIPTION
Is the dialyzer reused? Yes, how often?

Times

��No
Type of dialyzer membrane:
aPolysulfone
aCellulose triacetate
aOther: Specify:
Types of vascular graft being used:
�Wrist-arterio venous fistula
��Brachiocephalic fistula
��Arteriovenous graft (AVG)
��Catheter
Type of dialysate buffer:
�Acetate
�Low calcium
�Normal Calcium
�High Calcium
�Bicarbonate
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ANTHROPOMETRIC DATA
Measurements
Height(cm)
Interdialytic weight gain
Pre-dialysis wt. in kg
Post dialysis wt. in kg (dry
wt.)
Body Mass index (kg/m2)
IDWL

Date:

Date:

Date:

IDWL = [(pre dialysis weight (kg)/post dialysis weight (kg))/post dialysis weight (kg)]

BODY COMPOSITION -- MUSCLE MASS MEASUREMENTS
1st measure
Date:
Date:
Date:

2nd measure

Mean

Mid-arm circumference (cm)
Triceps skinfolds (mm)
Mid-arm circumference (cm)
Triceps skinfolds (mm)
Mid-arm circumference (cm)
Triceps skinfolds (mm)

MAMC (cm) = MAC (cm) – [( x TSF (cm)]
cAMA =

(

) ! " #$% (

)&'

– 10 (men)

cAMA =

(

) ! " #$% (

)&'

– 6.5 (women)

(!
(!

MUSCLE STRENGTH
Hand Grip Dynamometer
Hand Grip Strength (kg)
Left (L)
or Right
(R) hand

Dominant
Hand

Avg

Date:
Date:
Date:
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SD

CV

Test #1

Test
#2

Test
#3

BIOCHEMICAL DATA
a Fasting

a Not fasting

Renal Profile (PostDialysis)

Date:

Date:

Date:

Test Result

Test Result

Test Result

Date:

Date:

Date:

Test Result

Test Result

Test Result

Normal
Range

BUN (mg/dL)
Creat. (mg/dL)
Na (mEq/L)
K (mEq/L)
Corrected Ca (mg/dL)
Phosph (mg/dL)
Serum Albumin (g/dL)
Ca

Renal Profile (Pre-Dialysis)
BUN (mg/dL)
Creat. (mg/dL)
Na (mEq/L)
K (mEq/L)
Corrected Ca (mg/dL)
Phosph (mg/dL)
Serum Albumin (g/dL)
Ca
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Normal
Range

Lipids and Glucose
Profile
Total Cholesterol
(mg/dL)
Triglycerides (mg/dL)

Test Result

Test Result

Test Result

Normal
Range

Test Result

Test Result

Test Result

Normal
Range

HDL-C (mg/dL)
LDL-C (mg/dL)
Glucose (mg/dL)
HgbA1C (g/dL)

Hematology and Others
Serum TIBC (μg/dL)
Hemoglobin (g/dL)
Hematocrit (%)
Ferritin (ng/mL)
Kt/V
nPCR (g/kg/day)
hsCRP (mg/L)
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24-HOUR DIETARY RECALL (1)

Time/Meal

Home (H)
/ Outside
of Home
(O)

Food
Eaten

Quantity
(cups, tsp,
Tbsp.,
ounces,
grams, etc.)
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Preparation
Method (fried,
grilled, roasted,
stewed)

Source of
food (fresh,
frozen,
canned,
etc.)

24-HOUR DIETARY RECALL (2)

Time/Meal

Home
(H)/Outside
of Home (O)

Food
Eaten

Quantity
(cups, tsp,
Tbsp.,
ounces,
grams,
etc.)
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Preparation
Method (fried,
grilled,
roasted,
stewed)

Source of
food
(fresh,
frozen,
canned,
etc.)

24-HOUR DIETARY RECALL (3)

Time/Meal

Home
(H)/Outside
of Home (O)

Food
Eaten

Quantity
(cups, tsp,
Tbsp.,
ounces,
grams,
etc.)
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Preparation
Method (fried,
grilled,
roasted,
stewed)

Source of
food
(fresh,
frozen,
canned,
etc.)

MALNUTRTION INFLAMMTION SCORE (1)
(A) Patients related medical history:
1- Change in end dialysis dry weight (overall change in past 3-6 months):

0

1

2

3

No decrease in dry weight
or weight loss <0.5 kg

Minor weight loss
(>0.5 kg but <1 kg)

Weight loss more than
one kg but <5%

Weight loss >5%

2- Dietary intake:

0

1

2

Good appetite and no
Somewhat sub-optimal
deterioration of the
solid diet intake
dietary
intake pattern(GI) symptoms:
3- Gastrointestinal

0

1

No symptoms with good
Appetite

Mild symptoms, poor
appetite or
nauseated

Moderate overall
decrease to full
liquid diet

2
Occasional vomiting or
moderate GI symptoms

3
Hypo-caloric liquid
to starvation

3
Frequent diarrhea or
vomiting or
severe

4- Functional capacity (nutritionally related functional impairment):

0

1

Normal to improved
functional capacity,
feeling fine

Occasional difficulty
with
baseline ambulation,
orof
feeling
5- Co-morbidity including number
yearstired
on Dialysis:

2

3

Difficulty with otherwise
independent activities
(e.g., going to bathroom)

Bed/chair-ridden, or little
to no physical
activity

0

1

2

3

On dialysis less than one
year and healthy
otherwise

Dialyzed for 1-4 years, or
mild comorbidity

Dialyzed >4 years, or
moderate comorbidity (including

Any severe, multiple comorbidity (2 or
more MCC*)

(B) Physical Exam (according to SGA criteria):
6- Decreased fat stores or loss of subcutaneous fat (below eyes, triceps, biceps, chest):

0

1

2

Normal (no change)

mild
moderat
7- Signs of muscle wasting (temple, clavicle, scapula, ribs, quadriceps, knee,einterosseous):

3
Severe

0

1

2

3

Normal (no change)

mild

moderat
e

Severe

(C) Body mass index:
8- Body mass index: BMI = Wt.(kg) / Ht2(m)

0

1

2

3

BMI>20 kg/m2

BMI: 18-19.99 kg/m2

BMI: 16-17.99 kg/m2

BMI<16 kg/m2

(D) Laboratory Parameters:
9- Serum albumin:

0

1

2

3

Albumin> 4.0 g/dL

Albumin: 3.5-3.9 g/dL

Albumin: 3.0-3.4 g/dL

Albumin: <3.0 g/dL

10- Serum TIBC (total Iron Binding Capacity): ♣

0

1

2

3

TIBC> 250 mg/dL

TIBC: 200-249 mg/dL

TIBC: 150-199 mg/dL

TIBC: <150 mg/dL

Total Score = sum of above 10 components (0-30):
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MALNUTRTION INFLAMMTION SCORE (2)
(A) Patients related medical history:
1- Change in end dialysis dry weight (overall change in past 3-6 months):

0

1

2

3

No decrease in dry weight
or weight loss <0.5 kg

Minor weight loss
(>0.5 kg but <1 kg)

Weight loss more than
one kg but <5%

Weight loss >5%

2- Dietary intake:

0

1

2

Good appetite and no
Somewhat sub-optimal
deterioration of the
solid diet intake
dietary
intake pattern(GI) symptoms:
3- Gastrointestinal

0

1

No symptoms with good
Appetite

Mild symptoms, poor
appetite or
nauseated

Moderate overall
decrease to full
liquid diet

2
Occasional vomiting or
moderate GI symptoms

3
Hypo-caloric liquid
to starvation

3
Frequent diarrhea or
vomiting or
severe

4- Functional capacity (nutritionally related functional impairment):

0

1

Normal to improved
functional capacity,
feeling fine

Occasional difficulty
with
baseline ambulation,
orof
feeling
5- Co-morbidity including number
yearstired
on Dialysis:

2

3

Difficulty with otherwise
independent activities
(e.g., going to bathroom)

Bed/chair-ridden, or little
to no physical
activity

0

1

2

3

On dialysis less than one
year and healthy
otherwise

Dialyzed for 1-4 years, or
mild comorbidity

Dialyzed >4 years, or
moderate comorbidity (including

Any severe, multiple comorbidity (2 or
more MCC*)

(B) Physical Exam (according to SGA criteria):
6- Decreased fat stores or loss of subcutaneous fat (below eyes, triceps, biceps, chest):

0

1

2

Normal (no change)

mild
moderat
7- Signs of muscle wasting (temple, clavicle, scapula, ribs, quadriceps, knee,einterosseous):

3
Severe

0

1

2

3

Normal (no change)

mild

moderat
e

Severe

(C) Body mass index:
8- Body mass index: BMI = Wt.(kg) / Ht2(m)

0

1

2

3

BMI>20 kg/m2

BMI: 18-19.99 kg/m2

BMI: 16-17.99 kg/m2

BMI<16 kg/m2

(D) Laboratory Parameters:
9- Serum albumin:

0

1

2

3

Albumin> 4.0 g/dL

Albumin: 3.5-3.9 g/dL

Albumin: 3.0-3.4 g/dL

Albumin: <3.0 g/dL

10- Serum TIBC (total Iron Binding Capacity): ♣

0

1

2

3

TIBC> 250 mg/dL

TIBC: 200-249 mg/dL

TIBC: 150-199 mg/dL

TIBC: <150 mg/dL

Total Score = sum of above 10 components (0-30):
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MALNUTRTION INFLAMMTION SCORE (3)
(A) Patients related medical history:
1- Change in end dialysis dry weight (overall change in past 3-6 months):

0

1

2

3

No decrease in dry weight
or weight loss <0.5 kg

Minor weight loss
(>0.5 kg but <1 kg)

Weight loss more than
one kg but <5%

Weight loss >5%

2- Dietary intake:

0

1

2

Good appetite and no
Somewhat sub-optimal
deterioration of the
solid diet intake
dietary
intake pattern(GI) symptoms:
3- Gastrointestinal

0

1

No symptoms with good
Appetite

Mild symptoms, poor
appetite or
nauseated

Moderate overall
decrease to full
liquid diet

2
Occasional vomiting or
moderate GI symptoms

3
Hypo-caloric liquid
to starvation

3
Frequent diarrhea or
vomiting or
severe

4- Functional capacity (nutritionally related functional impairment):

0

1

Normal to improved
functional capacity,
feeling fine

Occasional difficulty
with
baseline ambulation,
orof
feeling
5- Co-morbidity including number
yearstired
on Dialysis:

2

3

Difficulty with otherwise
independent activities
(e.g., going to bathroom)

Bed/chair-ridden, or little
to no physical
activity

0

1

2

3

On dialysis less than one
year and healthy
otherwise

Dialyzed for 1-4 years, or
mild comorbidity

Dialyzed >4 years, or
moderate comorbidity (including

Any severe, multiple comorbidity (2 or
more MCC*)

(B) Physical Exam (according to SGA criteria):
6- Decreased fat stores or loss of subcutaneous fat (below eyes, triceps, biceps, chest):

0

1

2

Normal (no change)

mild
moderat
7- Signs of muscle wasting (temple, clavicle, scapula, ribs, quadriceps, knee,einterosseous):

3
Severe

0

1

2

3

Normal (no change)

Mild

moderat
e

Severe

(C) Body mass index:
8- Body mass index: BMI = Wt.(kg) / Ht2(m)

0

1

2

3

BMI>20 kg/m2

BMI: 18-19.99 kg/m2

BMI: 16-17.99 kg/m2

BMI<16 kg/m2

(D) Laboratory Parameters:
9- Serum albumin:

0

1

2

3

Albumin> 4.0 g/dL

Albumin: 3.5-3.9 g/dL

Albumin: 3.0-3.4 g/dL

Albumin: <3.0 g/dL

10- Serum TIBC (total Iron Binding Capacity): ♣

0

1

2

3

TIBC> 250 mg/dL

TIBC: 200-249 mg/dL

TIBC: 150-199 mg/dL

TIBC: <150 mg/dL

Total Score = sum of above 10 components (0-30):

108

109
REFERENCES
1.

Webster AC, Nagler EV, Morton RL, Masson P: Chronic kidney disease. The lancet
2017, 389:1238-1252.

2.

Saudi Centre of Organ Transplantation: Dialysis in the Kingdom of Saudi Arabia. Saudi
Journal of Kidney Diseases and Transplantation 2018, 29:1012-1020.

3.

Alkhlaif A, Alsuraimi A, Bawazir A: Epidemiological Profile of End-Stage Renal
Diseases in Riyadh, Saudi Arabia. Asian Journal of Medicine and Health 2020:16-27.

4.

Lukowsky LR, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K: Patterns and
predictors of early mortality in incident hemodialysis patients: new insights. Am J
Nephrol 2012, 35:548-558.

5.

Alharbi K, Enrione EB: Malnutrition is prevalent among hemodialysis patients in
Jeddah, Saudi Arabia. Saudi journal of kidney diseases and transplantation 2012,
23:598.

6.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral
metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol
2004, 15:2208-2218.

7.

Qureshi AR, Alvestrand A, Divino JC, Gutierrez A, Heimburger O, Lindholm B,
Bergstrom J: Inflammation, malnutrition, and cardiac disease as predictors of
mortality in hemodialysis patients. Journal of the American Society of Nephrology 2002,
13:S28-S36.

8.

Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances
cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648658.

110
9.

Carrero JJ, Thomas F, Nagy K, Arogundade F, Avesani CM, Chan M, Chmielewski M,
Cordeiro AC, Espinosa-Cuevas A, Fiaccadori E, et al: Global Prevalence of ProteinEnergy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational
Studies From the International Society of Renal Nutrition and Metabolism. J Ren Nutr
2018, 28:380-392.

10.

Al Saran K, Elsayed S, Molhem A, Aldrees A, Alzara H: Nutritional assessment of
patients on hemodialysis in a large dialysis center. Saudi J Kidney Dis Transpl 2011,
22:675-681.

11.

Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, Kaysen G, Mitch WE,
Price SR, Wanner C, Wang AY, et al: Etiology of the protein-energy wasting syndrome
in chronic kidney disease: a consensus statement from the International Society of
Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 2013, 23:77-90.

12.

Chan M, Kelly J, Batterham M, Tapsell L: Malnutrition (subjective global assessment)
scores and serum albumin levels, but not body mass index values, at initiation of
dialysis are independent predictors of mortality: a 10-year clinical cohort study.
Journal of Renal Nutrition 2012, 22:547-557.

13.

Baines LS, Jindal RM: Non-compliance in patients receiving haemodialysis: an indepth review. Nephron 2000, 85:1-7.

14.

StaJules DE, Goldfarb DS, Pompeii ML, Liebman SE, Sherman RA: Assessment and
misassessment of potassium, phosphorus, and protein in the hemodialysis diet. In
Seminars in dialysis. Wiley Online Library; 2018: 479-486.

111
15.

Shariatpanahi ZV, Shariatpanahi MV, Shahbazi S, Hossaini A, Abadi A: Effect of
Ramadan fasting on some indices of insulin resistance and components of the
metabolic syndrome in healthy male adults. Br J Nutr 2008, 100:147-151.

16.

Roky R, Houti I, Moussamih S, Qotbi S, Aadil N: Physiological and chronobiological
changes during Ramadan intermittent fasting. Ann Nutr Metab 2004, 48:296-303.

17.

Ajabnoor GM, Bahijri S, Borai A, Abdulkhaliq AA, Al-Aama JY, Chrousos GP: Health
impact of fasting in Saudi Arabia during Ramadan: association with disturbed
circadian rhythm and metabolic and sleeping patterns. PLoS One 2014, 9:e96500.

18.

Alabed H, Abuzayan K, Waterhouse J: Changes in Subjective and Objective Measures
of Performance in Ramadan. Int Sci Index 2013, 7:412-421.

19.

Altaee MY, Ahamed AJ: Anthropometric measurements and lipid Profile Study
during Ramadan Fasting. Medical Journal of Babylon 2005, 2:177-182.

20.

BaHammam A: Sleep pattern, daytime sleepiness, and eating habits during the month
of Ramadan. Sleep and Hypnosis 2003, 5:165-174.

21.

Bahammam A: Effect of fasting during Ramadan on sleep architecture, daytime
sleepiness and sleep pattern. Sleep and Biological Rhythms 2004, 2:135-143.

22.

BaHammam A: Assessment of sleep patterns, daytime sleepiness, and chronotype
during Ramadan in fasting and nonfasting individuals. Saudi Med J 2005, 26:616-622.

23.

Bahammam A: Does Ramadan fasting affect sleep? International journal of clinical
practice 2006, 60:1631-1637.

24.

Bahijri S, Borai A, Ajabnoor G, Abdul Khaliq A, AlQassas I, Al-Shehri D, Chrousos G:
Relative metabolic stability, but disrupted circadian cortisol secretion during the
fasting month of Ramadan. PLoS One 2013, 8:e60917.

112
25.

Baykan S: Effects of Ramadan on nutritional status. J Nutr Diet 1981, 10:119-125.

26.

Margolis SA, Reed RL: Effect of religious practices of Ramadan on sleep and perceived
sleepiness of medical students. Teach Learn Med 2004, 16:145-149.

27.

Qasrawi SO, Pandi-Perumal SR, BaHammam AS: The effect of intermittent fasting
during Ramadan on sleep, sleepiness, cognitive function, and circadian rhythm. Sleep
Breath 2017, 21:577-586.

28.

Shadman Z, Poorsoltan N, Akhoundan M, Larijani B, Soleymanzadeh M, Akhgar Zhand
C, Seyed Rohani ZA, Khoshniat Nikoo M: Ramadan major dietary patterns. Iran Red
Crescent Med J 2014, 16:e16801.

29.

Alshamsi S, Binsaleh F, Hejaili F, Karkar A, Moussa D, Raza H, Parbat P, Al Suwida A,
Alobaili S, AlSehli R, Al Sayyari A: Changes in biochemical, hemodynamic, and
dialysis adherence parameters in hemodialysis patients during Ramadan. Hemodial
Int 2016, 20:270-276.

30.

Megahed AF, El-Kannishy G, Sayed-Ahmed N: Status of fasting in Ramadan of chronic
hemodialysis patients all over Egypt: A multicenter observational study. Saudi J
Kidney Dis Transpl 2019, 30:339-349.

31.

Khazneh E, Qaddumi J, Hamdan Z, Qudaimat F, Sbitany A, Jebrin K, Sawalmeh O,
Abuiram Y, Shraim M: The effects of Ramadan fasting on clinical and biochemical
markers among hemodialysis patients: A prospective cohort study. PLoS One 2019,
14:e0218745.

32.

Imtiaz S, Salman B, Dhrolia MF, Nasir K, Abbas HN, Ahmadl A: Clinical and
Biochemical Parameters of Hemodialysis Patients Before and During Islamic Month
of Ramadan. Iranian Journal of Kidney Diseases 2016, 10:75-78.

113
33.

Adanan NIH, Md Ali MS, Lim JH, Zakaria NF, Lim CTS, Yahya R, Abdul Gafor AH,
Karupaiah T, Daud ZM: Investigating Physical and Nutritional Changes During
Prolonged Intermittent Fasting in Hemodialysis Patients: A Prospective Cohort
Study. J Ren Nutr 2020, 30:e15-e26.

34.

Nazar CM: Significance of diet in chronic kidney disease. J Nephropharmacol 2013,
2:37-43.

35.

Kidney International Organization: Chapter 1: Definition and classification of CKD.
Kidney Int Suppl (2011) 2013, 3:19-62.

36.

van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P,
Gansevoort RT, Chronic Kidney Disease Prognosis C, van der Velde M, et al: Lower
estimated glomerular filtration rate and higher albuminuria are associated with allcause and cardiovascular mortality. A collaborative meta-analysis of high-risk
population cohorts. Kidney Int 2011, 79:1341-1352.

37.

Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT,
Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic
kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011, 80:1728.

38.

Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de
Jong PE, Coresh J, Chronic Kidney Disease Prognosis C: Lower estimated GFR and
higher albuminuria are associated with adverse kidney outcomes. A collaborative
meta-analysis of general and high-risk population cohorts. Kidney Int 2011, 80:93-104.

114
39.

Consortium CKDP: Association of estimated glomerular filtration rate and
albuminuria with all-cause and cardiovascular mortality in general population
cohorts: a collaborative meta-analysis. The Lancet 2010, 375:2073-2081.

40.

Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, Stevens P, Bilous R,
Lamb E, Coresh J: KDIGO 2012 clinical practice guideline for the evaluation and
management of chronic kidney disease. Kidney Int 2013, 3:5-14.

41.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD: Global
Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.
PLoS One 2016, 11:e0158765.

42.

International Society of Nephrology: A call for Action on Kidney Disease - United
Nations High Level Meeting on NCDs. International Society of Nephrology 2018.

43.

Al-Sayyari AA, Shaheen FA: End stage chronic kidney disease in Saudi Arabia. A
rapidly changing scene. Saudi Med J 2011, 32:339-346.

44.

Ahmed HG, Ginawi IA, Al-Hazimi AM: Prevalence Estimates of Chronic Kidney
Disease in Hail Region, KSA: in a Comprehensive Survey. International Journal of
Science and Research 2014, 3:252-256.

45.

Alsuwaida AO, Farag YMK, Al Sayyari AA, Mousa D, Alhejaili FF, Al-Harbi A, Housawi
A, Mittal BV, Singh AK: Epidemiology of chronic kidney disease in the Kingdom of
Saudi Arabia (SEEK-Saudi investigators)-a pilot study. Saudi Journal of Kidney
Diseases and Transplantation 2010, 21:1066.

46.

Ginawi IA, Elasbali AA, Ahmed HG, Ashankyty IM, Altamimi T, Alhasan S, Al-Hazimi
AM: Population screening for chronic kidney disease and its associated risk factors:

115
a survey in Hail region, KSA. Journal of Public Health and Epidemiology 2013, 5:285290.
47.

Alruwaili ASM, Alrowili ASM, Alshammari MNO, Alanazi FSS, Alanazi NS, Alanazi
MT, Alanazi RA, Almarjan MSM, Alenezi MHM, Aljamal MS: Prevalence and some of
determinant factors of chronic kidney diseases among Saudi elderly in Arar, KSA.
Egyptian Journal of Hospital Medicine 2018, 73:6522-6530.

48.

Navab KD, Elboudwarej O, Gharif M, Yu J, Hama SY, Safarpour S, Hough GP, Vakili L,
Reddy ST, Navab M, Vaziri ND: Chronic inflammatory disorders and accelerated
atherosclerosis: chronic kidney disease. Curr Pharm Des 2011, 17:17-20.

49.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF,
Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: epidemiology,
mechanisms, and prevention. Lancet 2013, 382:339-352.

50.

Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod
A, Vanholder R, Walker R, Wang H: The burden of kidney disease: improving global
outcomes. Kidney Int 2004, 66:1310-1314.

51.

ESRD patients in 2013: A global perspective. . Fresenius Medical Care AG & Co 2014,
294.

52.

Grassmann A, Gioberge S, Moeller S, Brown G: ESRD patients in 2004: global overview
of patient numbers, treatment modalities and associated trends. Nephrol Dial
Transplant 2005, 20:2587-2593.

53.

Saudi Center for Organ Transplantation: Annual Report for Organ Transplantation in
Kingdom of Sausi Arabia. Saudi Center for Organ Transplantation 2017.

116
54.

Saudi Center for Organ Transplantation: Dialysis in the Kingdom of Saudi Arabia. Saudi
Journal of Kidney Diseases and Transplantation 2015, 26:839-848.

55.

Chukwuonye, II, Ogah OS, Anyabolu EN, Ohagwu KA, Nwabuko OC, Onwuchekwa U,
Chukwuonye ME, Obi EC, Oviasu E: Prevalence of chronic kidney disease in Nigeria:
systematic review of population-based studies. Int J Nephrol Renovasc Dis 2018,
11:165-172.

56.

Chen TK, Knicely DH, Grams ME: Chronic Kidney Disease Diagnosis and
Management: A Review. JAMA 2019, 322:1294-1304.

57.

Khan YH, Mallhi TH, Sarriff A, Khan AH, Tanveer N: Prevalence of Chronic Kidney
Disease in Asia: A Systematic Review of Population-Based Studies. J Coll Physicians
Surg Pak 2018, 28:960-966.

58.

International Diabetes Federation: International Diabetes Federation: IDF Diabetes
Atlas. Brussels, Belgium 2017.

59.

Weir MR: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007,
2:581-590.

60.

Persson F, Rossing P: Diagnosis of diabetic kidney disease: state of the art and future
perspective. Kidney Int Suppl (2011) 2018, 8:2-7.

61.

Alicic RZ, Rooney MT, Tuttle KR: Diabetic Kidney Disease: Challenges, Progress, and
Possibilities. Clin J Am Soc Nephrol 2017, 12:2032-2045.

62.

International Diabetes Federation: IDF DIABETES ATLAS. (9th ed.2019.

63.

Kingdom of Saudi Arabia Ministry of Health: Saudi Health Interview Survey Results. .
2013.

117
64.

Alramadan MJ, Magliano DJ, Almigbal TH, Batais MA, Afroz A, Alramadhan HJ,
Mahfoud WF, Alragas AM, Billah B: Glycaemic control for people with type 2 diabetes
in Saudi Arabia–an urgent need for a review of management plan. BMC endocrine
disorders 2018, 18:62.

65.

Al-Nuaim AR, Mirdad S, Al-Rubeaan K, Al-Mazrou Y, Al-Attas O, Al-Daghari N:
Pattern and factors associated with glycemic control of Saudi diabetic patients. Ann
Saudi Med 1998, 18:109-112.

66.

Al-Hayek AA, Robert AA, Alzaid AA, Nusair HM, Zbaidi NS, Al-Eithan MH, Sam AE:
Association between diabetes self-care, medication adherence, anxiety, depression,
and glycemic control in type 2 diabetes. Saudi Medical Journal 2012, 33:681-683.

67.

Alsulaiman TA, Al-Ajmi HA, Al-Qahtani SM, Fadlallah IM, Nawar NE, Shukerallah RE,
Nadeem SR, Al-Weheedy NM, Al-Sulaiman KA, Hassan AA, et al: Control of type 2
diabetes in King Abdulaziz Housing City (Iskan) population, Saudi Arabia. J Family
Community Med 2016, 23:1-5.

68.

Almutairi MA, Said SM, Zainuddin H: Predictors of poor glycemic control among type
two diabetic patients. American Journal of Medicine and Medical Sciences 2013, 3:1721.

69.

Azushima K, Gurley SB, Coffman TM: Modelling diabetic nephropathy in mice. Nat
Rev Nephrol 2018, 14:48-56.

70.

Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH:
Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013,
24:302-308.

118
71.

Alwakeel JS, Sulimani R, Al-Asaad H, Al-Harbi A, Tarif N, Al-Suwaida A, Al-Mohaya S,
Isnani AC, Alam A, Hammad D: Diabetes complications in 1952 type 2 diabetes mellitus
patients managed in a single institution in Saudi Arabia. Ann Saudi Med 2008, 28:260266.

72.

Al-Rubeaan K, Siddiqui K, Alghonaim M, Youssef AM, AlNaqeb D: The Saudi Diabetic
Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical
parameters. Ann Saudi Med 2018, 38:46-56.

73.

Al-Rubeaan K, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, Al-Mutlaq HM,
David SK, AlNaqeb D: Diabetic nephropathy and its risk factors in a society with a
type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PLoS One
2014, 9:e88956.

74.

Alghaythi S, Alsudayri M, Alshammari F, Alrashidi AG, Alghaithi AM, Alrashidi MF,
Bashir AI: Prevalence of Diabetes among Patients with Chronic Kidney Disease in
Hail Region. The Egyptian Journal of Hospital Medicine 2018, 71:2434-2443.

75.

Stefanski A, Schmidt KG, Waldherr R, Ritz E: Early increase in blood pressure and
diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int
1996, 50:1321-1326.

76.

Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC,
Chen SC, Qiu Y, Wang C, Li S, et al: CKD in the United States: Kidney Early
Evaluation Program (KEEP) and National Health and Nutrition Examination Survey
(NHANES) 1999-2004. Am J Kidney Dis 2008, 51:S13-20.

119
77.

Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA,
Maggioni AP, Kazakiewicz D, May HT: European Society of Cardiology:
Cardiovascular Disease Statistics 2019. European Heart Journal 2019.

78.

Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K,
Abate KH, Akinyemiju TF: Global burden of hypertension and systolic blood pressure
of at least 110 to 115 mm Hg, 1990-2015. Jama 2017, 317:165-182.

79.

El Bcheraoui C, Memish ZA, Tuffaha M, Daoud F, Robinson M, Jaber S, Mikhitarian S,
Al Saeedi M, AlMazroa MA, Mokdad AH, Al Rabeeah AA: Hypertension and its
associated risk factors in the kingdom of saudi arabia, 2013: a national survey. Int J
Hypertens 2014, 2014:564679.

80.

Hadlaq EM, Faraj Z, Al FG, Al FO, Abuabat M, Awan K: Early Screening of Diabetes
and Hypertension in Primary Care Dental Clinics at King Saud University in Riyadh,
Kingdom of Saudi Arabia. The journal of contemporary dental practice 2017, 18:652659.

81.

Aldiab A, Shubair MM, Al-Zahrani JM, Aldossari KK, Al-Ghamdi S, Househ M, Razzak
HA, El-Metwally A, Jradi H: Prevalence of hypertension and prehypertension and its
associated cardioembolic risk factors; a population based cross-sectional study in
Alkharj, Saudi Arabia. BMC Public Health 2018, 18:1327.

82.

Alzamanan MDY, Al Rayshan ASM, Alyami AS: Risk Factors of Chronic Renal Failure
in Adult Patients at King Khalid Hospital, Najran City, Saudi Arabia. The Egyptian
Journal of Hospital Medicine 2018, 70:88-91.

83.

Tedla FM, Brar A, Browne R, Brown C: Hypertension in chronic kidney disease:
navigating the evidence. Int J Hypertens 2011, 2011:132405.

120
84.

Aldhahi AA, Al-Suliman HR, Al Nahdi AAS, Asiri AA, Asiri IN, Khudhayri AM, Asiri
MA: Relationship between Renal Failure and Hypertension among Patients in
Riyadh, Saudi Arabia. Egyptian Journal of Hospital Medicine 2018, 73:6702-6707.

85.

Qunibi WY, Alsibai MB, Taher S, Akhtar M: Renal-Disease in Saudi-Arabia - a Study
of 147 Renal Biopsies. King Faisal Specialist Hospital Medical Journal 1984, 4:317-323.

86.

Mitwalli AH, Al Wakeel JS, Al Mohaya SS, Malik HG, Abu-Aisha H, Hassan OS, Akhtar
M: Pattern of glomerular disease in Saudi Arabia. Am J Kidney Dis 1996, 27:797-802.

87.

Huraib S, Al Khader A, Shaheen FA, Abu Aisha H, Souqiyyeh MZ, Al Mohana F, Soliman
M, Al Wakeel J, Mitwalli A, Al Mohaya S, et al: The spectrum of glomerulonephritis in
saudi arabia: the results of the saudi registry. Saudi J Kidney Dis Transpl 2000, 11:434441.

88.

AlMatham KI, AlFayez AF, AlHarthi RA, AlMutairi FS, Alrasheedi FS, Mustafa A,
Ahmed M, AlMatouq BA, AlRowaei FA: Glomerulonephritis disease pattern at Saudi
tertiary care center. Saudi Med J 2017, 38:1113-1117.

89.

Naqvi R: Glomerulonephritis Contributing to Chronic Kidney Disease. Urol Nephrol
Open Access J 2017, 5:00179.

90.

Alkhunaizi AM: Pattern of renal pathology among renal biopsy specimens in Eastern
Saudi Arabia. Saudi Medical Journal 2007, 28:1676-1681.

91.

Nawaz Z, Mushtaq F, Mousa D, Rehman E, Sulaiman M, Aslam N, Khawaja N: Pattern
of glomerular disease in the Saudi population: a single-center, five-year retrospective
study. Saudi J Kidney Dis Transpl 2013, 24:1265-1270.

92.

Al-Homrany M, Alghamdi S, Al-Hwiesh A, Mousa D, Alwakeel J, Mitwalli A, Alsaad K,
Alharbi A, Kari J: Pattern of renal diseases and the need for establishment of renal

121
biopsy registry in Saudi Arabia. Saudi Journal of Kidney Diseases and Transplantation
2019, 30:628.
93.

Jalalah SM: Patterns of primary glomerular diseases among adults in the western
region of Saudi Arabia. Saudi Journal of Kidney Diseases and Transplantation 2009,
20:295.

94.

Albirdisi MR, Al-Homood IA: Characteristics of lupus nephritis in Saudi lupus
patients: A retrospective observational study. Lupus 2020, 29:1638-1643.

95.

Koye DN, Magliano DJ, Nelson RG, Pavkov ME: The Global Epidemiology of Diabetes
and Kidney Disease. Adv Chronic Kidney Dis 2018, 25:121-132.

96.

Sjaarda J, Gerstein HC, Yusuf S, Treleaven D, Walsh M, Mann JFE, Hess S, Pare G: Blood
HER2 and Uromodulin as Causal Mediators of CKD. J Am Soc Nephrol 2018, 29:13261335.

97.

Eknoyan G, Levin NW: Foreword. American Journal of Kidney Diseases 2002, 39:S14S16.

98.

Evans PD, Taal MW: Epidemiology and causes of chronic kidney disease. Medicine
2011, 39:402-406.

99.

Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME: Obesity, kidney dysfunction and
hypertension: mechanistic links. Nat Rev Nephrol 2019, 15:367-385.

100.

Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, Kovesdy CP, KalantarZadeh K: Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis
2014, 56:415-425.

122
101.

Al-Quwaidhi AJ, Pearce MS, Critchley JA, Sobngwi E, O'Flaherty M: Trends and future
projections of the prevalence of adult obesity in Saudi Arabia, 1992-2022. East
Mediterr Health J 2014, 20:589-595.

102.

World Health Organization: Global Health Observatory (GHO) data. Overweight and
obesity. 2017.

103.

Memish ZA, El Bcheraoui C, Tuffaha M, Robinson M, Daoud F, Jaber S, Mikhitarian S,
Al Saeedi M, AlMazroa MA, Mokdad AH: Peer reviewed: obesity and associated
factors—Kingdom of Saudi Arabia, 2013. Preventing chronic disease 2014, 11.

104.

Al Dokhi L, Habib SS: Assessment of gender differences in body composition and
physical fitness scoring in Saudi adults by bioelectrical impedance analysis. Acta Clin
Croat 2013, 52:189-194.

105.

Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L: Obesity-associated
hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003, 12:195-200.

106.

Aljabri K, Bokhari S, Alshareef M, Khan P, Elsaoud H, Jalal M: Prevalence of chronic
kidney disease and its risk factors in Saudi adults. J Med Pract Rev 2018, 2:241-244.

107.

Al-Hamed MH, Kurdi W, Alsahan N, Alabdullah Z, Abudraz R, Tulbah M, Alnemer M,
Khan R, Al-Jurayb H, Alahmed A, et al: Genetic spectrum of Saudi Arabian patients
with antenatal cystic kidney disease and ciliopathy phenotypes using a targeted renal
gene panel. J Med Genet 2016, 53:338-347.

108.

Evans PD, Taal MW: Epidemiology and causes of chronic kidney disease. Medicine
2015, 43:450-453.

109.

Mattoo TK: Genetically transmitted renal diseases in children: a saudi perspective.
Saudi J Kidney Dis Transpl 1998, 9:105-109.

123
110.

Bondagji NS: Antenatal diagnosis, prevalence and outcome of congenital anomalies of
the kidney and urinary tract in Saudi Arabia. Urol Ann 2014, 6:36-40.

111.

Sallout BI, Al-Hoshan MS, Attyyaa RA, Al Suleimat AA: Antenatal diagnosis,
prevalence and outcome of major congenital anomalies in Saudi Arabia: a hospitalbased study. Ann Saudi Med 2008, 28:272-276.

112.

AlGhonaim MA, Fathalla AA: Vascular calcification in patients with chronic kidney
disease on dialysis in the Kingdom of Saudi Arabia: A cross-sectional study. Saudi J
Kidney Dis Transpl 2019, 30:571-580.

113.

Bockenhauer D, Medlar AJ, Ashton E, Kleta R, Lench N: Genetic testing in renal disease.
Pediatr Nephrol 2012, 27:873-883.

114.

El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, Qurachi MM, Al-Omar AA: Regional
variations in the prevalence of consanguinity in Saudi Arabia. Saudi Med J 2007,
28:1881-1884.

115.

El Mouzan MI, Al Salloum AA, Al Herbish AS, Qurachi MM, Al Omar AA:
Consanguinity and major genetic disorders in Saudi children: a community-based
cross-sectional study. Ann Saudi Med 2008, 28:169-173.

116.

Liebman SE, Lamontagne SP, Huang LS, Messing S, Bushinsky DA: Smoking in dialysis
patients: a systematic review and meta-analysis of mortality and cardiovascular
morbidity. Am J Kidney Dis 2011, 58:257-265.

117.

Orth SR, Hallan SI: Smoking: a risk factor for progression of chronic kidney disease
and for cardiovascular morbidity and mortality in renal patients--absence of evidence
or evidence of absence? Clin J Am Soc Nephrol 2008, 3:226-236.

124
118.

Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE: Smoking
is related to albuminuria and abnormal renal function in nondiabetic persons. Ann
Intern Med 2000, 133:585-591.

119.

Mahmood FM: Prevalence and prevention of lifestyle-related diseases in Saudi Arabia.
Int J Health Sci (Qassim) 2018, 12:1-2.

120.

Ginawi IA, Ahmed HG, Al-Hazimi AM: Assessment of risk factors for chronic kidney
disease in Saudi Arabia. Hypertension 2014, 1.

121.

Al Zaben F, Khalifa DA, Sehlo MG, Al Shohaib S, Shaheen F, Alhozali H, Hariri AO,
Ahmad RG, Kabli MR, Koenig HG: Depression in patients with chronic kidney disease
on dialysis in Saudi Arabia. Int Urol Nephrol 2014, 46:2393-2402.

122.

Carrero JJ, Stenvinkel P: Inflammation in End‐Stage Renal Disease—What Have We
Learned in 10 Years? In Seminars in dialysis. Wiley Online Library; 2010: 498-509.

123.

Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T:
Strong association between malnutrition, inflammation, and atherosclerosis in
chronic renal failure. Kidney international 1999, 55:1899-1911.

124.

Jankowska M, Cobo G, Lindholm B, Stenvinkel P: Inflammation and protein-energy
wasting in the uremic milieu. In Expanded Hemodialysis. Volume 191: Karger
Publishers; 2017: 58-71

125.

Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of
death in chronic dialysis patients. Nephrol Dial Transplant 1999, 14:1956-1960.

126.

Al-Muammar M, Fetohy E: Nutritional Status, Dietary Practices and Biochemical
Parameters of Hemodialysis Patients in Riyadh. Journal of High Institute of Public
Health 2011, 41:219-237.

125
127.

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough
PA, Kasiske BL, Kelepouris E, Klag MJ: Kidney disease as a risk factor for
development of cardiovascular disease: a statement from the American Heart
Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure
Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003,
108:2154-2169.

128.

Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL,
Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction:
a high-risk combination. Ann Intern Med 2002, 137:563-570.

129.

Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB: The impact of
renal insufficiency on clinical outcomes in patients undergoing percutaneous
coronary interventions. J Am Coll Cardiol 2002, 39:1113-1119.

130.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the
risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004,
351:1296-1305.

131.

Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, Salem DN, Levey
AS, Sarnak MJ: Cardiovascular outcomes and all-cause mortality: exploring the
interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006, 48:392401.

132.

Fort J: Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl 2005,
68:S25-29.

133.

Van Duong T, Wong T-C, Su C-T, Chen H-H, Chen T-W, Chen T-H, Hsu Y-H, Peng S-J,
Kuo K-L, Liu H-C: Associations of dietary macronutrients and micronutrients with

126
the traditional and nontraditional risk factors for cardiovascular disease among
hemodialysis patients: A clinical cross-sectional study. Medicine 2018, 97.
134.

Hu J, La Vecchia C, Morrison H, Negri E, Mery L, Canadian Cancer Registries
Epidemiology Research G: Salt, processed meat and the risk of cancer. Eur J Cancer
Prev 2011, 20:132-139.

135.

Ash S, Campbell KL, Bogard J, Millichamp A: Nutrition prescription to achieve positive
outcomes in chronic kidney disease: a systematic review. Nutrients 2014, 6:416-451.

136.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF,
Matsushita K, Wen CP: Chronic kidney disease and cardiovascular risk: epidemiology,
mechanisms, and prevention. The Lancet 2013, 382:339-352.

137.

Lacson Jr E, Ikizler TA, Lazarus JM, Teng M, Hakim RM: Potential impact of nutritional
intervention on end-stage renal disease hospitalization, death, and treatment costs.
Journal of Renal Nutrition 2007, 17:363-371.

138.

Kovesdy CP: Malnutrition in dialysis patients—the need for intervention despite
uncertain benefits. In Seminars in dialysis. Wiley Online Library; 2016: 28-34.

139.

Shan Z, Guo Y, Hu FB, Liu L, Qi Q: Association of Low-Carbohydrate and Low-Fat
Diets With Mortality Among US Adults. JAMA Internal Medicine 2020.

140.

Ahmed H, Ginawi I, Alogla S, Ismael R, Alqufayi A: Assessment of the Relationship
between CVD and CKD in a Community based Survey. J Cardiol Curr Res 2016,
6:00221.

141.

Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk
factors predict coronary heart disease in chronic kidney disease: results from the
atherosclerosis risk in communities study. J Am Soc Nephrol 2005, 16:529-538.

127
142.

Qunibi WY: Dyslipidemia in dialysis patients. In Seminars in dialysis. Wiley Online
Library; 2015: 345-353.

143.

Al-Khader AA, Al-Hasani MK, Dhar JM, Al-Sulaiman M: Effect of diet during
Ramadan on patients on chronic haemodialysis. Saudi medical journal 1991, 12:30-31.

144.

Kaysen GA: Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr
2009, 19:73-77.

145.

Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A, Kanbay M: Disorders
of Lipid Metabolism in Chronic Kidney Disease. Blood Purif 2018, 46:144-152.

146.

Gluba-Brzózka A, Franczyk B, Banach M, Rysz-Górzyńska M: Do HDL and LDL
subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
International urology and nephrology 2017, 49:155-164.

147.

Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, Iqbal R, Kumar R,
Wentzel-Viljoen E, Rosengren A, et al: Associations of fats and carbohydrate intake
with cardiovascular disease and mortality in 18 countries from five continents
(PURE): a prospective cohort study. Lancet 2017, 390:2050-2062.

148.

Chiu S, Williams PT, Krauss RM: Effects of a very high saturated fat diet on LDL
particles in adults with atherogenic dyslipidemia: A randomized controlled trial.
PLoS One 2017, 12:e0170664.

149.

Brassard D, Laramee C, Provencher V, Vohl MC, Robitaille J, Lemieux S, Lamarche B:
Consumption of low nutritive value foods and cardiometabolic risk factors among
French-speaking adults from Quebec, Canada: the PREDISE study. Nutr J 2019,
18:49.

128
150.

Adam A, Osama S, Muhammad KI: Nutrition and food consumption patterns in the
Kingdom of Saudi Arabia. Pakistan Journal of Nutrition 2014, 13:181.

151.

Al-Kaabba AF, Al-Hamdan NA, El Tahir A, Abdalla AM, Saeed AA, Hamza MA:
Prevalence and correlates of dyslipidemia among adults in Saudi Arabia: results from
a national survey. Open Journal of Endocrine and Metabolic Diseases 2012, 2:89.

152.

Bakhotmah BA: The puzzle of self-reported weight gain in a month of fasting
(Ramadan) among a cohort of Saudi families in Jeddah, Western Saudi Arabia. Nutr
J 2011, 10:84.

153.

Mitwalli AH, Alam AA, Al Wakeel JS, Isnani AC: Dyslipidemia in dialysis patients.
Saudi J Kidney Dis Transpl 2011, 22:689-694.

154.

Al-Hwiesh A: Study of Lipid Abnormalities in Patients Maintained on Haemodialysis
or Automated Peritoneal Dialysis in the Eastern Province of Saudi Arabia. 1: 346.
doi: 10.4172/scientificreports. 346 Page 2 of 4 Volume 1• Issue 7• 2012 at solution
densities of 1.006 g/mL, 1.019 g/mL, 1.063 g/mL and 1.21 g/mL, respectively. All
lipoprotein density classes were dialyzed against 015 mol/L NaCl containing 005% EDTA
(pH 70) 2012.

155.

O'Seaghdha CM, Foley RN: Septicemia, access, cardiovascular disease, and death in
dialysis patients. Perit Dial Int 2005, 25:534-540.

156.

Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG: Vintage, nutritional status,
and survival in hemodialysis patients. Kidney Int 2000, 57:1176-1181.

157.

Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, Kopple JD,
Kalantar-Zadeh K: Serum and dialysate potassium concentrations and survival in
hemodialysis patients. Clin J Am Soc Nephrol 2007, 2:999-1007.

129
158.

Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu J,
Mau LW, McBean M, et al: Excerpts from the US Renal Data System 2009 Annual
Data Report. Am J Kidney Dis 2010, 55:S1-420, A426-427.

159.

Foley RN, Chen SC, Solid CA, Gilbertson DT, Collins AJ: Early mortality in patients
starting dialysis appears to go unregistered. Kidney Int 2014, 86:392-398.

160.

Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, Balkrishnan R,
Bragg-Gresham J, Cao J, Chen JL, et al: US Renal Data System 2016 Annual Data
Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2017,
69:A7-A8.

161.

Robinson BM, Zhang JY, Morgenstern H, Bradbury BD, Ng LJ, McCullough KP, Gillespie
BW, Hakim R, Rayner H, Fort J, et al: Worldwide, mortality risk is high soon after
initiation of hemodialysis. Kidney International 2014, 85:158-165.

162.

Hazara AM, Bhandari S: Early Mortality Rates After Commencement of Maintenance
Hemodialysis: A Systematic Review and Meta-Analysis. Ther Apher Dial 2019.

163.

Zhao X, Wang M, Zuo L: Early mortality risk in incident Chinese hemodialysis
patients: a retrospective cohort study. Ren Fail 2017, 39:526-532.

164.

Chung SH, Lindholm B, Lee HB: Influence of initial nutritional status on continuous
ambulatory peritoneal dialysis patient survival. Perit Dial Int 2000, 20:19-26.

165.

Rysz J, Franczyk B, Cialkowska-Rysz A, Gluba-Brzozka A: The Effect of Diet on the
Survival of Patients with Chronic Kidney Disease. Nutrients 2017, 9:495.

166.

Luis D, Zlatkis K, Comenge B, Garcia Z, Navarro JF, Lorenzo V, Carrero JJ: Dietary
Quality and Adherence to Dietary Recommendations in Patients Undergoing
Hemodialysis. J Ren Nutr 2016, 26:190-195.

130
167.

Slomowitz LA, Monteon FJ, Grosvenor M, Laidlaw SA, Kopple JD: Effect of energy
intake on nutritional status in maintenance hemodialysis patients. Kidney Int 1989,
35:704-711.

168.

Kopple JD: National kidney foundation K/DOQI clinical practice guidelines for
nutrition in chronic renal failure. Am J Kidney Dis 2001, 37:S66-70.

169.

Ikizler TA, Flakoll PJ, Parker RA, Hakim RM: Amino acid and albumin losses during
hemodialysis. Kidney Int 1994, 46:830-837.

170.

Ikizler TA, Pupim LB, Brouillette JR, Levenhagen DK, Farmer K, Hakim RM, Flakoll PJ:
Hemodialysis stimulates muscle and whole body protein loss and alters substrate
oxidation. Am J Physiol Endocrinol Metab 2002, 282:E107-116.

171.

Hu E, Coresh J, Anderson C, Appel L, Grams M, Crews D, Mills K, He J, Scialla J, Rahman
M: Dietary Patterns and Risk of Chronic Kidney Disease Progression and All-Cause
Mortality: Findings from the CRIC study. Current Developments in Nutrition 2020,
4:1415-1415.

172.

Laville M, Fouque D: Nutritional aspects in hemodialysis. Kidney Int Suppl 2000,
76:S133-139.

173.

Mitch WE: Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin
Invest 2002, 110:437-439.

174.

Steinman TI: ESRD in the geriatric population: the crisis of managed care and the
opportunity of disease management. In Seminars in dialysis. Wiley Online Library;
2002: 84-87.

131
175.

de Araújo IC, Kamimura MA, Draibe SA, Canziani MEF, Manfredi SR, Avesani CM,
Sesso R, Cuppari L: Nutritional parameters and mortality in incident hemodialysis
patients. Journal of Renal Nutrition 2006, 16:27-35.

176.

Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ, Kopple JD: Normalized
protein nitrogen appearance is correlated with hospitalization and mortality in
hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr 2003, 13:15-25.

177.

Koppe L, Fouque D, Kalantar-Zadeh K: Kidney cachexia or protein-energy wasting in
chronic kidney disease: facts and numbers. J Cachexia Sarcopenia Muscle 2019,
10:479-484.

178.

Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H,
Guarnieri G, Ikizler TA, Kaysen G, et al: A proposed nomenclature and diagnostic
criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int
2008, 73:391-398.

179.

El-Soadaa SS, Abdelhafez AM, Zahran SS: Nutritional Assessment of Patients under
Hemodialysis in King Faisal Hospital in Makkah, Saudi Arabia. J Am Sci 2013, 6:9.

180.

Cupisti A, D'Alessandro C, Valeri A, Capitanini A, Meola M, Betti G, Barsotti G: Food
intake and nutritional status in stable hemodialysis patients. Renal failure 2010, 32:4754.

181.

Kang SS, Chang JW, Park Y: Nutritional Status Predicts 10-Year Mortality in Patients
with End-Stage Renal Disease on Hemodialysis. Nutrients 2017, 9:399.

182.

Seiler WO: Clinical pictures of malnutrition in ill elderly subjects. Nutrition 2001,
17:496-498.

132
183.

Ekramzadeh M, Mazloom Z, Jafari P, Ayatollahi M, Sagheb MM: Major barriers
responsible for malnutrition in hemodialysis patients: challenges to optimal nutrition.
Nephrourol Mon 2014, 6:e23158.

184.

de Oliveira Santin FG, Bigogno FG, Rodrigues JCD, Cuppari L, Avesani CM: Concurrent
and predictive validity of composite methods to assess nutritional status in older
adults on hemodialysis. Journal of Renal Nutrition 2016, 26:18-25.

185.

Wolfson M, Strong CJ, Minturn D, Gray DK, Kopple JD: Nutritional status and
lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 1984,
39:547-555.

186.

Macdiarmid J, Blundell J: Assessing dietary intake: Who, what and why of underreporting. Nutr Res Rev 1998, 11:231-253.

187.

Nielsen SJ, Adair L: An alternative to dietary data exclusions. J Am Diet Assoc 2007,
107:792-799.

188.

Choi HY, Ha SK: Potassium balances in maintenance hemodialysis. Electrolyte Blood
Press 2013, 11:9-16.

189.

Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB: Serum Potassium Levels and
Mortality in Hemodialysis Patients: A Retrospective Cohort Study. Am J Nephrol
2016, 44:179-186.

190.

Kalantar-Zadeh K, Fouque D: Nutritional Management of Chronic Kidney Disease. N
Engl J Med 2017, 377:1765-1776.

191.

Daud M, Azuan Z: Multifaceted Nutritional Intervention In Hemodialysis Patients.
2014.

133
192.

Agarwal R: Hypervolemia is associated with increased mortality among hemodialysis
patients. Hypertension 2010, 56:512-517.

193.

Martin LC, Franco RJ, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barretti BB, Balbi
AL, Barsanti R, Padovani C, Gavras H: Association between hypervolemia and
ventricular hypertrophy in hemodialysis patients. Am J Hypertens 2004, 17:1163-1169.

194.

Weir MR: Hypervolemia and blood pressure: powerful indicators of increased
mortality among hemodialysis patients. Am Heart Assoc; 2010.

195.

Chou JA, Kalantar-Zadeh K: Volume Balance and Intradialytic Ultrafiltration Rate in
the Hemodialysis Patient. Curr Heart Fail Rep 2017, 14:421-427.

196.

Al Wakeel JS, Mitwalli AH, Al Mohaya S, Abu-Aisha H, Tarif N, Malik GH, Hammad D:
Morbidity and mortality in ESRD patients on dialysis. Saudi J Kidney Dis Transpl
2002, 13:473-477.

197.

Al Wakeel JS: Kidney function and metabolic profile of chronic kidney disease and
hemodialysis patients during Ramadan fasting. Iran J Kidney Dis 2014, 8:321-328.

198.

Sakr AH: Fasting in Islam. J Am Diet Assoc 1975, 67:17-21.

199.

Iraki L, Bogdan A, Hakkou F, Amrani N, Abkari A, Touitou Y: Ramadan diet restrictions
modify the circadian time structure in humans. A study on plasma gastrin, insulin,
glucose, and calcium and on gastric pH. J Clin Endocrinol Metab 1997, 82:1261-1273.

200.

Ali Z, Abizari AR: Ramadan fasting alters food patterns, dietary diversity and body
weight among Ghanaian adolescents. Nutr J 2018, 17:75.

201.

Roky R, Chapotot F, Hakkou F, Benchekroun MT, Buguet A: Sleep during Ramadan
intermittent fasting. J Sleep Res 2001, 10:319-327.

134
202.

Angel JF, Angel JF, SCHWARTZ NE: Metabolic changes resulting from decreased
meal frequency in adult male Muslims during the Ramadan fast. 1975.

203.

BaHammam A, Alrajeh M, Albabtain M, Bahammam S, Sharif M: Circadian pattern of
sleep, energy expenditure, and body temperature of young healthy men during the
intermittent fasting of Ramadan. Appetite 2010, 54:426-429.

204.

Frost G, Pirani S: Meal frequency and nutritional intake during Ramadan: a pilot
study. Hum Nutr Appl Nutr 1987, 41:47-50.

205.

Hassan A, Meo S, Usmani A, Shaikh T: Diabetes during Ramadan–PRE-approach
model: presentation, risk stratification, education. Eur Rev Med Pharmacol Sci 2014,
18:1798-1805.

206.

Meo SA, Hassan A: Physiological changes during fasting in Ramadan. J Pak Med Assoc
2015, 65:S6-S14.

207.

Bogdan A, Bouchareb B, Touitou Y: Ramadan fasting alters endocrine and
neuroendocrine circadian patterns. Meal–time as a synchronizer in humans? Life
sciences 2001, 68:1607-1615.

208.

Fernando HA, Zibellini J, Harris RA, Seimon RV, Sainsbury A: Effect of Ramadan
Fasting on Weight and Body Composition in Healthy Non-Athlete Adults: A
Systematic Review and Meta-Analysis. Nutrients 2019, 11.

209.

Mohktar MS, Ibrahim F: Assessment of salat taraweeh and fasting effect on body
composition. In 4th Kuala Lumpur International Conference on Biomedical Engineering
2008. Springer; 2008: 133-136.

135
210.

Lessan N, Saadane I, Alkaf B, Hambly C, Buckley AJ, Finer N, Speakman JR, Barakat
MT: The effects of Ramadan fasting on activity and energy expenditure. Am J Clin
Nutr 2018, 107:54-61.

211.

el Ati J, Beji C, Danguir J: Increased fat oxidation during Ramadan fasting in healthy
women: an adaptative mechanism for body-weight maintenance. Am J Clin Nutr 1995,
62:302-307.

212.

Ezzat S, Amin M: Energy intake, dietary pattern and physical activity during
Ramadan. International Journal of Food, Nutrition and Public Health 2013, 6:291.

213.

Gharbi M, Akrout M, Zouari B: [Food intake during and outside Ramadan]. East
Mediterr Health J 2003, 9:131-140.

214.

Sadiya A, Ahmed S, Siddieg HH, Babas IJ, Carlsson M: Effect of Ramadan fasting on
metabolic markers, body composition, and dietary intake in Emiratis of Ajman
(UAE) with metabolic syndrome. Diabetes Metab Syndr Obes 2011, 4:409-416.

215.

Chandalia HB, Bhargav A, Kataria V: Dietary pattern during Ramadan fasting and its
effect on the metabolic control of diabetes. Practical Diabetes International 1987,
4:287-290.

216.

Beltaifa L, Bouguerra R, Ben CS, Jabrane H, El-Khadhi A, Ben MR, Doghri T: Food
intake, and anthropometrical and biological parameters in adult Tunisians during
fasting at Ramadan. Eastern Mediterranean health journal= La revue de sante de la
Mediterranee orientale= al-Majallah al-sihhiyah li-sharq al-mutawassit 2002, 8:603-611.

217.

Yeoh EC, Zainudin SB, Loh WN, Chua CL, Fun S, Subramaniam T, Sum CF, Lim SC:
Fasting during Ramadan and Associated Changes in Glycaemia, Caloric Intake and

136
Body Composition with Gender Differences in Singapore. Ann Acad Med Singap 2015,
44:202-206.
218.

Ibrahim WH, Habib HM, Jarrar AH, Al Baz SA: Effect of Ramadan fasting on markers
of oxidative stress and serum biochemical markers of cellular damage in healthy
subjects. Ann Nutr Metab 2008, 53:175-181.

219.

Nachvak SM, Pasdar Y, Pirsaheb S, Darbandi M, Niazi P, Mostafai R, Speakman JR:
Effects of Ramadan on food intake, glucose homeostasis, lipid profiles and body
composition composition. Eur J Clin Nutr 2019, 73:594-600.

220.

Karaagaoglu N, Yucecan S: Some behavioral changes observed among fasting subjects,
their nutritional habits and energy expenditure in Ramadan. International journal of
food sciences and nutrition 2000, 51:125.

221.

Traditional Ramadan Foods from around the World. Available online: https://www.
nutrition.org.uk/healthyliving/seasons/ramadan.html?start=1

[

https://www.nutrition.org.uk/healthyliving/seasons/ramadan.html?start=1 ]
222.

Lamine F, Bouguerra R, Jabrane J, Marrakchi Z, Ben Rayana MC, Ben Slama C, Gaigi S:
Food intake and high density lipoprotein cholesterol levels changes during ramadan
fasting in healthy young subjects. Tunis Med 2006, 84:647-650.

223.

Poh B, Zawiah H, Ismail M, Henry C: Changes in body weight, dietary intake and
activity pattern of adolescents during Ramadan. Malays J Nutr 1996, 2:1-10.

224.

Suriani I, Shamsuddin K, Abdul Latif K, Saad HA: The effect of the Malaysian Food
Guideline guidance on a group of overweight and obese women during Ramadan.
Saudi Med J 2015, 36:40-45.

137
225.

Trepanowski JF, Bloomer RJ: The impact of religious fasting on human health. Nutr J
2010, 9:57.

226.

Ibrahim NSI, Hardinsyah H, Setiawan B: Hydration status and liver function of young
men before and after Ramadan fasting. Jurnal Gizi dan Pangan 2018, 13:33-38.

227.

Mirmiran P, Bahadoran Z, Gaeini Z, Moslehi N, Azizi F: Effects of Ramadan
intermittent fasting on lipid and lipoprotein parameters: An updated meta-analysis.
Nutr Metab Cardiovasc Dis 2019, 29:906-915.

228.

Kul S, Savaş E, Öztürk Z, Karadağ G: Does Ramadan fasting alter body weight and
blood lipids and fasting blood glucose in a healthy population? A meta-analysis.
Journal of religion and health 2014, 53:929-942.

229.

Aksungar FB, Topkaya AE, Akyildiz M: Interleukin-6, C-reactive protein and
biochemical parameters during prolonged intermittent fasting. Ann Nutr Metab 2007,
51:88-95.

230.

Maideen P, Mohamed N, Jumale Ab, Balasubramaniam R: Adverse health effects
associated with Islamic fasting-A literature review. Journal of Fasting and Health 2017,
5:113-118.

231.

Leiper JB, Molla AM, Molla AM: Effects on health of fluid restriction during fasting
in Ramadan. Eur J Clin Nutr 2003, 57 Suppl 2:S30-38.

232.

Hendawy A: Effect of fasting on renal physiology. Journal of Nutrition, Fasting and
Health 2014, 2:110-112.

233.

Boobes Y, Bernieh B, Al Hakim MR: Fasting Ramadan in kidney transplant patients
is safe. Saudi J Kidney Dis Transpl 2009, 20:198-200.

138
234.

Said T, Nampoory M, Haleem M, Nair M, Johny K, Samhan M, Al-Mousawi M: Ramadan
fast in kidney transplant recipients: a prospective comparative study. In
Transplantation proceedings. Elsevier Science Publishing Company, Inc.; 2003: 26142616.

235.

Arslan Y, Kiziltan G: Nutrition-related cardiovascular risk factors in hemodialysis
patients. J Ren Nutr 2010, 20:185-192.

236.

Badimon L, Chagas P, Chiva-Blanch G: Diet and Cardiovascular Disease: Effects of
Foods and Nutrients in Classical and Emerging Cardiovascular Risk Factors. Curr
Med Chem 2019, 26:3639-3651.

237.

NasrAllah MM, Osman NA: Fasting during the month of Ramadan among patients
with chronic kidney disease: renal and cardiovascular outcomes. Clinical kidney
journal 2014, 7:348-353.

238.

Imtiaz S, Nasir K, Dhrolia MF, Hussain M, Abbas HN, Ahmad A: Mortality Trend
Among Hemodialysis Patients During the Islamic Month of Ramadan: A 24 Years
Retrospective Study. Jcpsp-Journal of the College of Physicians and Surgeons Pakistan
2015, 25:189-192.

239.

Bragazzi NL: Ramadan fasting and chronic kidney disease: A systematic review. J Res
Med Sci 2014, 19:665-676.

240.

Bernieh B, Al Hakim MR, Boobes Y, Abu Zidan FM: Fasting Ramadan in chronic
kidney disease patients: clinical and biochemical effects. Saudi J Kidney Dis Transpl
2010, 21:898-902.

139
241.

El-Wakil HS, Desoky I, Lotfy N, Adam AG: Fasting the month of Ramadan by
Muslims: could it be injurious to their kidneys? Saudi Journal of Kidney Diseases and
Transplantation 2007, 18:349.

242.

Mbarki H, Tazi N, Najdi A, Tachfouti N, Arrayhani M, Sqalli T: Effects of fasting during
Ramadan on renal function of patients with chronic kidney disease. Saudi J Kidney
Dis Transpl 2015, 26:320-324.

243.

Al Muhanna FA: Ramadan fasting and renal failure. Saudi Med J 1998, 19:319-321.

244.

Bakhit AA, Kurdi AM, Wadera JJ, Alsuwaida AO: Effects of Ramadan fasting on
moderate to severe chronic kidney disease. A prospective observational study. Saudi
Med J 2017, 38:48-52.

245.

Kara E, Sahin OZ, Kizilkaya B, Ozturk B, Pusuroglu G, Yildirim S, Sevinc M, Sahutoglu
T: Fasting in Ramadan is not associated with deterioration of chronic kidney disease:
A prospective observational study. Saudi Journal of Kidney Diseases and
Transplantation 2017, 28:68.

246.

Hassan S, Hassan F, Abbas N, Hassan K, Khatib N, Edgim R, Fadol R, Khazim K: Does
Ramadan Fasting Affect Hydration Status and Kidney Function in CKD Patients?
Annals of Nutrition and Metabolism 2018, 72:241-247.

247.

Chowdhury A, Khan H, Lasker SS, Chowdhury TA: Fasting outcomes in people with
diabetes and chronic kidney disease in East London during Ramadan 2018: The East
London diabetes in Ramadan survey. Diabetes Res Clin Pract 2019, 152:166-170.

248.

Dogan I, Eser B, Kayadibi H: The effect of Ramadan fasting on renal functions in
patients with chronic kidney disease. Turkish Journal of Biochemistry 2019.

140
249.

Baloglu I, Turkmen K, Kocyigit I, Altunoren O, Demirtas L, Zararsiz G, Eroglu E: The
effect of Ramadan fasting on kidney function in patients with chronic kidney disease.
Int Urol Nephrol 2020, 52:1337-1343.

250.

Wan Md Adnan WA, Zaharan NL, Wong MH, Lim SK: The effects of intermittent
fasting during the month of Ramadan in chronic haemodialysis patients in a tropical
climate country. PLoS One 2014, 9:e114262.

251.

Garrow JS, Webster J: Quetelet's index (W/H2) as a measure of fatness. International
journal of obesity 1985, 9:147-153.

252.

Heymsfield SB, McManus C, Smith J, Stevens V, Nixon DW: Anthropometric
measurement of muscle mass: revised equations for calculating bone-free arm muscle
area. Am J Clin Nutr 1982, 36:680-690.

253.

Delanaye P, Quinonez K, Buckinx F, Krzesinski J, Bruyère O: Hand grip strength
measurement in haemodialysis patients: before or after the session? Clinical kidney
journal 2017, 11:555-558.

254.

Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC: A modified quantitative
subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transplant
1999, 14:1732-1738.

255.

Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF,
Sypniewska G, Wiklund O, Borén J: Fasting is not routinely required for determination
of a lipid profile: clinical and laboratory implications including flagging at desirable
concentration cut-points—a joint consensus statement from the European
Atherosclerosis Society and European Federation of Clinical Chemistry and
Laboratory Medicine. European heart journal 2016, 37:1944-1958.

141
256.

Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clinical chemistry 1972, 18:499-502.

257.

Harris JA, Benedict FG: A biometric study of basal metabolism in man. Carnegie institution
of Washington; 1919.

258.

National Kidney Foundation Kidney Disease Outcomes Quality Initiative: Clinical
practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000, 35:S1S140.

259.

Tashkandi B, Kaur D, Latifi E, Tallman DA, Chinna K, Daud ZAM, Karupaiah T, Alhozali
H, Khosla P: Lipids, Lipoprotein Distribution and Nutritional Parameters over the
Ramadan Period in Hemodialysis Patients. Nutrients 2019, 11:2225.

260.

Black AE, Cole TJ: Within- and between-subject variation in energy expenditure
measured by the doubly-labelled water technique: implications for validating
reported dietary energy intake. Eur J Clin Nutr 2000, 54:386-394.

261.

Fouque D, Vennegoor M, Ter Wee P, Wanner C, Basci A, Canaud B, Haage P, Konner K,
Kooman J, Martin-Malo A: Raymond Vanholder EBPG Guideline on Nutrition
Nephrol. Dial Transplant, May 2007, 22.

262.

Huang TT, Roberts SB, Howarth NC, McCrory MA: Effect of screening out implausible
energy intake reports on relationships between diet and BMI. Obes Res 2005, 13:12051217.

263.

McCrory MA, McCrory MA, Hajduk CL, Roberts SB: Procedures for screening out
inaccurate reports of dietary energy intake. Public Health Nutr 2002, 5:873-882.

142
264.

Harangi M, Szentpéteri A, Nádró B, Lőrincz H, Seres I, Páll D, Paragh G: HDL
subfraction distribution and HDL function in untreated dyslipidemic patients. Vessel
Plus 2017, 1:166-173.

265.

Krychtiuk KA, Kastl SP, Pfaffenberger S, Lenz M, Hofbauer SL, Wonnerth A, Koller L,
Katsaros KM, Pongratz T, Goliasch G, et al: Association of small dense LDL serum
levels and circulating monocyte subsets in stable coronary artery disease. PLoS One
2015, 10:e0123367.

266.

Cleeman J, Grundy S, Becker D, Clark L: Expert panel on detection, evaluation and
treatment of high blood cholesterol in adults. Executive summary of the third report
of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP
III). Jama 2001, 285:2486-2497.

267.

Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, Kovesdy CP, Kopple JD,
Kalantar-Zadeh K: Association of Malnutrition-Inflammation Score with quality of life
and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney
Dis 2009, 53:298-309.

268.

Hwang SH, Lee DH, Min J, Jeon JY: Handgrip Strength as a Predictor of All-Cause
Mortality in Patients With Chronic Kidney Disease Undergoing Dialysis: A MetaAnalysis of Prospective Cohort Studies. J Ren Nutr 2019, 29:471-479.

269.

Tallman DA, Latifi E, Kaur D, Sulaheen A, Ikizler TA, Chinna K, Mat Daud ZA,
Karupaiah T, Khosla P: Dietary Patterns and Health Outcomes among African
American Maintenance Hemodialysis Patients. Nutrients 2020, 12:797.

270.

Varady KA, Bhutani S, Klempel MC, Kroeger CM: Comparison of effects of diet versus
exercise weight loss regimens on LDL and HDL particle size in obese adults.2011.

143
271.

Varady KA, Bhutani S, Klempel MC, Lamarche B: Improvements in LDL particle size
and distribution by short-term alternate day modified fasting in obese adults. Br J
Nutr 2011, 105:580-583.

272.

Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA: Alternate day
fasting and endurance exercise combine to reduce body weight and favorably alter
plasma lipids in obese humans. Obesity (Silver Spring) 2013, 21:1370-1379.

273.

Varady KA, Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Haus JM, Hoddy KK,
Calvo Y: Alternate day fasting for weight loss in normal weight and overweight
subjects: a randomized controlled trial. Nutr J 2013, 12:146.

274.

Hoddy K, Kroeger C, Trepanowski J, Barnosky A, Bhutani S, Varady KA: Meal timing
during alternate day fasting: Impact on body weight and cardiovascular disease risk in
obese adults.2015.

275.

Morilla RG, Rodrigo JR, Caravaca AS, Gutierrez CV, Villaverde GR, Moreno BAP:
Dietary Modifications, Engaged in Young Muslims of Ramadan Fasting. Nutricion
Hospitalaria 2009, 24:738-743.

276.

Vaz IMF, Freitas ATVDS, Peixoto MDRG, Ferraz SF, Campos MIVAM: Is energy intake
underreported in hemodialysis patients? Jornal Brasileiro de Nefrologia 2015, 37:359366.

277.

Mafra D, Moraes C, Leal VO, Farage NE, Stockler-Pinto MB, Fouque D: Underreporting
of energy intake in maintenance hemodialysis patients: a cross-sectional study. J Ren
Nutr 2012, 22:578-583.

144
278.

Shapiro BB, Bross R, Morrison G, Kalantar-Zadeh K, Kopple JD: Self-Reported
Interview-Assisted Diet Records Underreport Energy Intake in Maintenance
Hemodialysis Patients. J Ren Nutr 2015, 25:357-363.

279.

Trijsburg L, Geelen A, Hollman PC, Hulshof PJ, Feskens EJ, Van't Veer P, Boshuizen HC,
de Vries JH: BMI was found to be a consistent determinant related to misreporting of
energy, protein and potassium intake using self-report and duplicate portion
methods. Public Health Nutr 2017, 20:598-607.

280.

Subar AF, Kipnis V, Troiano RP, Midthune D, Schoeller DA, Bingham S, Sharbaugh CO,
Trabulsi J, Runswick S, Ballard-Barbash R: Using intake biomarkers to evaluate the
extent of dietary misreporting in a large sample of adults: the OPEN study. American
journal of epidemiology 2003, 158:1-13.

281.

Gibson RS, Charrondiere UR, Bell W: Measurement errors in dietary assessment using
self-reported 24-hour recalls in low-income countries and strategies for their
prevention. Advances in Nutrition 2017, 8:980-991.

282.

Previdelli AN, Gomez G, Kovalskys I, Fisberg M, Cortes LY, Pareja RG, Liria MR, Garcia
MCY, Herrera-Cuenca M, Rigotti A, et al: Prevalence and determinants of misreporting
of energy intake among Latin American populations: results from ELANS study. Nutr
Res 2019, 68:9-18.

283.

Banna JC, Fialkowski MK, Townsend MS: Misreporting of dietary intake affects
estimated nutrient intakes in low-income Spanish-speaking women. J Acad Nutr Diet
2015, 115:1124-1133.

145
284.

Yuan M, Pickering RT, Singer M, Moore L: Dietary Saturated Fat Is Associated with
Larger LDL Particle Size and Reduced CVD Risk in Framingham Offspring Study
(P08-128-19). Current Developments in Nutrition 2019, 3:nzz044. P008-128-019.

285.

Talebi S, Bagherniya M, Atkin SL, Askari G, Orafai HM, Sahebkar A: The beneficial
effects of nutraceuticals and natural products on small dense LDL levels, LDL
particle number and LDL particle size: a clinical review. Lipids Health Dis 2020,
19:66.

286.

DiNicolantonio JJ, O’Keefe JH: Effects of dietary fats on blood lipids: a review of direct
comparison trials. Archives of Disease in childhood; 2018.

287.

Pinart M, Jeran S, Boeing H, Stelmach-Mardas M, Standl M, Schulz H, Harris C, von Berg
A, Herberth G, Koletzko S, et al: Dietary Macronutrient Composition in Relation to
Circulating HDL and Non-HDL Cholesterol: A Federated Individual-Level Analysis
of Cross-Sectional Data from Adolescents and Adults in 8 European Studies. J Nutr
2021.

288.

Finelli C, Crispino P, Gioia S, La Sala N, D'Amico L, La Grotta M, Miro O, Colarusso D:
The improvement of large High-Density Lipoprotein (HDL) particle levels, and
presumably HDL metabolism, depend on effects of low-carbohydrate diet and weight
loss. EXCLI J 2016, 15:166-176.

289.

Schulze MB, Hoffmann K: Methodological approaches to study dietary patterns in
relation to risk of coronary heart disease and stroke. Br J Nutr 2006, 95:860-869.

290.

Cameron JD, Sigal RJ, Kenny GP, Alberga AS, Prud’homme D, Phillips P, Doucette S,
Goldfield G: Body composition and energy intake—skeletal muscle mass is the

146
strongest predictor of food intake in obese adolescents: the HEARTY trial. Applied
Physiology, Nutrition, and Metabolism 2016, 41:611-617.
291.

Jang BY, Bu SY: Total energy intake according to the level of skeletal muscle mass in
Korean adults aged 30 years and older: an analysis of the Korean National Health
and Nutrition Examination Surveys (KNHANES) 2008-2011. Nutr Res Pract 2018,
12:222-232.

292.

Antunes AA, Delatim Vannini F, de Arruda Silveira LV, Martin LC, Barretti P, Caramori
JC: Influence of protein intake and muscle mass on survival in chronic dialysis
patients. Ren Fail 2010, 32:1055-1059.

293.

Loerenzo V, De Bonis E, Rufino M, Hernandez D, Rebollo S, Rodriguez A, Torres A:
Caloric rather than protein deficiency predominates in stable chronic haemodialysis
patients. Nephrology Dialysis Transplantation 1995, 10:1885-1889.

294.

Moreau-Gaudry X, Jean G, Genet L, Lataillade D, Legrand E, Kuentz F, Fouque D: A
simple protein-energy wasting score predicts survival in maintenance hemodialysis
patients. J Ren Nutr 2014, 24:395-400.

295.

Essadik R, Msaad R, Lebrazi H, Taki H, Tahri EH, Kettani A, Madkouri G, Ramdani B,
Saile R: Assessing the prevalence of protein-energy wasting in haemodialysis patients:
A cross-sectional monocentric study. Nephrol Ther 2017, 13:537-543.

296.

Mpio I, Cleaud C, Arkouche W, Laville M: [Results of therapeutics strategy of proteinenergy wasting in chronic hemodialysis: a prospective study during 12 months].
Nephrol Ther 2015, 11:97-103.

147
297.

Gracia-Iguacel C, Gonzalez-Parra E, Perez-Gomez MV, Mahillo I, Egido J, Ortiz A,
Carrero JJ: Prevalence of protein-energy wasting syndrome and its association with
mortality in haemodialysis patients in a centre in Spain. Nefrologia 2013, 33:495-505.

298.

Kanazawa Y, Nakao T, Murai S, Okada T, Matsumoto H: Diagnosis and prevalence of
protein-energy wasting and its association with mortality in Japanese haemodialysis
patients. Nephrology (Carlton) 2017, 22:541-547.

299.

Yasui S, Shirai Y, Tanimura M, Matsuura S, Saito Y, Miyata K, Ishikawa E, Miki C,
Hamada Y: Prevalence of protein-energy wasting (PEW) and evaluation of diagnostic
criteria in Japanese maintenance hemodialysis patients. Asia Pac J Clin Nutr 2016,
25:292-299.

300.

Anton-Perez G, Santana-Del-Pino A, Henriquez-Palop F, Monzon T, Sanchez AY, Valga
F, Morales-Umpierrez A, Garcia-Canton C, Rodriguez-Perez JC, Carrero JJ: Diagnostic
Usefulness of the Protein Energy Wasting Score in Prevalent Hemodialysis Patients.
J Ren Nutr 2018, 28:428-434.

301.

Chuang SY, Hsu YY, Chen RC, Liu WL, Pan WH: Abdominal Obesity and Low Skeletal
Muscle Mass Jointly Predict Total Mortality and Cardiovascular Mortality in an
Elderly Asian Population. J Gerontol A Biol Sci Med Sci 2016, 71:1049-1055.

302.

Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, Stenvinkel P,
Lindholm B: Obese sarcopenia in patients with end-stage renal disease is associated
with inflammation and increased mortality. The American journal of clinical nutrition
2007, 86:633-638.

148
303.

Wannamethee SG, Shaper AG, Lennon L, Whincup PH: Decreased muscle mass and
increased central adiposity are independently related to mortality in older men. Am J
Clin Nutr 2007, 86:1339-1346.

304.

Landi F, Zuccala G, Gambassi G, Incalzi RA, Manigrasso L, Pagano F, Carbonin P,
Bernabei R: Body mass index and mortality among older people living in the
community. Journal of the American Geriatrics Society 1999, 47:1072-1076.

305.

Chung W-S, Ho F-M, Cheng N-C, Lee M-C, Yeh C-J: BMI and all-cause mortality
among middle-aged and older adults in Taiwan: a population-based cohort study.
Public Health Nutrition 2015, 18:1839-1846.

306.

Cheng FW, Gao X, Mitchell DC, Wood C, Still CD, Rolston D, Jensen GL: Body mass
index and all‐cause mortality among older adults. Obesity 2016, 24:2232-2239.

307.

Wu HC, Tseng SF, Wang WJ, Chen HJ, Lee LC: Association between obesity with low
muscle mass and dialysis mortality. Internal Medicine Journal 2017, 47:1282-1291.

308.

Polinder-Bos HA, van Diepen M, Dekker FW, Hoogeveen EK, Franssen CF, Gansevoort
RT, Gaillard CA: Lower body mass index and mortality in older adults starting
dialysis. Scientific reports 2018, 8:1-9.

309.

Doshi M, Streja E, Rhee CM, Park J, Ravel VA, Soohoo M, Moradi H, Lau WL, Mehrotra
R, Kuttykrishnan S, et al: Examining the robustness of the obesity paradox in
maintenance hemodialysis patients: a marginal structural model analysis. Nephrol
Dial Transplant 2016, 31:1310-1319.

310.

Sahathevan S, Se CH, Ng SH, Chinna K, Harvinder GS, Chee WS, Goh BL, Gafor HA,
Bavanandan S, Ahmad G, Karupaiah T: Assessing protein energy wasting in a

149
Malaysian haemodialysis population using self-reported appetite rating: a crosssectional study. BMC Nephrol 2015, 16:99.
311.

Moradi H, Streja E, Kashyap ML, Vaziri ND, Fonarow GC, Kalantar-Zadeh K: Elevated
high-density lipoprotein cholesterol and cardiovascular mortality in maintenance
hemodialysis patients. Nephrol Dial Transplant 2014, 29:1554-1562.

312.

Chang TI, Streja E, Soohoo M, Kim TW, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri
ND, Kalantar-Zadeh K, Moradi H: Association of Serum Triglyceride to HDL
Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident
Hemodialysis Patients. Clin J Am Soc Nephrol 2017, 12:591-602.

313.

Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND,
KalantaraZadeh K, Moradi H: Inverse Association Between Serum Non–High‐
Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing
Incident Hemodialysis. Journal of the American Heart Association 2018, 7:e009096.

150
ABSTRACT
HEALTH AND NUTRITION STATUS OF HEMODIALYSIS PATIENTS DURING
RAMADAN IN SAUDI ARABIA
by
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August 2021
Advisor: Dr. Pramod Khosla
Major : Nutrition and Food Science
Degree : Doctor of Philosophy
During Ramadan R month, Muslims abstain from eating, drinking, and medication from
sunrise to sunset, and this causes some changes in their lifestyle and often eating habits (quantity
and quality). These changes could lead to affect their health and nutritional status. Among
Hemodialysis (HD) patients, malnutrition is common, and it is associated with mortality. Some
HD patients opt to fast R which could have an impact on their nutritional and health status. Thus,
the primary objective of this study was to document nutritional changes before, during, and after
Ramadan on biochemical and health parameters in HD patients. A prospective cohort study was
included 45 KF undergoing HD patients from an out-patient HD clinic in Saudi Arabia, who were
18 years of age or older, not pregnant, and who had been on dialysis treatment for three months at
least. Subjects were evaluated for routine biochemical, anthropometric including hand-grip
strength (HGS), mid-arm muscle circumference (MAMC), plasma lipids, and lipoproteins on a
monthly basis every four weeks before, during as well as one and two months after R. in addition,
the dietary assessment was carried out using 24 h recalls. Then the changes of these markers were
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evaluated by dividing the subjects depend on first: their reporting energy intake (calculated from
their ratio of energy intake (EI) and total energy expenditure (TEE)) to acceptable- reporters (AR:
EI/TEE > 0.76) and under-reporters (UR: EI/TEE < 0.76). Second, depending on their malnutrition
indicators according to protein-energy wasting (PEW) using the International Society of Renal
Nutrition and Metabolism (ISRNM) criteria to PEW and Non-PEW group. The findings of this
study revealed no changes were seen in terms of clinical and biochemical markers during R;
however, there was only a temporary change in lipoprotein particle size distribution and MIS
during Ramadan. Moreover, the intake of energy and nutrients was higher during Ramadan. This
high intake showed a significant change in LDL particle size and malnutrition inflammation score
(MIS). Finally, PEW was prevalent in our samples with no change in the food intake during the
study period. The data suggests that there is transient change and most of them are not clinically
significant, and Ramadan does not have an impact on health and nutritional status.
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